CA2832031C - Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same - Google Patents
Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same Download PDFInfo
- Publication number
- CA2832031C CA2832031C CA2832031A CA2832031A CA2832031C CA 2832031 C CA2832031 C CA 2832031C CA 2832031 A CA2832031 A CA 2832031A CA 2832031 A CA2832031 A CA 2832031A CA 2832031 C CA2832031 C CA 2832031C
- Authority
- CA
- Canada
- Prior art keywords
- cell
- disease
- cancer
- measuring
- metabolic activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002503 metabolic effect Effects 0.000 title claims abstract description 273
- 238000000034 method Methods 0.000 title claims abstract description 119
- 238000012544 monitoring process Methods 0.000 title description 16
- 230000001225 therapeutic effect Effects 0.000 title description 5
- 230000020477 pH reduction Effects 0.000 claims abstract description 79
- 230000036962 time dependent Effects 0.000 claims abstract description 27
- 230000028327 secretion Effects 0.000 claims abstract description 24
- 210000004027 cell Anatomy 0.000 claims description 205
- 206010028980 Neoplasm Diseases 0.000 claims description 144
- 201000011510 cancer Diseases 0.000 claims description 128
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 98
- 201000010099 disease Diseases 0.000 claims description 96
- 239000000523 sample Substances 0.000 claims description 68
- 238000011282 treatment Methods 0.000 claims description 37
- 208000023275 Autoimmune disease Diseases 0.000 claims description 25
- 208000026935 allergic disease Diseases 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 239000003112 inhibitor Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 21
- 210000004698 lymphocyte Anatomy 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 15
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 11
- 231100000252 nontoxic Toxicity 0.000 claims description 11
- 230000003000 nontoxic effect Effects 0.000 claims description 11
- 239000012472 biological sample Substances 0.000 claims description 10
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 206010052779 Transplant rejections Diseases 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 210000002865 immune cell Anatomy 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 238000003556 assay Methods 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 description 88
- 239000000047 product Substances 0.000 description 47
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 38
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 36
- OBJOZRVSMLPASY-UHFFFAOYSA-N 8-hydroxypyrene-1,3,6-trisulfonic acid Chemical compound C1=C2C(O)=CC(S(O)(=O)=O)=C(C=C3)C2=C2C3=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1 OBJOZRVSMLPASY-UHFFFAOYSA-N 0.000 description 35
- 210000001519 tissue Anatomy 0.000 description 32
- 230000001363 autoimmune Effects 0.000 description 29
- 210000000987 immune system Anatomy 0.000 description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 25
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 25
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 25
- 239000008103 glucose Substances 0.000 description 25
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 24
- 206010006187 Breast cancer Diseases 0.000 description 23
- 208000026310 Breast neoplasm Diseases 0.000 description 23
- 210000004369 blood Anatomy 0.000 description 22
- 239000008280 blood Substances 0.000 description 22
- 210000000481 breast Anatomy 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 21
- 239000003153 chemical reaction reagent Substances 0.000 description 21
- 238000005259 measurement Methods 0.000 description 21
- 206010020751 Hypersensitivity Diseases 0.000 description 20
- 239000012224 working solution Substances 0.000 description 20
- 230000006682 Warburg effect Effects 0.000 description 19
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 18
- 238000003745 diagnosis Methods 0.000 description 17
- 230000006536 aerobic glycolysis Effects 0.000 description 16
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 238000007418 data mining Methods 0.000 description 15
- 238000001514 detection method Methods 0.000 description 15
- 230000004044 response Effects 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 14
- 238000012549 training Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 210000000265 leukocyte Anatomy 0.000 description 13
- 206010025135 lupus erythematosus Diseases 0.000 description 13
- 230000010627 oxidative phosphorylation Effects 0.000 description 13
- 230000009610 hypersensitivity Effects 0.000 description 12
- 239000008363 phosphate buffer Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 235000014655 lactic acid Nutrition 0.000 description 11
- 239000004310 lactic acid Substances 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 239000000021 stimulant Substances 0.000 description 10
- 238000007621 cluster analysis Methods 0.000 description 9
- 238000011161 development Methods 0.000 description 9
- 230000018109 developmental process Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 230000037353 metabolic pathway Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000007815 allergy Effects 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 206010008027 Cerebellar atrophy Diseases 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 208000025966 Neurological disease Diseases 0.000 description 7
- 230000006538 anaerobic glycolysis Effects 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 230000005784 autoimmunity Effects 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 201000001119 neuropathy Diseases 0.000 description 7
- 230000007823 neuropathy Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- 230000005748 tumor development Effects 0.000 description 7
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 6
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 6
- 230000035508 accumulation Effects 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- -1 ammonium ions Chemical class 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000003066 decision tree Methods 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000000762 glandular Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 238000011088 calibration curve Methods 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000005284 excitation Effects 0.000 description 5
- 230000006539 extracellular acidification Effects 0.000 description 5
- 239000007850 fluorescent dye Substances 0.000 description 5
- 230000034659 glycolysis Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 5
- 238000001139 pH measurement Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 5
- 229960002930 sirolimus Drugs 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 208000023328 Basedow disease Diseases 0.000 description 4
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 208000015023 Graves' disease Diseases 0.000 description 4
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 201000002481 Myositis Diseases 0.000 description 4
- 206010028665 Myxoedema Diseases 0.000 description 4
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 4
- 206010045240 Type I hypersensitivity Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 4
- 238000004422 calculation algorithm Methods 0.000 description 4
- 208000018631 connective tissue disease Diseases 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000000446 fuel Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000007477 logistic regression Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 208000003786 myxedema Diseases 0.000 description 4
- 230000002956 necrotizing effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000002611 ovarian Effects 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 201000007094 prostatitis Diseases 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000004448 titration Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 208000000209 Isaacs syndrome Diseases 0.000 description 3
- 102000016200 MART-1 Antigen Human genes 0.000 description 3
- 108010010995 MART-1 Antigen Proteins 0.000 description 3
- 201000011152 Pemphigus Diseases 0.000 description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
- 208000024799 Thyroid disease Diseases 0.000 description 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 230000000469 anti-sperm effect Effects 0.000 description 3
- 208000010928 autoimmune thyroid disease Diseases 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000032625 disorder of ear Diseases 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 208000000509 infertility Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000006705 mitochondrial oxidative phosphorylation Effects 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 239000002858 neurotransmitter agent Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 3
- 239000000107 tumor biomarker Substances 0.000 description 3
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010001935 American trypanosomiasis Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 2
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
- 208000008037 Arthrogryposis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000024699 Chagas disease Diseases 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010011953 Decreased activity Diseases 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 208000026492 Isaac syndrome Diseases 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 206010028424 Myasthenic syndrome Diseases 0.000 description 2
- 206010029240 Neuritis Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000016222 Pancreatic disease Diseases 0.000 description 2
- 206010034277 Pemphigoid Diseases 0.000 description 2
- 208000027086 Pemphigus foliaceus Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 2
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 241000272534 Struthio camelus Species 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 208000018359 Systemic autoimmune disease Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000025150 arthrogryposis multiplex congenita Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 201000004339 autoimmune neuropathy Diseases 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 208000000594 bullous pemphigoid Diseases 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 208000012601 choreatic disease Diseases 0.000 description 2
- 201000005637 crescentic glomerulonephritis Diseases 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000007850 distal arthrogryposis Diseases 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 229960000301 factor viii Drugs 0.000 description 2
- 231100000562 fetal loss Toxicity 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 208000007475 hemolytic anemia Diseases 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000010801 machine learning Methods 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000009607 mammography Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 206010063344 microscopic polyangiitis Diseases 0.000 description 2
- 230000001832 mitochondrialike Effects 0.000 description 2
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 208000015124 ovarian disease Diseases 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000007793 ph indicator Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 238000007781 pre-processing Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000010823 ratiometric pH measurement Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 206010000871 Acute monocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010058285 Allergy to arthropod bite Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004659 Biliary cirrhosis Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241001673112 Citrus clementina Species 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000828585 Gari Species 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000005548 Hexokinase Human genes 0.000 description 1
- 108700040460 Hexokinases Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000024781 Immune Complex disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007811 Latex Hypersensitivity Diseases 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 description 1
- 101150097381 Mtor gene Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 108700028031 Myelin Basic Proteins 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 108091093037 Peptide nucleic acid Proteins 0.000 description 1
- 208000025237 Polyendocrinopathy Diseases 0.000 description 1
- 208000034943 Primary Sjögren syndrome Diseases 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039251 Rubber sensitivity Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 241000159243 Toxicodendron radicans Species 0.000 description 1
- 206010054000 Type II hypersensitivity Diseases 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 208000024340 acute graft versus host disease Diseases 0.000 description 1
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000011467 adoptive cell therapy Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 238000013473 artificial intelligence Methods 0.000 description 1
- 208000026764 autoimmune bullous skin disease Diseases 0.000 description 1
- 208000037896 autoimmune cutaneous disease Diseases 0.000 description 1
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000003339 best practice Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 208000019748 bullous skin disease Diseases 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000013145 classification model Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000000485 dysgerminoma of ovary Diseases 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000007387 excisional biopsy Methods 0.000 description 1
- 238000011985 exploratory data analysis Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003269 fluorescent indicator Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000007386 incisional biopsy Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006525 intracellular process Effects 0.000 description 1
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000005391 latex allergy Diseases 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000001809 melena Anatomy 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 201000010225 mixed cell type cancer Diseases 0.000 description 1
- 208000029638 mixed neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 230000001538 myasthenic effect Effects 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000024691 pancreas disease Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 230000008026 type II hypersensitivity Effects 0.000 description 1
- 230000028063 type III hypersensitivity Effects 0.000 description 1
- 208000025883 type III hypersensitivity disease Diseases 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000034280 venom allergy Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
Abstract
A method of measuring a metabolic activity (MA) of a cell is provided. The method comprising independently measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of: (i) non-volatile soluble metabolic products; (ii) non-volatile soluble metabolic products and volatile soluble metabolic products; and (iii) volatile soluble metabolic products; wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell. Also provided are clinical methods which make use of the assay.
Description
METHODS OF MONITORING AND ANALYZING METABOLIC ACTIVITY
PROFILES DIAGNOSTIC AND THERAPEUTIC USES OF SAME
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to methods of monitoring and analyzing metabolic activity profiles and diagnostic or therapeutic uses of same, or specifically relates to cancer diagnosis by metabolic activity monitoring of blood samples.
A major problem in disease treatment remains early detection and staging.
Early detection enables therapeutic treatment from the onset of the disease resulting in successful treatment in many cases. Staging of a disease might indicate on the appropriate protocol of medication which might be decisive for optimal treatment. For example today, millions of people are living with cancer or have had cancer.
Cancer is the second most common cause of death in the United States, exceeded only by heart disease. Cancer accounts for nearly 1 out of every 4 deaths in the United States. The sooner a cancer is diagnosed and treated, the better the survival chances are.
All known methods for detection of cancer focus on identifying mostly the malignant tissue and/or its pathological cancer biomarkers secreted to the circulation.
However, these diagnostic methods are only unfortunately effective at relatively advanced stages of the disease.
The Warburg effect is the observation that most cancer cells predominantly produce energy by a high rate of glycolysis followed by lactic acid production n in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria like most normal cells [Kim JW, Dang CV (2006).
"Cancer's molecular sweet tooth and the Warburg effect". Cancer Res. 66 (18): 8927-30].
Second, in 1920s Otto Warburg found that cancer cells19'20, in contrast to normal differentiated cells, primarily rely on aerobic glycolysis rather than on mitochondrial oxidative phosphorylation to generate ATP as the fuel for energy needed for cellular processes. This historical phenomenon was termed "the Warburg effect"21. Otto Warburg postulated that this change in metabolism is the fundamental cause of cancer [Warburg 0 (1956). "On the origin of cancer cells". Science 123 (3191): 309-14], a claim now known as the Warburg hypothesis. About 50 years later the Warburg effect
PROFILES DIAGNOSTIC AND THERAPEUTIC USES OF SAME
FIELD AND BACKGROUND OF THE INVENTION
The present invention, in some embodiments thereof, relates to methods of monitoring and analyzing metabolic activity profiles and diagnostic or therapeutic uses of same, or specifically relates to cancer diagnosis by metabolic activity monitoring of blood samples.
A major problem in disease treatment remains early detection and staging.
Early detection enables therapeutic treatment from the onset of the disease resulting in successful treatment in many cases. Staging of a disease might indicate on the appropriate protocol of medication which might be decisive for optimal treatment. For example today, millions of people are living with cancer or have had cancer.
Cancer is the second most common cause of death in the United States, exceeded only by heart disease. Cancer accounts for nearly 1 out of every 4 deaths in the United States. The sooner a cancer is diagnosed and treated, the better the survival chances are.
All known methods for detection of cancer focus on identifying mostly the malignant tissue and/or its pathological cancer biomarkers secreted to the circulation.
However, these diagnostic methods are only unfortunately effective at relatively advanced stages of the disease.
The Warburg effect is the observation that most cancer cells predominantly produce energy by a high rate of glycolysis followed by lactic acid production n in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria like most normal cells [Kim JW, Dang CV (2006).
"Cancer's molecular sweet tooth and the Warburg effect". Cancer Res. 66 (18): 8927-30].
Second, in 1920s Otto Warburg found that cancer cells19'20, in contrast to normal differentiated cells, primarily rely on aerobic glycolysis rather than on mitochondrial oxidative phosphorylation to generate ATP as the fuel for energy needed for cellular processes. This historical phenomenon was termed "the Warburg effect"21. Otto Warburg postulated that this change in metabolism is the fundamental cause of cancer [Warburg 0 (1956). "On the origin of cancer cells". Science 123 (3191): 309-14], a claim now known as the Warburg hypothesis. About 50 years later the Warburg effect
2 was also observed in activated lympocytes in vitro see e.g., Maclver et al.
2008 J.
Leukocyte Biology 84:1-9; and DeBerardinis Cell Metabolism 7:11-20. The Warburg effect was found also in the immune system where activated T cells22'23 rapidly hyperinduce glycolysis, for example by over-expression of glucose transporters (GLUT)24.
The Warburg effect has important medical applications, as high aerobic glycolysis by malignant tumors is utilized clinically to diagnose and monitor treatment responses of cancers by imaging uptake of 2-18F-2-deoxyglucose (FDG) (a radioactive modified hexokinase substrate) with positron emission tomography (PET). See also W02007/102146. However, these methods are cumbersome and expensive by requiring high-tech facilities or in-situ tissue biopsies.
Therefore, non-invasive methods for early and simple diagnosis are needed.
SUMMARY OF THE INVENTION
According to an aspect of some embodiments of the present invention there is provided a method of measuring a metabolic activity (MA) of a cell, the method comprising independently measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
(iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell.
According to an aspect of some embodiments of the present invention there is provided a method of diagnosing a disease associated with a modified metabolic activity in a subject-in-need thereof, the method comprising:
(a) providing a biological sample of the subject which comprises a cell;
(b) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
2008 J.
Leukocyte Biology 84:1-9; and DeBerardinis Cell Metabolism 7:11-20. The Warburg effect was found also in the immune system where activated T cells22'23 rapidly hyperinduce glycolysis, for example by over-expression of glucose transporters (GLUT)24.
The Warburg effect has important medical applications, as high aerobic glycolysis by malignant tumors is utilized clinically to diagnose and monitor treatment responses of cancers by imaging uptake of 2-18F-2-deoxyglucose (FDG) (a radioactive modified hexokinase substrate) with positron emission tomography (PET). See also W02007/102146. However, these methods are cumbersome and expensive by requiring high-tech facilities or in-situ tissue biopsies.
Therefore, non-invasive methods for early and simple diagnosis are needed.
SUMMARY OF THE INVENTION
According to an aspect of some embodiments of the present invention there is provided a method of measuring a metabolic activity (MA) of a cell, the method comprising independently measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
(iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell.
According to an aspect of some embodiments of the present invention there is provided a method of diagnosing a disease associated with a modified metabolic activity in a subject-in-need thereof, the method comprising:
(a) providing a biological sample of the subject which comprises a cell;
(b) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
3 (ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in the metabolic activity compared to that of a normal unaffected cell sample examined under identical conditions is indicative of a disease associated with modified metabolic activity.
According to an aspect of some embodiments of the present invention there is provided a method of individually optimizing disease treatment, the method 0 comprising:
(a) contacting a biological sample of the subject which comprises a cell with at least one medicament;
(b) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the .. metabolic activity of the cell and whereas a shift in the metabolic activity of the cells towards that of a normal healthy cell sample examined under identical conditions is indicative of an efficacious medicament for the disease.
According to an aspect of some embodiments of the present invention there is provided a method of monitoring disease treatment in a subject, the method comprising:
(a) administering at least one medicament against the disease to the subject;
(b) retrieving a biological sample which comprises a cell of the subject following the administering;
(c) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in the metabolic activity compared to that of a normal unaffected cell sample examined under identical conditions is indicative of a disease associated with modified metabolic activity.
According to an aspect of some embodiments of the present invention there is provided a method of individually optimizing disease treatment, the method 0 comprising:
(a) contacting a biological sample of the subject which comprises a cell with at least one medicament;
(b) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the .. metabolic activity of the cell and whereas a shift in the metabolic activity of the cells towards that of a normal healthy cell sample examined under identical conditions is indicative of an efficacious medicament for the disease.
According to an aspect of some embodiments of the present invention there is provided a method of monitoring disease treatment in a subject, the method comprising:
(a) administering at least one medicament against the disease to the subject;
(b) retrieving a biological sample which comprises a cell of the subject following the administering;
(c) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
4 (ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in the metabolic activity of the cells towards that of a normal healthy cell sample examined under identical conditions is indicative of an efficacious treatment of the disease.
According to an aspect of some embodiments of the present invention there is provided a method of disease treatment in a subject in need thereof, the method 0 comprising:
(a) diagnosing a presence of the disease in the subject according to the method of claim 2;
(b) treating the subject based on the diagnosis.
According to an aspect of some embodiments of the present invention there is provided a method of identifying an agent capable of altering a metabolic activity of cells, the method comprising:
(a) subjecting cells to an agent;
(b) measuring the metabolic activity of the cells following (a) and optionally prior to (a) according to the method of claim 1, wherein a shift in the acidification profiles is indicative of an agent capable of altering a metabolic activity of cells.
According to some embodiments of the invention, the extracellular environment comprises a defined solution having a calibrated buffer capacity.
According to some embodiments of the invention, the buffer comprises a phosphate buffered saline.
According to some embodiments of the invention, the cell comprises a leukocyte.
According to some embodiments of the invention, the cells comprise a cancer cell.
According to some embodiments of the invention, the cells comprise a peripheral blood mononuclear cell (PBMC).
According to some embodiments of the invention, the disease comprises cancer.
According to some embodiments of the invention, the biological sample comprises a blood sample.
According to some embodiments of the invention, the disease is selected from the group consisting of cancer, pathogenic infection and an autoimmune disease.
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in the metabolic activity of the cells towards that of a normal healthy cell sample examined under identical conditions is indicative of an efficacious treatment of the disease.
According to an aspect of some embodiments of the present invention there is provided a method of disease treatment in a subject in need thereof, the method 0 comprising:
(a) diagnosing a presence of the disease in the subject according to the method of claim 2;
(b) treating the subject based on the diagnosis.
According to an aspect of some embodiments of the present invention there is provided a method of identifying an agent capable of altering a metabolic activity of cells, the method comprising:
(a) subjecting cells to an agent;
(b) measuring the metabolic activity of the cells following (a) and optionally prior to (a) according to the method of claim 1, wherein a shift in the acidification profiles is indicative of an agent capable of altering a metabolic activity of cells.
According to some embodiments of the invention, the extracellular environment comprises a defined solution having a calibrated buffer capacity.
According to some embodiments of the invention, the buffer comprises a phosphate buffered saline.
According to some embodiments of the invention, the cell comprises a leukocyte.
According to some embodiments of the invention, the cells comprise a cancer cell.
According to some embodiments of the invention, the cells comprise a peripheral blood mononuclear cell (PBMC).
According to some embodiments of the invention, the disease comprises cancer.
According to some embodiments of the invention, the biological sample comprises a blood sample.
According to some embodiments of the invention, the disease is selected from the group consisting of cancer, pathogenic infection and an autoimmune disease.
5 According to some embodiments of the invention, the measuring is effected using a non-toxic membrane impermeable probe selected from the group consisting of a pH probe, a CO2 probe and NH3 probe and a lactate probe.
According to some embodiments of the invention, the pH probe comprises a ratiometric pH probe.
to According to some embodiments of the invention, the pH probe comprises HPT S .
According to some embodiments of the invention, the non-volatile metabolites comprise lactate.
According to some embodiments of the invention, the volatile metabolites .. comprise NH3 and CO2.
According to some embodiments of the invention, the measuring acidification profile of (i) is effected in air-exposed chambers.
According to some embodiments of the invention, the measuring acidification profile of (ii) is effected in air-sealed chambers.
According to some embodiments of the invention, the measuring acidification profiles is effected at a constant temperature.
According to some embodiments of the invention, the constant temperature comprises 37 C.
According to some embodiments of the invention, the method further comprises subjecting the cell to a stimulant or inhibitor prior to, or concomitant with measuring the acidification profile.
According to some embodiments of the invention, the stimulant or inhibitor comprises a cell.
According to some embodiments of the invention, the stimulant or inhibitor comprises a cell-free antigen.
According to some embodiments of the invention, the pH probe comprises a ratiometric pH probe.
to According to some embodiments of the invention, the pH probe comprises HPT S .
According to some embodiments of the invention, the non-volatile metabolites comprise lactate.
According to some embodiments of the invention, the volatile metabolites .. comprise NH3 and CO2.
According to some embodiments of the invention, the measuring acidification profile of (i) is effected in air-exposed chambers.
According to some embodiments of the invention, the measuring acidification profile of (ii) is effected in air-sealed chambers.
According to some embodiments of the invention, the measuring acidification profiles is effected at a constant temperature.
According to some embodiments of the invention, the constant temperature comprises 37 C.
According to some embodiments of the invention, the method further comprises subjecting the cell to a stimulant or inhibitor prior to, or concomitant with measuring the acidification profile.
According to some embodiments of the invention, the stimulant or inhibitor comprises a cell.
According to some embodiments of the invention, the stimulant or inhibitor comprises a cell-free antigen.
6 According to some embodiments of the invention, the stimulating cell comprises a lymphocytes and the cell comprises a non-syngeneic lymphocyte with respect to the lymphocyte.
According to some embodiments of the invention, the measuring acidification profiles is effected in commercial fluorescence multi well plate scanner.
According to some embodiments of the invention, signal to noise filtering of the MA test background measures is carried out by k-means cluster analysis.
According to some embodiments of the invention, the diagnostic decisions by the metabolic activity measures are subject to at least two decision tree models.
According to some embodiments of the invention, the decision tree models are selected from the group of CS, C&R Tree and CHAID.
According to some embodiments of the invention, the method further comprises separating the cell from the extracellular environment.
According to some embodiments of the invention, the separating is by ficoll separation under centrifugation.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
BRIEF DESCRIPTION OF THE DRAWINGS
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
According to some embodiments of the invention, the measuring acidification profiles is effected in commercial fluorescence multi well plate scanner.
According to some embodiments of the invention, signal to noise filtering of the MA test background measures is carried out by k-means cluster analysis.
According to some embodiments of the invention, the diagnostic decisions by the metabolic activity measures are subject to at least two decision tree models.
According to some embodiments of the invention, the decision tree models are selected from the group of CS, C&R Tree and CHAID.
According to some embodiments of the invention, the method further comprises separating the cell from the extracellular environment.
According to some embodiments of the invention, the separating is by ficoll separation under centrifugation.
Unless otherwise defined, all technical and/or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the invention, exemplary methods and/or materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and are not intended to be necessarily limiting.
BRIEF DESCRIPTION OF THE DRAWINGS
Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of embodiments of the invention. In this regard, the description taken with the drawings makes apparent to those skilled in the art how embodiments of the invention may be practiced.
7 In the drawings:
FIG. 1 is a schematic representation of the differences between oxidative phosphorylation, anaerobic glycolysis, and aerobic glycolysis (also known as the "Warburg effect").
FIG. 2 is a graph showing pH-dependent absorption spectra of 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS).
FIGs. 3A-D are graphs showing pH and acidity calibration of working solution at 2 mM and 10 mM phosphate buffers saline, at 1 M HPTS. OPEN; The acidification steps were monitored at 37 C without seal. CLOSE; The acidification steps were monitored at 37 C after the multi-well plate was sealed.
X axis; The Ratio: (Fluorescence Intensity at Ex. 403nm) / (Fluorescence Intensity at Ex. 455nm.) Right Y axis (triangles): The accumulated quantity of HC1 ( mol/m1) as obtained by the sequential addition of 1N HC1.
Left Y axis (circles): The appropriate pH values as measured by pH glass electrode. Figures 3A-B - Working solution with 2 mM phosphate buffer saline.
Figures 3C-D - Working solution with 10 mM phosphate buffer saline.
FIGs. 4A-B are graphs showing calibration curves at HPTS concentrations of 1 iuM and 10 iLiM at 10 mM phosphate buffer saline.
X axis: The Ratio: (Fluorescence Intensity at Ex. 403nm) / (Fluorescence Intensity at Ex. 455nm.) Right Y axis (triangles): The accumulated quantity of HC1 ( mol/m1) as obtained by the sequential addition of IN HC1.
Left Y axis (circles): The appropriate pH values as measured by pH glass electrode. (Figure 4A) Final concentration of HPTS is 1 M. (Figure 4B) Final concentration of HPTS is 10 M.
FIGs. 5A-D show k-means cluster analysis of the HPTS reference rate Values.
Figures 5A-C - x-axis point on probe's standardized values received from "OPEN", and y-axis point on probe's standardized values received from "CLOSE"
measurements.
Figure 5A - Examination of all values from all tests donors (N = 730 observations) before cluster analysis. Figure 5B - k-means cluster analysis of probe data indicates on
FIG. 1 is a schematic representation of the differences between oxidative phosphorylation, anaerobic glycolysis, and aerobic glycolysis (also known as the "Warburg effect").
FIG. 2 is a graph showing pH-dependent absorption spectra of 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS).
FIGs. 3A-D are graphs showing pH and acidity calibration of working solution at 2 mM and 10 mM phosphate buffers saline, at 1 M HPTS. OPEN; The acidification steps were monitored at 37 C without seal. CLOSE; The acidification steps were monitored at 37 C after the multi-well plate was sealed.
X axis; The Ratio: (Fluorescence Intensity at Ex. 403nm) / (Fluorescence Intensity at Ex. 455nm.) Right Y axis (triangles): The accumulated quantity of HC1 ( mol/m1) as obtained by the sequential addition of 1N HC1.
Left Y axis (circles): The appropriate pH values as measured by pH glass electrode. Figures 3A-B - Working solution with 2 mM phosphate buffer saline.
Figures 3C-D - Working solution with 10 mM phosphate buffer saline.
FIGs. 4A-B are graphs showing calibration curves at HPTS concentrations of 1 iuM and 10 iLiM at 10 mM phosphate buffer saline.
X axis: The Ratio: (Fluorescence Intensity at Ex. 403nm) / (Fluorescence Intensity at Ex. 455nm.) Right Y axis (triangles): The accumulated quantity of HC1 ( mol/m1) as obtained by the sequential addition of IN HC1.
Left Y axis (circles): The appropriate pH values as measured by pH glass electrode. (Figure 4A) Final concentration of HPTS is 1 M. (Figure 4B) Final concentration of HPTS is 10 M.
FIGs. 5A-D show k-means cluster analysis of the HPTS reference rate Values.
Figures 5A-C - x-axis point on probe's standardized values received from "OPEN", and y-axis point on probe's standardized values received from "CLOSE"
measurements.
Figure 5A - Examination of all values from all tests donors (N = 730 observations) before cluster analysis. Figure 5B - k-means cluster analysis of probe data indicates on
8 26 clusters presented with different colors. Five clusters were found small (observations < 6) and therefore were discarded (outliers). Figures 5C-D - 34 observations (4.66%) from 730 observations were excluded (red). The remaining 696 observations (95.34%) (blue) are presented in 21 separate clusters in (Figure 5B). Then the mean values of "OPEN" and mean values of "CLOSE" states were recalculated for each donor.
FIGs. 6A-C are MA profiles for increasing glucose concentration obtained for typical healthy and cancer donors x axis: Glucose concentration (mM). y axis:
Metabolic activity rate of hPBMCs in units of picomo1H+/W/hour/2500 PBMCs for Figures 6B-C and picomo1H+411/hour for Figure 6C. The acidification kinetics is .. measured during 1 hour of incubation at 37 C. "OPEN" state cycle of the multi well plate during 30 minutes. In this state there is gas ventilation of CO2 and NH3, so that only lactate acid production (including other non-volatile organic acids) contributes to the equivalent acidic accumulation in each well. "CLOSE" state cycle of the same multi well plate during 30 minutes. In this hermetically sealed state, CO2 and NH3 react at equilibrium with water to form carbonic acid and ammonium ions. The acidity level is produced by both the lactic and carbonic acid anions around pH 7.3. The NH4 basic cation is evaluated here to titrate the acidity level. "CLOSE"-"OPEN" = CO2 +
(- NH3)).
(Figure 6A) a control record of the MA test including the probe HPTS and glucose, but without cells. (Figure 6B) MA profiles of a 45 years old female representing a typical healthy donor (similar profiles arc obtained for different age and gender).
(Figure 6C) MA profiles of a 37 years old female with Breast idc cancer at stage 2 and before treatment. Note induced MA changes between healthy and diseased samples may be detected already in the basal state (control sample without stimulants).
FIGs. 7A-D are graphs showing a case study follow-up of MA profiles for increasing glucose obtained for a 65 years old female with breast cancer compare to a 69 years old healthy male. Black - "CLOSE"; Red - "OPEN"; Blue - "C-0" =
"CLOSE"-"OPEN". Figures 7A - MA profiles of peripheral blood mononuclear cells (PBMCs) of a 69 years old healthy male. Figures 7B-D show 3 follow-up MA
profiles of peripheral blood mononuclear cells (PBMCs) of a 65 years old female with breast idc cancer. X axis: Glucose concentration (mM). Y axis: Metabolic activity rate of PBMCs in units of picomol4tl/hour/2500 PBMCs. (Figure 7B) The first MA test of the follow-up patient, already suspicious by the test results to have cancer (time =0).
(Figure 7C)
FIGs. 6A-C are MA profiles for increasing glucose concentration obtained for typical healthy and cancer donors x axis: Glucose concentration (mM). y axis:
Metabolic activity rate of hPBMCs in units of picomo1H+/W/hour/2500 PBMCs for Figures 6B-C and picomo1H+411/hour for Figure 6C. The acidification kinetics is .. measured during 1 hour of incubation at 37 C. "OPEN" state cycle of the multi well plate during 30 minutes. In this state there is gas ventilation of CO2 and NH3, so that only lactate acid production (including other non-volatile organic acids) contributes to the equivalent acidic accumulation in each well. "CLOSE" state cycle of the same multi well plate during 30 minutes. In this hermetically sealed state, CO2 and NH3 react at equilibrium with water to form carbonic acid and ammonium ions. The acidity level is produced by both the lactic and carbonic acid anions around pH 7.3. The NH4 basic cation is evaluated here to titrate the acidity level. "CLOSE"-"OPEN" = CO2 +
(- NH3)).
(Figure 6A) a control record of the MA test including the probe HPTS and glucose, but without cells. (Figure 6B) MA profiles of a 45 years old female representing a typical healthy donor (similar profiles arc obtained for different age and gender).
(Figure 6C) MA profiles of a 37 years old female with Breast idc cancer at stage 2 and before treatment. Note induced MA changes between healthy and diseased samples may be detected already in the basal state (control sample without stimulants).
FIGs. 7A-D are graphs showing a case study follow-up of MA profiles for increasing glucose obtained for a 65 years old female with breast cancer compare to a 69 years old healthy male. Black - "CLOSE"; Red - "OPEN"; Blue - "C-0" =
"CLOSE"-"OPEN". Figures 7A - MA profiles of peripheral blood mononuclear cells (PBMCs) of a 69 years old healthy male. Figures 7B-D show 3 follow-up MA
profiles of peripheral blood mononuclear cells (PBMCs) of a 65 years old female with breast idc cancer. X axis: Glucose concentration (mM). Y axis: Metabolic activity rate of PBMCs in units of picomol4tl/hour/2500 PBMCs. (Figure 7B) The first MA test of the follow-up patient, already suspicious by the test results to have cancer (time =0).
(Figure 7C)
9 time = + 10.5 months¨ The second MA test just after routine mammography diagnosed by the physicians to have breast idc Cancer in stage 3. (Figure 7D) time=
+14.5 months ¨ The sixth MA test was carried out after surgical removal of tumor of 2.2x2.4cm in left breast and after 2 months of 3 chemotherapy treatments.
FIGs. 8A-D are graphs showing MA profiles for increasing PSA concentration obtained for typical healthy donors, breast cancer patient and breast cancer recovered donor.
Figure 8A - a control record of the MA test including the probe HPTS and PSA, but without cells (Figures 8B-D) MA profiles of peripheral blood mononuclear cells (PBMCs) of 3 different donors. X axis: PSA concentration (p.g/m1). Y axis:
metabolic activity rate of PBMCs in units of picomole H+/1i1/hour/2500 PBMCs for Figures and picomole H+/Ial/hour for Figure 8A . The acidification kinetics is measured during 1 hour of incubation at 37 c. Black - "CLOSE"; Red - "OPEN"; Blue - "C-0" =
"CLOSE"-"OPEN" . (Figure 8A) MA profiles of a 59 years old female, representing a typical healthy donor. (Figure 8B) MA profiles of a 37 years old female with breast idc cancer in stage 2 and before any treatment. (Figure 8C) MA profiles of a 50 years old female recovered from breast cancer 18 years prior to the MA test.
FIGs. 9A-D show model building and classification evaluation for the MA test results.
Figures 9A-B - First group of donors in the age above 40 (n=42). Figures 9C-D -Second group of donors in the age between 22 to 81 years old. Figures 9A, C -The two tables present the best models with the best cutting point of the best classification. "0"
refers to "OPEN" state, "C" refers to "CLOSE" state and "C-0" refers to "CLOSE
-OPEN" state. TP refers to true positive, FN refers to false negative, TN
refers to true negative and FP refers to false positive Figures 9 B,D - two graphs for the evaluation and comparison of the models performance by the cumulative gain charts. The y axis shows the percentage of donors classified by the models to have cancer. This is a percentage of the total donors (healthy and cancer patients). The x axis shows the percentage of patients classified to have cancer, which is a fraction of the 42 total donors for the first group and 67 total donors for the second group. Presented are the 4 best models that were able to classify with high accuracy both healthy donors and cancer patients. The fourth model is a logistic regression model from the family of regression models. Black line refer to random response rate (if randomly classified X%
of donors, X% of cancer patients are obtained). Sky blue line refers to the theoretical best model. Red line refers to CHAID model, Green line refers to C5 algorithm, Yellow line refers to C&R tree model and Blue line refer to logistic model.
5 FIGs. 10A-D
present evaluating model results of the MA test using a validation set of 30% of the donors. Figures 10A-B - First group of donors in the age above 40 (n=42). Figures 10C, D - Second group of donors in the age from 22 to 81 years old. (a, c) Data as described in figure 9 was randomly partitioned into two groups of "Training"
and "Testing" using the clementine software V13Ø Figure 10A - Validation set
+14.5 months ¨ The sixth MA test was carried out after surgical removal of tumor of 2.2x2.4cm in left breast and after 2 months of 3 chemotherapy treatments.
FIGs. 8A-D are graphs showing MA profiles for increasing PSA concentration obtained for typical healthy donors, breast cancer patient and breast cancer recovered donor.
Figure 8A - a control record of the MA test including the probe HPTS and PSA, but without cells (Figures 8B-D) MA profiles of peripheral blood mononuclear cells (PBMCs) of 3 different donors. X axis: PSA concentration (p.g/m1). Y axis:
metabolic activity rate of PBMCs in units of picomole H+/1i1/hour/2500 PBMCs for Figures and picomole H+/Ial/hour for Figure 8A . The acidification kinetics is measured during 1 hour of incubation at 37 c. Black - "CLOSE"; Red - "OPEN"; Blue - "C-0" =
"CLOSE"-"OPEN" . (Figure 8A) MA profiles of a 59 years old female, representing a typical healthy donor. (Figure 8B) MA profiles of a 37 years old female with breast idc cancer in stage 2 and before any treatment. (Figure 8C) MA profiles of a 50 years old female recovered from breast cancer 18 years prior to the MA test.
FIGs. 9A-D show model building and classification evaluation for the MA test results.
Figures 9A-B - First group of donors in the age above 40 (n=42). Figures 9C-D -Second group of donors in the age between 22 to 81 years old. Figures 9A, C -The two tables present the best models with the best cutting point of the best classification. "0"
refers to "OPEN" state, "C" refers to "CLOSE" state and "C-0" refers to "CLOSE
-OPEN" state. TP refers to true positive, FN refers to false negative, TN
refers to true negative and FP refers to false positive Figures 9 B,D - two graphs for the evaluation and comparison of the models performance by the cumulative gain charts. The y axis shows the percentage of donors classified by the models to have cancer. This is a percentage of the total donors (healthy and cancer patients). The x axis shows the percentage of patients classified to have cancer, which is a fraction of the 42 total donors for the first group and 67 total donors for the second group. Presented are the 4 best models that were able to classify with high accuracy both healthy donors and cancer patients. The fourth model is a logistic regression model from the family of regression models. Black line refer to random response rate (if randomly classified X%
of donors, X% of cancer patients are obtained). Sky blue line refers to the theoretical best model. Red line refers to CHAID model, Green line refers to C5 algorithm, Yellow line refers to C&R tree model and Blue line refer to logistic model.
5 FIGs. 10A-D
present evaluating model results of the MA test using a validation set of 30% of the donors. Figures 10A-B - First group of donors in the age above 40 (n=42). Figures 10C, D - Second group of donors in the age from 22 to 81 years old. (a, c) Data as described in figure 9 was randomly partitioned into two groups of "Training"
and "Testing" using the clementine software V13Ø Figure 10A - Validation set
10 included 70%
of the donors for the first group. Figure 10C - Validation set included 70% of the donors for the second group. Figures 10A, C - Two graphs for the evaluation and comparison of the models performance made by the cumulative gains charts after random data partition. The y axis shows the percentage of donors classified by the models to have cancer. This is a percentage of the total donors (healthy & cancer patients). The x axis shows the percentage of patients classified to have cancer. The "Training" set are used to build the data mining model on 70% of the donors.
The remaining 30% of the donors are later used to evaluate the classification result on the "Testing" set using the models that were generated in the training set (CHAID, Logistic, C5, C&R tree). As described in figure 9, sky blue line refers to the theoretical best model, Red line to CHAID model, Green line to C5 algorithm, Yellow line to C&R
tree model ,Blue line to logistic model and black line refers to random model.
Figures 10B, D - The two tables present the best model with the best cutting point of the best classification after random data partition. "0" refers to "OPEN" state, "C"
refers to "CLOSE" state and "C-0" refers to "CLOSE - OPEN" state. TP refers to true positive, FN refers to false negative, TN refers to true negative and FP refers to false positive. In both groups of donors C5 was the best performer in the "Testing" set while in the "Training" set C&R tree was the best performer.
FIG. 11 depicts a working hypothesis: metabolic activity profiles of hPBMCs as a mirror image of tumor development. Cancer development is considered to be associated with changes in the physiological function of the immune system that might be reflected in different metabolic activity (MA) profiles of the hPBMCs. The Y axis presents the two arms of metabolic pathways', namely - oxidative phosphorylation
of the donors for the first group. Figure 10C - Validation set included 70% of the donors for the second group. Figures 10A, C - Two graphs for the evaluation and comparison of the models performance made by the cumulative gains charts after random data partition. The y axis shows the percentage of donors classified by the models to have cancer. This is a percentage of the total donors (healthy & cancer patients). The x axis shows the percentage of patients classified to have cancer. The "Training" set are used to build the data mining model on 70% of the donors.
The remaining 30% of the donors are later used to evaluate the classification result on the "Testing" set using the models that were generated in the training set (CHAID, Logistic, C5, C&R tree). As described in figure 9, sky blue line refers to the theoretical best model, Red line to CHAID model, Green line to C5 algorithm, Yellow line to C&R
tree model ,Blue line to logistic model and black line refers to random model.
Figures 10B, D - The two tables present the best model with the best cutting point of the best classification after random data partition. "0" refers to "OPEN" state, "C"
refers to "CLOSE" state and "C-0" refers to "CLOSE - OPEN" state. TP refers to true positive, FN refers to false negative, TN refers to true negative and FP refers to false positive. In both groups of donors C5 was the best performer in the "Testing" set while in the "Training" set C&R tree was the best performer.
FIG. 11 depicts a working hypothesis: metabolic activity profiles of hPBMCs as a mirror image of tumor development. Cancer development is considered to be associated with changes in the physiological function of the immune system that might be reflected in different metabolic activity (MA) profiles of the hPBMCs. The Y axis presents the two arms of metabolic pathways', namely - oxidative phosphorylation
11 versus aerobic glycolysis. The X axis presents the stages of tumor development from healthy to metastasized cancer. Quiescent cells (Q) have a dominant basal rate of oxidative phosphorylation. Under initial stages of tumor development there is "clonal expansion" of relevant tissue specific sub group of Q (Qi) into antitumor effector killer cells (Eki), which at later stages are probably transformed into protumor effector feeder cells (Efi). Concomitantly, immune tolerance and anergy succumb into the metastasized stage, where both tissue specific effector subgroups may be exhausted, including their respective quiescent subgroup (Qi). The present results reveal a metabolic shift from dominant oxidative phosphorylation preferred by hPBMCs of healthy donors to dominant aerobic glycolysis ("Warburg Effect") preferred by hPBMCs of various cancer patients at the stages of local tumor development (stage 1-3). The shift towards aerobic glycolysis may be related to a dominant Efi subgroup and possibly also Eki subgroup. The ability of tissue-specific early detection of cancer (stage 0) will be examined by a follow up protocol. It is expected to be revealed as enhanced/reduced metabolic activation under stimulation by tissue - specific antigens, compared to those obtained for healthy donors. In early metastasized cancer (stage 4) a gradual backward shift towards dominant oxidative phosphorylation is expected, yielding a diagnostic tool for the appropriate treatment. The above schematic description of characteristic metabolic activity profiles is presented by the striped orange line which is related to the difference "close - open" results of the MA test, which indicate the Warburg effect shift of hPBMCs.
FIG. 12 is a flowchart of the MA test protocol and analysis framework. The sequential phases A-E of the MA test framework fit those detailed in Example 1 of the Examples section which follows.
FIGs. 13A-I MA Profiles for Increasing Glucose Concentration Obtained for for typical healthy, cancer, and autoimmune lupus donors. X axis: Glucose concentration (mM). Y axis:
Metabolic activity rate of PBMCin units of picomole H Vul/hour/2500 cells. The acidification kinetics is measured during 1 hour of incubation at Figures 13A, D, G - "CLOSE"; 13B, E, H - "OPEN"; 13C, F, I - "C-0" =
"CLOSE"-"OPEN". Figures 13A-C - Representative MA profiles of a typical healthy
FIG. 12 is a flowchart of the MA test protocol and analysis framework. The sequential phases A-E of the MA test framework fit those detailed in Example 1 of the Examples section which follows.
FIGs. 13A-I MA Profiles for Increasing Glucose Concentration Obtained for for typical healthy, cancer, and autoimmune lupus donors. X axis: Glucose concentration (mM). Y axis:
Metabolic activity rate of PBMCin units of picomole H Vul/hour/2500 cells. The acidification kinetics is measured during 1 hour of incubation at Figures 13A, D, G - "CLOSE"; 13B, E, H - "OPEN"; 13C, F, I - "C-0" =
"CLOSE"-"OPEN". Figures 13A-C - Representative MA profiles of a typical healthy
12 donor. Figures 13D-F - Representative MA profiles of a typical cancer patient.
Figures 13G-I - MA profiles of a patient with systemic lupus (an autoimmune disease).
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
The present invention, in some embodiments thereof, relates to methods of monitoring and analyzing metabolic activity profiles and diagnostic or therapeutic uses of same, or specifically relates to cancer diagnosis by metabolic activity monitoring of blood samples.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Today, high-throughput methods are urgently required for early detection and staging of various diseases. For example, the sooner a cancer is found and treated, the better the survival chances are. Furthermore identifying the disease's stage ensures the appropriate treatment.
The present inventors have realized that in contrast to standard approaches for diseases detection that analyze various in situ parameters or relevant circulatory markers associated with the disease that allow disease detection at relatively late stages, the immune system might mirror disease state already at onset of the disease.
Since the immune system is naturally responsible to combat disease development already at early stages it would be beneficial to identify characteristic profiles of relevant immune responses. Variation of such profiles of the metabolic activity of the immune system along with disease development may become useful also for disease staging. For example, in homeostasis, the immune system activity should be well controlled;
hyperactivity is associated with autoimmune diseases while cancer development is probably related to hypoactivity of the immune system. These opposite routs might be indicated by general and more specific MA profiles in response to various nutrients and stimulants.
The present inventors have thus devised a ground-breaking, clinically-oriented approach for quantitative measurement of the metabolic activity of relevant cell populations, as an indicator of disease. The assay measures the rate of the metabolic
Figures 13G-I - MA profiles of a patient with systemic lupus (an autoimmune disease).
DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION
The present invention, in some embodiments thereof, relates to methods of monitoring and analyzing metabolic activity profiles and diagnostic or therapeutic uses of same, or specifically relates to cancer diagnosis by metabolic activity monitoring of blood samples.
Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not necessarily limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways.
Today, high-throughput methods are urgently required for early detection and staging of various diseases. For example, the sooner a cancer is found and treated, the better the survival chances are. Furthermore identifying the disease's stage ensures the appropriate treatment.
The present inventors have realized that in contrast to standard approaches for diseases detection that analyze various in situ parameters or relevant circulatory markers associated with the disease that allow disease detection at relatively late stages, the immune system might mirror disease state already at onset of the disease.
Since the immune system is naturally responsible to combat disease development already at early stages it would be beneficial to identify characteristic profiles of relevant immune responses. Variation of such profiles of the metabolic activity of the immune system along with disease development may become useful also for disease staging. For example, in homeostasis, the immune system activity should be well controlled;
hyperactivity is associated with autoimmune diseases while cancer development is probably related to hypoactivity of the immune system. These opposite routs might be indicated by general and more specific MA profiles in response to various nutrients and stimulants.
The present inventors have thus devised a ground-breaking, clinically-oriented approach for quantitative measurement of the metabolic activity of relevant cell populations, as an indicator of disease. The assay measures the rate of the metabolic
13 activity of microliter cellular samples, by monitoring extracellular acidification using a pH-sensitive impermeable fluorescence probe.
As is illustrated in the Examples section which follows, using the metabolic activity (MA) analysis, the present inventors have revealed a significant shift between different metabolic pathways monitored on PBMCs obtained from cancer patients and healthy donors. This shift may be adopted as a diagnostic tool, for a clear-cut differentiation between healthy and cancer patients by monitoring characteristic changes in the metabolic activity of PBMCs (Figures 6-10, 13). These significant preliminary findings were obtained by comparing the MA test results in "open" versus "close" (air-sealed) wells. Both records enable to measure the accumulations of soluble versus volatile metabolic products (lactic acid versus CO2 and NH3), thereby differentiating between three metabolic pathways - oxidative phosphorylation, anaerobic glycolysis and aerobic glycolysis, as interpreted below.
Non activated T cells (naive T cells), like most normal differentiated cells, rely .. primarily on mitochondrial oxidative phosphorylation to efficiently generate ATP for the energy needed for cellular processes, and the volatile CO2 product. In the absence of oxygen they must rely on much less efficient metabolic pathway of ATP
production, associated with lactic acid production known as anaerobic glycolysis. In contrast, most cancer cells18 are found to rely on aerobic glycolysis, which is similar to the anaerobic glycolysis despite the presence of oxygen. This phenomenon was originally found by Otto Warburg in relation to cancer cells, and termed "the Warburg effect". The present inventors revealed the presence of the "Warburg effect" in fresh PBMCs of cancer patients. . Without being bound by theory, the immunometabolic rational of the "Warburg effect", namely the shift between naive and activated lymphocytes in fresh .. PBMCs of cancer patients, may be related to the need of aggressive and effective physiological function of activated T cells in the tumor cells neighborhood, where at early stages before angiogenesis it is probably oxygen deficient. This idea is consistent with the fact that tumor cells are initially adapted to oxygen deficiency through the "Warburg effect".
In light of the above metabolic pathways, the end products, CO2 and lactate contribute directly to the acidification examined by the MA test.
As is illustrated in the Examples section which follows, using the metabolic activity (MA) analysis, the present inventors have revealed a significant shift between different metabolic pathways monitored on PBMCs obtained from cancer patients and healthy donors. This shift may be adopted as a diagnostic tool, for a clear-cut differentiation between healthy and cancer patients by monitoring characteristic changes in the metabolic activity of PBMCs (Figures 6-10, 13). These significant preliminary findings were obtained by comparing the MA test results in "open" versus "close" (air-sealed) wells. Both records enable to measure the accumulations of soluble versus volatile metabolic products (lactic acid versus CO2 and NH3), thereby differentiating between three metabolic pathways - oxidative phosphorylation, anaerobic glycolysis and aerobic glycolysis, as interpreted below.
Non activated T cells (naive T cells), like most normal differentiated cells, rely .. primarily on mitochondrial oxidative phosphorylation to efficiently generate ATP for the energy needed for cellular processes, and the volatile CO2 product. In the absence of oxygen they must rely on much less efficient metabolic pathway of ATP
production, associated with lactic acid production known as anaerobic glycolysis. In contrast, most cancer cells18 are found to rely on aerobic glycolysis, which is similar to the anaerobic glycolysis despite the presence of oxygen. This phenomenon was originally found by Otto Warburg in relation to cancer cells, and termed "the Warburg effect". The present inventors revealed the presence of the "Warburg effect" in fresh PBMCs of cancer patients. . Without being bound by theory, the immunometabolic rational of the "Warburg effect", namely the shift between naive and activated lymphocytes in fresh .. PBMCs of cancer patients, may be related to the need of aggressive and effective physiological function of activated T cells in the tumor cells neighborhood, where at early stages before angiogenesis it is probably oxygen deficient. This idea is consistent with the fact that tumor cells are initially adapted to oxygen deficiency through the "Warburg effect".
In light of the above metabolic pathways, the end products, CO2 and lactate contribute directly to the acidification examined by the MA test.
14 Moreover, another end product which is considered to play a major role in the MA test is Ammonia (NH3). One of the primary sources of cell energy is protein catabolism, which is the process of protein brake down to amino acids. Amino groups are removed from amino acids and converted to ammonia. Another source of cellular NH3 production is through metabolic pathways of purines and pyrimidines making up the two groups of nitrogenous bases. In the present measurement system, as in vivo, vital cells must maintain the cytoplasm in a constant pH of about 7.2 ¨ 7.4 by secretion of the metabolic acidic and basic products, such as lactic acid, carbonic acids and the ammonium base.
to These findings already assure that by communicating with the immune system the physiologically-oriented MA analysis could have significant implications for developing new ways to detect, diagnose and treat cancer, as well as other diseases.
Thus, according to an aspect of the invention, there is provided a method of measuring a metabolic activity (MA) of a cell. The method comprising independently (i.e., separately) measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of:
non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
(iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity pathway of the cells.
As used herein "metabolic activity pathway" refers to the relative contribution of mitochondrial oxidative phosphorylation, anaerobic glycolysis, aerobic glycolysis and NH3- production to energy production.
The profiles may have a spike configuration or a monotonic saturated behavior.
A spikes profile typically reflects receptor mediated stimulation of metabolic activity which is expected to be more specific compared to the concentration dependent nutrient response. The latter response is generally a monotonic saturated profile.
As used herein "cell" refers to a prokaryotic or a eukaryotic cell for which the above metabolic activity can be measured. The cell can be a bacteria, yeast, plant, insect or mammalian cell. According to a specific embodiment, the cell is a human cell. It will be appreciated that the cell may refer to a single cell but may also refer to a plurality of cells. The cells may be isolated cells (having no tissue organization) or cells in a tissue or tissue fragment. According to a specific embodiment, when the cells are PBMCs, the assay is done on 103-101 cells. According to a specific embodiment the number of cells is 106-107.
5 The cell may be a differentiated cell, a non-differentiated cell (e.g., stem cell) or a dedifferentiated cell.
According to a specific embodiment, the cell is a cell of the immune system, that is a white blood cell (i.e., a leukocyte). Examples include, a neutrophil, an eosinophil, a basophil, a lymphocyte (T cell or B cell), a monocytc, a macrophage and a dendritic cell.
10 According to another embodiment, the cell is a pathogenic or diseased cell of any tissue such as a cancer cell. Other diseases and medical conditions which can be detected according to the present teachings are provided below.
Other cells which may be analyzed according to the present teachings include, but are not limited to, en embryonic cell (such as for IVF qualification), a red blood cell,
to These findings already assure that by communicating with the immune system the physiologically-oriented MA analysis could have significant implications for developing new ways to detect, diagnose and treat cancer, as well as other diseases.
Thus, according to an aspect of the invention, there is provided a method of measuring a metabolic activity (MA) of a cell. The method comprising independently (i.e., separately) measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of:
non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
(iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity pathway of the cells.
As used herein "metabolic activity pathway" refers to the relative contribution of mitochondrial oxidative phosphorylation, anaerobic glycolysis, aerobic glycolysis and NH3- production to energy production.
The profiles may have a spike configuration or a monotonic saturated behavior.
A spikes profile typically reflects receptor mediated stimulation of metabolic activity which is expected to be more specific compared to the concentration dependent nutrient response. The latter response is generally a monotonic saturated profile.
As used herein "cell" refers to a prokaryotic or a eukaryotic cell for which the above metabolic activity can be measured. The cell can be a bacteria, yeast, plant, insect or mammalian cell. According to a specific embodiment, the cell is a human cell. It will be appreciated that the cell may refer to a single cell but may also refer to a plurality of cells. The cells may be isolated cells (having no tissue organization) or cells in a tissue or tissue fragment. According to a specific embodiment, when the cells are PBMCs, the assay is done on 103-101 cells. According to a specific embodiment the number of cells is 106-107.
5 The cell may be a differentiated cell, a non-differentiated cell (e.g., stem cell) or a dedifferentiated cell.
According to a specific embodiment, the cell is a cell of the immune system, that is a white blood cell (i.e., a leukocyte). Examples include, a neutrophil, an eosinophil, a basophil, a lymphocyte (T cell or B cell), a monocytc, a macrophage and a dendritic cell.
10 According to another embodiment, the cell is a pathogenic or diseased cell of any tissue such as a cancer cell. Other diseases and medical conditions which can be detected according to the present teachings are provided below.
Other cells which may be analyzed according to the present teachings include, but are not limited to, en embryonic cell (such as for IVF qualification), a red blood cell,
15 a platelet, a bacterial-infected cell, a fungus-infected cell, and a viral infected cell.
Thus, the cell may refer to an isolated population of cells which comprise a highly purified subset of specific cells i.e., homogenic cell population (e.g,. > 80 %
purity), e.g., T cells, or a heterogenic cell population which comprises various types of immune cells such as peripheral blood leukocytes (PBL) or mononuclear cells.
Cells may be non-cultured, cultured primary cells or cloned cells (e.g., cell-line).
The cells may be adherent cells or cells in suspension.
According to further embodiments, the cells can be non-genetically modified or genetically modified.
As used herein "independently measuring" refers to separate measuring of items (ii) and possibly (iii). Although it will be appreciated, according to a specific embodiment, that (iii) is the result of subtracting (i) from (ii). These separate measurements can be performed in parallel, simultaneously, on identical yet separate cell samples, or sequentially on a single cell sample (as described in the Examples section which follows).
Thus, measuring extracellular acidification profile is performed by the calibrated curve of acidification (Table 1).
Thus, the cell may refer to an isolated population of cells which comprise a highly purified subset of specific cells i.e., homogenic cell population (e.g,. > 80 %
purity), e.g., T cells, or a heterogenic cell population which comprises various types of immune cells such as peripheral blood leukocytes (PBL) or mononuclear cells.
Cells may be non-cultured, cultured primary cells or cloned cells (e.g., cell-line).
The cells may be adherent cells or cells in suspension.
According to further embodiments, the cells can be non-genetically modified or genetically modified.
As used herein "independently measuring" refers to separate measuring of items (ii) and possibly (iii). Although it will be appreciated, according to a specific embodiment, that (iii) is the result of subtracting (i) from (ii). These separate measurements can be performed in parallel, simultaneously, on identical yet separate cell samples, or sequentially on a single cell sample (as described in the Examples section which follows).
Thus, measuring extracellular acidification profile is performed by the calibrated curve of acidification (Table 1).
16 Measurement of metabolic activity is performed by calculating the accumulated acidification in relation to the fluorescencently measured pH changes in the extracellular environment of the cells (e.g., pmol/u1/hour/2500ce11s) in "open" and "close" state. It will be appreciated that, according to a specific embodiment, this measurement is performed only in the extracellular environment of the cell and not intracellularly. Extracellular pH measurement is advantageous since in the extracellular environment there is a persistent acidic accumulation versus a relatively small average changes in the transient intracellular responses due to homeostatic physiological regulation; there is no physiological interference of the extracellular probe with .. intracellular processes; there is a comparative high signal to noise ratio of the extracellular ratiometric fluorescent probe; simplicity of fluorescent medium (calibrated buffer capacity) preparation versus cellular manipulations; there is no background fluorescence in contrast to significant leakage of intracellular probes;
kinetic measurements are made with no need for permeabilization procedures, thereby allowing the analysis of live cells in real-time; there are minimal problems associated with quenching and oxidation effects; and finally simultaneous high throughput kinetic measurements are enabled without the above hurdles.
As used herein "an extracellular environment" of the cell refers to a natural environment e.g., blood or plasma, or an artificial environment such as a culture medium According to a specific embodiment, the MA test is effected in a defined solution (all components are known) having a calibrated buffered capacity.
It will be appreciated that the buffer capacity should ensure minor changes in the physiological pH.
According to a specific embodiment, the buffer is a phosphate buffer (e.g., phosphate buffer saline 1-10 mM or 10 mM phosphate buffer). It will be appreciated that low buffer concentration is required for acidification measurements at low cell concentration. According to a specific embodiment 10mM phosphate buffer saline is used for 2.5x106 cells/ml.
Thus, kinetics of metabolic activity is monitored during the incubation by a .. minor acidification process of a HPTS fluorescence calibrated buffer capacity.
Figures 3A-D and 4A-D describe the working solution calibration and probe calibration, respectively.
kinetic measurements are made with no need for permeabilization procedures, thereby allowing the analysis of live cells in real-time; there are minimal problems associated with quenching and oxidation effects; and finally simultaneous high throughput kinetic measurements are enabled without the above hurdles.
As used herein "an extracellular environment" of the cell refers to a natural environment e.g., blood or plasma, or an artificial environment such as a culture medium According to a specific embodiment, the MA test is effected in a defined solution (all components are known) having a calibrated buffered capacity.
It will be appreciated that the buffer capacity should ensure minor changes in the physiological pH.
According to a specific embodiment, the buffer is a phosphate buffer (e.g., phosphate buffer saline 1-10 mM or 10 mM phosphate buffer). It will be appreciated that low buffer concentration is required for acidification measurements at low cell concentration. According to a specific embodiment 10mM phosphate buffer saline is used for 2.5x106 cells/ml.
Thus, kinetics of metabolic activity is monitored during the incubation by a .. minor acidification process of a HPTS fluorescence calibrated buffer capacity.
Figures 3A-D and 4A-D describe the working solution calibration and probe calibration, respectively.
17 According to a specific embodiment, measuring the acidification profiles is performed at a constant temperature, e.g., 20-40 C or specifically, at optimal growth temperature, say 37 C for mammalian cells.
As described hereinabove, the extracellular acidification profiles are indicative of the identity of the various metabolic products secreted by the cell.
As shown in Figures 1, a tumor or proliferative tissue (e.g., activated T
cells) use preferentially aerobic glycolysis which is characterized mainly by the secretion of Lactate to the medium. In contrast, a differentiated tissue will employ oxidative phosphorylation or anaerobic glycolysis and therefore will secrete CO2 or lactate, .. dependent on the availability of oxygen, respectively.
According to a specific embodiment, time dependent acidification profile due to secretion of non-volatile soluble metabolic products mainly lactate is performed in an air-exposed chamber. Under such conditions ("open"), there is gas ventilation of CO2 and NH3, so that only lactate acid production (including other non-volatile organic acids) .. contributes to the equivalent acidic accumulation in each well.
According to a specific embodiment, time dependent acidification profile due to secretion of non-volatile soluble metabolic products and volatile soluble metabolic products is effected in an air-sealed chamber. In the hermetically sealed state ("close"), CO2 and NH3 react at equilibrium with water to form carbonic acid and basic ammonium ions. In this state, however, the NH4 + basic cation titrates the acidity level produced by both the lactic and carbonic acid anions around pH 7.
According to a specific embodiment, the acidification kinetics is measured in minutes sequence of air "open" and "closed" states of the multi well plate.
By the appropriate rates (V), of acidification (+) and basic titration (-), the total measured rates of acidification in the open state (Vopen) and the closed state (\/closed) are described by the coupled equations:
Vopen = V( lactic acid).
Vclose = V(lactic acid) + V(carbonic acid) ¨ V(ammonium base).
Using this configuration, the time-dependent acidification profile due to .. secretion of volatile soluble metabolic products is calculated by the subtraction of the profiles of (ii) ¨(i).
As described hereinabove, the extracellular acidification profiles are indicative of the identity of the various metabolic products secreted by the cell.
As shown in Figures 1, a tumor or proliferative tissue (e.g., activated T
cells) use preferentially aerobic glycolysis which is characterized mainly by the secretion of Lactate to the medium. In contrast, a differentiated tissue will employ oxidative phosphorylation or anaerobic glycolysis and therefore will secrete CO2 or lactate, .. dependent on the availability of oxygen, respectively.
According to a specific embodiment, time dependent acidification profile due to secretion of non-volatile soluble metabolic products mainly lactate is performed in an air-exposed chamber. Under such conditions ("open"), there is gas ventilation of CO2 and NH3, so that only lactate acid production (including other non-volatile organic acids) .. contributes to the equivalent acidic accumulation in each well.
According to a specific embodiment, time dependent acidification profile due to secretion of non-volatile soluble metabolic products and volatile soluble metabolic products is effected in an air-sealed chamber. In the hermetically sealed state ("close"), CO2 and NH3 react at equilibrium with water to form carbonic acid and basic ammonium ions. In this state, however, the NH4 + basic cation titrates the acidity level produced by both the lactic and carbonic acid anions around pH 7.
According to a specific embodiment, the acidification kinetics is measured in minutes sequence of air "open" and "closed" states of the multi well plate.
By the appropriate rates (V), of acidification (+) and basic titration (-), the total measured rates of acidification in the open state (Vopen) and the closed state (\/closed) are described by the coupled equations:
Vopen = V( lactic acid).
Vclose = V(lactic acid) + V(carbonic acid) ¨ V(ammonium base).
Using this configuration, the time-dependent acidification profile due to .. secretion of volatile soluble metabolic products is calculated by the subtraction of the profiles of (ii) ¨(i).
18 Measuring the kinetics of extracellular acidification is performed using a non-toxic membrane impermeable probe. Examples include, but are not limited to, a ratiometric pH probe, a CO2 probe, an NH3 probe, a lactate probe and a combination of same. According to a specific embodiment the ratiometric technique is required for the high sensitivity at pH buffered conditions.
Examples of specific probes which can be used according to the present teachings include, but are not limited to, HPTS, CFDA and carboxy fluorescein.
Such probes are commercially available such as from Molecular Probes.
According to a specific embodiment, measuring the acidification is effected using the ratiometric pH probe 8-Hydroxypyrene-1,3,6-trisulfonic acid (HPTS).
HPTS is a cost effective, non-toxic, highly water-soluble membrane-impermeant pH indicator with a pKa of ¨ 7.3 in aqueous buffers. HPTS exhibits a pH-dependent absorption shift, allowing ratiometric pH measurements as function of the ratio between the fluorescence intensities at 513nm that are measured sequentially under excitation at 455nm and 403 nm. This method is essential for the present sensitive measurements of minor pH changes in the physiological range around pH 7.
According to a specific embodiment. the fluorescent probe is attached to a nanoparticle, as nanosensors, in order to expand the ratiometric specific optical monitoring of various metabolic products: CO2, NH3, lactic acid etc.
Intracellular fluorescence measurements arc extremely useful in basic research of the physiological mechanisms of stimulation, e.g. for calcium mobilization and membrane depolarization.
However, under the homeostatic cellular response, these intracellular stimulation signals become transient. Therefore they are considered much less suitable for sensitive monitoring of PBLs stimulation, compared to the ongoing accumulative extracellular acidification that is recorded in the MA test. Such extracellular monitoring may be better facilitated by attachment of ratiometric molecular optical probes to nanoparticles.
Extracellular monitoring is biocompatible, minimizing negative effects common to intracellular probes measurements, pointing on the advantage of the extracellular methods not only in basic research but also for various clinical applications in different cell types.
The acidification profiles are presented by the rate of secretion of H20-H+
equivalents, in units of picomole/W/hour/2500cells (see Figures 6-8, 13).
Examples of specific probes which can be used according to the present teachings include, but are not limited to, HPTS, CFDA and carboxy fluorescein.
Such probes are commercially available such as from Molecular Probes.
According to a specific embodiment, measuring the acidification is effected using the ratiometric pH probe 8-Hydroxypyrene-1,3,6-trisulfonic acid (HPTS).
HPTS is a cost effective, non-toxic, highly water-soluble membrane-impermeant pH indicator with a pKa of ¨ 7.3 in aqueous buffers. HPTS exhibits a pH-dependent absorption shift, allowing ratiometric pH measurements as function of the ratio between the fluorescence intensities at 513nm that are measured sequentially under excitation at 455nm and 403 nm. This method is essential for the present sensitive measurements of minor pH changes in the physiological range around pH 7.
According to a specific embodiment. the fluorescent probe is attached to a nanoparticle, as nanosensors, in order to expand the ratiometric specific optical monitoring of various metabolic products: CO2, NH3, lactic acid etc.
Intracellular fluorescence measurements arc extremely useful in basic research of the physiological mechanisms of stimulation, e.g. for calcium mobilization and membrane depolarization.
However, under the homeostatic cellular response, these intracellular stimulation signals become transient. Therefore they are considered much less suitable for sensitive monitoring of PBLs stimulation, compared to the ongoing accumulative extracellular acidification that is recorded in the MA test. Such extracellular monitoring may be better facilitated by attachment of ratiometric molecular optical probes to nanoparticles.
Extracellular monitoring is biocompatible, minimizing negative effects common to intracellular probes measurements, pointing on the advantage of the extracellular methods not only in basic research but also for various clinical applications in different cell types.
The acidification profiles are presented by the rate of secretion of H20-H+
equivalents, in units of picomole/W/hour/2500cells (see Figures 6-8, 13).
19 Any of the above acidification profiles can be used as an indicator of the metabolic activity of the cell. Alternatively, only one of the measured profiles is indicative of the metabolic activity of the cell.
As mentioned, the metabolic activity of the cell can be measured in naïve cells or activated/effector cells which have been exposed to different concentrations of a stimulant or an inhibitor.
As used herein a "stimulant" or an "inhibitor" refers to an entity that increases, decreases or changes a metabolic pathway of a cell in response thereto.
For instance, if the cell is a lymphocyte then the stimulant is an antigen that is recognized by the TCR or SCR and leads to clonal expansion or antibody production.
Specific stimulants or inhibitors are listed in Table 1 below.
Table 1 Units Concentration Role ug/m1 0.4 - 50 PHA-L is a potent mitogen for lymphocytes H (PHA) tig/m1 0.8 ¨ 100 ConA is a lectin that binds to glycoproteins C
(CONA) expressed on the T cell surface, thereby mimicking the T cell receptor activation which bypasses the requirement of co-stimulatory signals.
ng/ml 0.03 ¨ 10 Phorbol myristate acetate (PMA) mimic P (PMA) diacyglycerol and activates protein kinase C and thus eventually T cells. PMA acts selectively on a T-lymphocyte subpepulation that has high affinity for sheep erythrocytes (SRBC) and is distinct from that responsive to PHA.
ng/ml 0.03 - 10 Lipopolysaccharide (LPS) strongly activates S (LPS) macrophages, monocytes and B cells.
ug/ml 0.4 - 50 Myalin basic protein (MBP)-specific lymphocytes M
(MBP) (CD4,CD8 cells, and NK cells (CD56 + CD3-)) (26) (87-99aa) ug/ml 0.08 - 1 A normal tissue antigen. This peptide (H-Ala-Ala-N(MelanA) Gly-lle-Gly-lle-Leu-Thr-Val-OH) is the (27-35aa) immunodominant epitope recognized by most melanoma-specific, cytoxic T lymphocytes (CTL).
ug/ml 0.4 - 50 A normal prostate tissue specific antigen. This A(PSA) peptide is recognized by cytotoxic T lymphocytes (146-154aa) (CTL). It is found as a biochemical marker of prostate cancer and breast cancer.
mM 0.04 - 5 It has been known for many years that lymphocytes G
(glucose) and macrophages utilize glucose at a high rate, and until the important role of glutamine was identified, glucose was considered to the only fuel used to provide energy for cells of the immune system.
mM 0.03 - 4 Glutamine is utilized at high rates by isolated cells L (1-glutamine) of the immune system. It is an alternative energy source especially for cells that have high energy demands.
nM 0.6 - 50 Inhibits the mammalian target of rapamycin (Mtor) R (Rapamycin) pathway by directly binding the mTOR Complexl (Mtorcl). A recent study report that rapamycin might be particularly effective in blocking of activated T and B lymphocytes. Another study report that it selectively promotes activation and expansion of highly suppressive T regulatory cells.
Other Examples are provided are provided hereinbelow.
The stimulant or inhibitor may be a cell or cell-associated stimulant or inhibitor.
Examples of stimulating cells include, but are not limited to, leukocytes, stem cells, 5 platelets, red blood cells, bacteria and fungi. Such a cellular stimulant or inhibitor may refer to an intact cell or a cell fragment e.g., cell membrane.
The use of a cell stimulant is specifically advantageous in mixed lymphocyte reactions (MLR) for use in transplantation applications such as for prediction of graft rejection (tissue matching), preventing or treating graft versus host disease or graft 10 rejection. In such a case the stimulant is a lymphocyte that is non-syngeneic with respect to the cell.
Alternatively, the stimulant or inhibitor may be cell-free such as a cell-free antigen (e.g., soluble antigen, virus, a cellular bioloigical fluid). Specific examples of cell-free stimulants or inhibitors, include, but are not limited to, metabolites, nutrients 15 (e.g., glucose), mitogens, peptides, cytokines, hormones, vitamins, drugs, antibodies, neurotransmitters, cancer specific antigens and various disease-associated tissue-specific normal antigens (TNAs).
Specific examples of MHC-restricted antigens (peptides) include but arc not limited to CEA (Carcinoembryonic Antigen), MUC-1, HER2, CD340, MAGE and
As mentioned, the metabolic activity of the cell can be measured in naïve cells or activated/effector cells which have been exposed to different concentrations of a stimulant or an inhibitor.
As used herein a "stimulant" or an "inhibitor" refers to an entity that increases, decreases or changes a metabolic pathway of a cell in response thereto.
For instance, if the cell is a lymphocyte then the stimulant is an antigen that is recognized by the TCR or SCR and leads to clonal expansion or antibody production.
Specific stimulants or inhibitors are listed in Table 1 below.
Table 1 Units Concentration Role ug/m1 0.4 - 50 PHA-L is a potent mitogen for lymphocytes H (PHA) tig/m1 0.8 ¨ 100 ConA is a lectin that binds to glycoproteins C
(CONA) expressed on the T cell surface, thereby mimicking the T cell receptor activation which bypasses the requirement of co-stimulatory signals.
ng/ml 0.03 ¨ 10 Phorbol myristate acetate (PMA) mimic P (PMA) diacyglycerol and activates protein kinase C and thus eventually T cells. PMA acts selectively on a T-lymphocyte subpepulation that has high affinity for sheep erythrocytes (SRBC) and is distinct from that responsive to PHA.
ng/ml 0.03 - 10 Lipopolysaccharide (LPS) strongly activates S (LPS) macrophages, monocytes and B cells.
ug/ml 0.4 - 50 Myalin basic protein (MBP)-specific lymphocytes M
(MBP) (CD4,CD8 cells, and NK cells (CD56 + CD3-)) (26) (87-99aa) ug/ml 0.08 - 1 A normal tissue antigen. This peptide (H-Ala-Ala-N(MelanA) Gly-lle-Gly-lle-Leu-Thr-Val-OH) is the (27-35aa) immunodominant epitope recognized by most melanoma-specific, cytoxic T lymphocytes (CTL).
ug/ml 0.4 - 50 A normal prostate tissue specific antigen. This A(PSA) peptide is recognized by cytotoxic T lymphocytes (146-154aa) (CTL). It is found as a biochemical marker of prostate cancer and breast cancer.
mM 0.04 - 5 It has been known for many years that lymphocytes G
(glucose) and macrophages utilize glucose at a high rate, and until the important role of glutamine was identified, glucose was considered to the only fuel used to provide energy for cells of the immune system.
mM 0.03 - 4 Glutamine is utilized at high rates by isolated cells L (1-glutamine) of the immune system. It is an alternative energy source especially for cells that have high energy demands.
nM 0.6 - 50 Inhibits the mammalian target of rapamycin (Mtor) R (Rapamycin) pathway by directly binding the mTOR Complexl (Mtorcl). A recent study report that rapamycin might be particularly effective in blocking of activated T and B lymphocytes. Another study report that it selectively promotes activation and expansion of highly suppressive T regulatory cells.
Other Examples are provided are provided hereinbelow.
The stimulant or inhibitor may be a cell or cell-associated stimulant or inhibitor.
Examples of stimulating cells include, but are not limited to, leukocytes, stem cells, 5 platelets, red blood cells, bacteria and fungi. Such a cellular stimulant or inhibitor may refer to an intact cell or a cell fragment e.g., cell membrane.
The use of a cell stimulant is specifically advantageous in mixed lymphocyte reactions (MLR) for use in transplantation applications such as for prediction of graft rejection (tissue matching), preventing or treating graft versus host disease or graft 10 rejection. In such a case the stimulant is a lymphocyte that is non-syngeneic with respect to the cell.
Alternatively, the stimulant or inhibitor may be cell-free such as a cell-free antigen (e.g., soluble antigen, virus, a cellular bioloigical fluid). Specific examples of cell-free stimulants or inhibitors, include, but are not limited to, metabolites, nutrients 15 (e.g., glucose), mitogens, peptides, cytokines, hormones, vitamins, drugs, antibodies, neurotransmitters, cancer specific antigens and various disease-associated tissue-specific normal antigens (TNAs).
Specific examples of MHC-restricted antigens (peptides) include but arc not limited to CEA (Carcinoembryonic Antigen), MUC-1, HER2, CD340, MAGE and
20 prolactin (others are listed in Renkvist et al. 2001 "A listing of human tumor antigens recognized by T cells". Cancer Immunol. Immunotherapy 50:3-15.
The stimulant or inhibitor is contacted with the cell at various concentrations.
The stimulant or inhibitor is selected according to the suspected pathology.
For example, in in-vitro fertilization applications the ongoing MA of the embryo secretions
The stimulant or inhibitor is contacted with the cell at various concentrations.
The stimulant or inhibitor is selected according to the suspected pathology.
For example, in in-vitro fertilization applications the ongoing MA of the embryo secretions
21 to it's extracellular fluid are examined. Alternatively or additionally, the MA stimulation profiles of the mother PBLs are examined by stimulation of the embryo secretions.
In screening tests, the cells are contacted with a plurality of stimulants or inhibitors, and the acidification profiles are concomitantly monitored for each such reaction.
Thus, the MA test, as described above can be performed on a limited number of samples (e.g., using a tissue culture dish) or on a plurality of samples, screening response to a plurality of stimulants/inhibitors or screening a plurality of samples from different patients or a combination of same. High throughput screening can be performed using a multi well plate, a multi well plate reader (for detecting the fluorescent signal), a CCD camera applying image analysis or fiber optics matrices.
According to an embodiment of the invention, the resultant acidification profiles are recorded and stored in a database such as on a computer readable medium so as to enable data manipulation and construction of computational models. As used herein, "computer readable medium" refers to any medium which can be read and accessed directly by a computer. Such media include, but are not limited to, magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape;
optical storage media such as optical discs or CD-ROM; electrical storage media such as RAM
and ROM; and hybrids of these categories such as magnetic/optical storage media.
Selection and use of appropriate storage media is well within the capabilities of one of ordinary skill in the art.
As used herein, "recorded" refers to a process of storing information on computer readable medium.
The robustness and accurateness of the present methodology suggests its use in numerous clinical applications.
Thus, according to an aspect of the invention there is provided a method of diagnosing a disease associated with a modified metabolic activity in a subject-in-need thereof, the method comprising:
(a) providing a biological sample of the subject which comprises a cell;
(b) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
In screening tests, the cells are contacted with a plurality of stimulants or inhibitors, and the acidification profiles are concomitantly monitored for each such reaction.
Thus, the MA test, as described above can be performed on a limited number of samples (e.g., using a tissue culture dish) or on a plurality of samples, screening response to a plurality of stimulants/inhibitors or screening a plurality of samples from different patients or a combination of same. High throughput screening can be performed using a multi well plate, a multi well plate reader (for detecting the fluorescent signal), a CCD camera applying image analysis or fiber optics matrices.
According to an embodiment of the invention, the resultant acidification profiles are recorded and stored in a database such as on a computer readable medium so as to enable data manipulation and construction of computational models. As used herein, "computer readable medium" refers to any medium which can be read and accessed directly by a computer. Such media include, but are not limited to, magnetic storage media, such as floppy discs, hard disc storage medium, and magnetic tape;
optical storage media such as optical discs or CD-ROM; electrical storage media such as RAM
and ROM; and hybrids of these categories such as magnetic/optical storage media.
Selection and use of appropriate storage media is well within the capabilities of one of ordinary skill in the art.
As used herein, "recorded" refers to a process of storing information on computer readable medium.
The robustness and accurateness of the present methodology suggests its use in numerous clinical applications.
Thus, according to an aspect of the invention there is provided a method of diagnosing a disease associated with a modified metabolic activity in a subject-in-need thereof, the method comprising:
(a) providing a biological sample of the subject which comprises a cell;
(b) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
22 (ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in of thethe metabolic activity compared to that of a normal unaffected cell sample examined under identical conditions is indicative of a disease associated with modified metabolic activity.
The subject may be a healthy animal or a human subject undergoing a routine well-being check up. Alternatively, the subject may be at risk of having a disease associated with a modified metabolic activity such as cancer (e.g., a genetically predisposed subject, a subject with medical and/or family history of cancer, a subject who has been exposed to carcinogens, occupational hazard, environmental hazard) and/or a subject who exhibits suspicious clinical signs of cancer [e.g., blood in the stool or melena, unexplained pain, sweating, unexplained fever, unexplained loss of weight up .. to anorexia, changes in bowel habits (constipation and/or diarrhea), tenesmus (sense of incomplete defecation, for rectal cancer specifically), anemia and/or general weakness).
As used herein "a disease associated with a modified metabolic activity"
refers to a disease that is characterized by a cell population that has undergone a shift in metabolic activity as compared to an identical cell population taken from a normal, healthy (unaffected with the disease). That cell population that has undergone a shift in metabolic activity, can be a pathogenic cell population (i.e., disease-causing cells e.g,.
cancer cells) or a non-pathogenic cell population (e.g., disease combating cells e.g., immune cells such as in the case of solid-tumor). For instance, as described hereinabove, in oncology, most cancer cells predominantly and some populations of the immune system undergoing clonal expansion produce energy by a high rate of glycolysis followed by lactic acid production in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria like most normal cells (see Figure 1).
Cellular biological samples which can be used in accordance with the present teachings include, but are not limited to, blood (e.g., peripheral blood leukocytes, peripheral blood mononuclear cells, whole blood, cord blood), a solid tissue biopsy, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in of thethe metabolic activity compared to that of a normal unaffected cell sample examined under identical conditions is indicative of a disease associated with modified metabolic activity.
The subject may be a healthy animal or a human subject undergoing a routine well-being check up. Alternatively, the subject may be at risk of having a disease associated with a modified metabolic activity such as cancer (e.g., a genetically predisposed subject, a subject with medical and/or family history of cancer, a subject who has been exposed to carcinogens, occupational hazard, environmental hazard) and/or a subject who exhibits suspicious clinical signs of cancer [e.g., blood in the stool or melena, unexplained pain, sweating, unexplained fever, unexplained loss of weight up .. to anorexia, changes in bowel habits (constipation and/or diarrhea), tenesmus (sense of incomplete defecation, for rectal cancer specifically), anemia and/or general weakness).
As used herein "a disease associated with a modified metabolic activity"
refers to a disease that is characterized by a cell population that has undergone a shift in metabolic activity as compared to an identical cell population taken from a normal, healthy (unaffected with the disease). That cell population that has undergone a shift in metabolic activity, can be a pathogenic cell population (i.e., disease-causing cells e.g,.
cancer cells) or a non-pathogenic cell population (e.g., disease combating cells e.g., immune cells such as in the case of solid-tumor). For instance, as described hereinabove, in oncology, most cancer cells predominantly and some populations of the immune system undergoing clonal expansion produce energy by a high rate of glycolysis followed by lactic acid production in the cytosol, rather than by a comparatively low rate of glycolysis followed by oxidation of pyruvate in mitochondria like most normal cells (see Figure 1).
Cellular biological samples which can be used in accordance with the present teachings include, but are not limited to, blood (e.g., peripheral blood leukocytes, peripheral blood mononuclear cells, whole blood, cord blood), a solid tissue biopsy, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the
23 respiratory, intestinal and genitourinary tracts, synovial fluid, amniotic fluid and chorionic Biopsies include, but are not limited to, surgical biopsies including incisional or excisional biopsy, fine needle aspirates and the like, complete resections or body fluids.
Methods of biopsy retrieval are well known in the art.
As used herein the term "diagnosis" or "diagnosing" refers to determining presence or absence of a pathology (e.g., a disease, disorder, condition or syndrome), classifying a pathology or a symptom, determining a severity of the pathology, monitoring pathology progression, forecasting an outcome of a pathology and/or prospects of recovery and screening of a subject for a specific disease.
According to the instant teachings the acidification profiles of a normal, healthy (unaffected) sample of identical cell composition are determined under identical conditions which were used to monitor the cells of the subject.
Once acidification profiles are obtained (e.g., with or without stimulant/inhibitor), the profile(s) are recorded. A shift (i.e., a change) in the metabolic activity between the cells of the subject and those of the control (normal, unaffected), as evidenced from the acidification profiles obtained under identical conditions, is indicative of a disease associated with the modified metabolic activity profiles.
The results of the metabolic activity assay may be subject to decision tree models which classify the results and assist in final diagnosis. According to a preferred embodiment, at least two models are combined (see Figures 9 & 10). Examples of such models include, but are not limited to, CHATD, C5 and C&R Tree. The Logistic model may be further applied.
Examples of medical conditions which can be diagnosed and treated (as is further described hereinbelow) according to the present teachings include, but are not limited to, cancer, pathogenic infection and autoimmune diseases. Specific examples are provided infra.
Inflammatory diseases - Include, but are not limited to, chronic inflammatory diseases and acute inflammatory diseases.
Inflammatory diseases associated with hypersensitivity Examples of hypersensitivity include, but are not limited to, Type I
hypersensitivity, Type 11 hypersensitivity, Type III hypersensitivity, Type IV
Methods of biopsy retrieval are well known in the art.
As used herein the term "diagnosis" or "diagnosing" refers to determining presence or absence of a pathology (e.g., a disease, disorder, condition or syndrome), classifying a pathology or a symptom, determining a severity of the pathology, monitoring pathology progression, forecasting an outcome of a pathology and/or prospects of recovery and screening of a subject for a specific disease.
According to the instant teachings the acidification profiles of a normal, healthy (unaffected) sample of identical cell composition are determined under identical conditions which were used to monitor the cells of the subject.
Once acidification profiles are obtained (e.g., with or without stimulant/inhibitor), the profile(s) are recorded. A shift (i.e., a change) in the metabolic activity between the cells of the subject and those of the control (normal, unaffected), as evidenced from the acidification profiles obtained under identical conditions, is indicative of a disease associated with the modified metabolic activity profiles.
The results of the metabolic activity assay may be subject to decision tree models which classify the results and assist in final diagnosis. According to a preferred embodiment, at least two models are combined (see Figures 9 & 10). Examples of such models include, but are not limited to, CHATD, C5 and C&R Tree. The Logistic model may be further applied.
Examples of medical conditions which can be diagnosed and treated (as is further described hereinbelow) according to the present teachings include, but are not limited to, cancer, pathogenic infection and autoimmune diseases. Specific examples are provided infra.
Inflammatory diseases - Include, but are not limited to, chronic inflammatory diseases and acute inflammatory diseases.
Inflammatory diseases associated with hypersensitivity Examples of hypersensitivity include, but are not limited to, Type I
hypersensitivity, Type 11 hypersensitivity, Type III hypersensitivity, Type IV
24 hypersensitivity, immediate hypersensitivity, antibody mediated hypersensitivity, immune complex mediated hypersensitivity, T lymphocyte mediated hypersensitivity and DTH.
Type I or immediate hypersensitivity, such as asthma.
Type II hypersensitivity include, but are not limited to, rheumatoid diseases, rheumatoid autoimmune diseases, rheumatoid arthritis (Krenn V. et al., Histol Histopathol 2000 Jul;15 (3):791), spondylitis, ankylosing spondylitis (Jan Voswinkel et al., Arthritis Res 2001; 3 (3): 189), systemic diseases, systemic autoimmune diseases, systemic lupus erythematosus (Erikson J. et al., Immunol Res 1998;17 (1-2):49), sclerosis, systemic sclerosis (Renaudineau Y. et al., Clin Diagn Lab Immunol. 1999 Mar;6 (2):156);
Chan .. OT. et al., Immunol Rev 1999 Jun;169:107), glandular diseases, glandular autoimmune diseases, pancreatic autoimmune diseases, diabetes, Type I diabetes (Zimmet P.
Diabetes Res Clin Pract 1996 Oct;34 Suppl:S125), thyroid diseases, autoimmune thyroid diseases, Graves' disease (Orgiazzi J. Endocrinol Metab Clin North Am 2000 Jun;29 (2):339), thyroiditis, spontaneous autoimmune thyroiditis (Braley-Mullen H. and Yu S, J
Immunol 2000 Dec 15;165 (12):7262), Hashimoto's thyroiditis (Toyoda N. et al., Nippon Rinsho 1999 Aug;57 (8):1810), myxedema, idiopathic myxedema (Mitsuma T. Nippon Rinsho.
1999 Aug;57 (8):1759); autoimmune reproductive diseases, ovarian diseases, ovarian autoimmunity (Garza KM. et al., J Reprod Immunol 1998 Feb;37 (2):87), autoimmune anti-sperm infertility (Diekman AB. et al., Am J Reprod Immunol. 2000 Mar;43 (3):134), repeated fetal loss (Tincani A. et al., Lupus 1998;7 Suppl 2:S107-9), neurodegenerative diseases, neurological diseases, neurological autoimmune diseases, multiple sclerosis (Cross AH. et al., J Neuroimmunol 2001 Jan 1;112 (1-2):1), Alzheimer's disease (Oron L.
et al., J Neural Transm Suppl. 1997;49:77), myasthenia gravis (Infante AJ. And Kraig E, Int Rev Immunol 1999;18 (1-2):83), motor neuropathies (Kornberg AJ. J Clin Neurosci.
2000 May;7 (3):191), Guillain-Barre syndrome, neuropathies and autoimmune neuropathies (Kusunoki S. Am J Med Sci. 2000 Apr;319 (4):234), myasthenic diseases, Lambert-Eaton myasthenic syndrome (Takamori M. Am J Med Sci. 2000 Apr;319 (4):204), paraneoplastic neurological diseases, cerebellar atrophy, paraneoplastic cerebellar atrophy, non-paraneoplastic stiff man syndrome, cerebellar atrophies, progressive cerebellar atrophies, encephalitis, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome, polyendocrinopathies, autoimmune polyendocrinopathies (Antoine JC. and Honnorat J. Rev Neurol (Paris) 2000 Jan;156 (1):23); neuropathies, dysimmune neuropathies (Nobile-Orazio E. et al., Electroencephalogr Clin Neurophysiol Suppl 1999;50:419); neuromyotonia, acquired neuromyotonia, arthrogryposis multiplex congenita (Vincent A. et al., Ann N Y
Acad Sci.
1998 May 13;841:482), cardiovascular diseases, cardiovascular autoimmune diseases, 5 atherosclerosis (Matsuura E. et al., Lupus. 1998;7 Suppl 2:S135), myocardial infarction (Vaarala 0. Lupus. 1998;7 Suppl 2:S132), thrombosis (Tincani A. et al., Lupus 1998;7 Suppl 2:S107-9), granulomatosis, Wegener's granulomatosis, arteritis, Takayasu's arteritis and Kawasaki syndrome (Praprotnik S. et al., Wien Klin Wochenschr 2000 Aug
Type I or immediate hypersensitivity, such as asthma.
Type II hypersensitivity include, but are not limited to, rheumatoid diseases, rheumatoid autoimmune diseases, rheumatoid arthritis (Krenn V. et al., Histol Histopathol 2000 Jul;15 (3):791), spondylitis, ankylosing spondylitis (Jan Voswinkel et al., Arthritis Res 2001; 3 (3): 189), systemic diseases, systemic autoimmune diseases, systemic lupus erythematosus (Erikson J. et al., Immunol Res 1998;17 (1-2):49), sclerosis, systemic sclerosis (Renaudineau Y. et al., Clin Diagn Lab Immunol. 1999 Mar;6 (2):156);
Chan .. OT. et al., Immunol Rev 1999 Jun;169:107), glandular diseases, glandular autoimmune diseases, pancreatic autoimmune diseases, diabetes, Type I diabetes (Zimmet P.
Diabetes Res Clin Pract 1996 Oct;34 Suppl:S125), thyroid diseases, autoimmune thyroid diseases, Graves' disease (Orgiazzi J. Endocrinol Metab Clin North Am 2000 Jun;29 (2):339), thyroiditis, spontaneous autoimmune thyroiditis (Braley-Mullen H. and Yu S, J
Immunol 2000 Dec 15;165 (12):7262), Hashimoto's thyroiditis (Toyoda N. et al., Nippon Rinsho 1999 Aug;57 (8):1810), myxedema, idiopathic myxedema (Mitsuma T. Nippon Rinsho.
1999 Aug;57 (8):1759); autoimmune reproductive diseases, ovarian diseases, ovarian autoimmunity (Garza KM. et al., J Reprod Immunol 1998 Feb;37 (2):87), autoimmune anti-sperm infertility (Diekman AB. et al., Am J Reprod Immunol. 2000 Mar;43 (3):134), repeated fetal loss (Tincani A. et al., Lupus 1998;7 Suppl 2:S107-9), neurodegenerative diseases, neurological diseases, neurological autoimmune diseases, multiple sclerosis (Cross AH. et al., J Neuroimmunol 2001 Jan 1;112 (1-2):1), Alzheimer's disease (Oron L.
et al., J Neural Transm Suppl. 1997;49:77), myasthenia gravis (Infante AJ. And Kraig E, Int Rev Immunol 1999;18 (1-2):83), motor neuropathies (Kornberg AJ. J Clin Neurosci.
2000 May;7 (3):191), Guillain-Barre syndrome, neuropathies and autoimmune neuropathies (Kusunoki S. Am J Med Sci. 2000 Apr;319 (4):234), myasthenic diseases, Lambert-Eaton myasthenic syndrome (Takamori M. Am J Med Sci. 2000 Apr;319 (4):204), paraneoplastic neurological diseases, cerebellar atrophy, paraneoplastic cerebellar atrophy, non-paraneoplastic stiff man syndrome, cerebellar atrophies, progressive cerebellar atrophies, encephalitis, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome, polyendocrinopathies, autoimmune polyendocrinopathies (Antoine JC. and Honnorat J. Rev Neurol (Paris) 2000 Jan;156 (1):23); neuropathies, dysimmune neuropathies (Nobile-Orazio E. et al., Electroencephalogr Clin Neurophysiol Suppl 1999;50:419); neuromyotonia, acquired neuromyotonia, arthrogryposis multiplex congenita (Vincent A. et al., Ann N Y
Acad Sci.
1998 May 13;841:482), cardiovascular diseases, cardiovascular autoimmune diseases, 5 atherosclerosis (Matsuura E. et al., Lupus. 1998;7 Suppl 2:S135), myocardial infarction (Vaarala 0. Lupus. 1998;7 Suppl 2:S132), thrombosis (Tincani A. et al., Lupus 1998;7 Suppl 2:S107-9), granulomatosis, Wegener's granulomatosis, arteritis, Takayasu's arteritis and Kawasaki syndrome (Praprotnik S. et al., Wien Klin Wochenschr 2000 Aug
25;112 (15-16):660); anti-factor VIII autoimmune disease (Lacroix-Desmazes S.
et al., 10 Semin Thromb Hemost.2000;26 (2):157); vasculitises, necrotizing small vessel vasculitises, microscopic polyangiitis, Churg and Strauss syndrome, glomerulonephritis, pauci-immune focal necrotizing glomerulonephritis, crescentic glomerulonephritis (Noel LH. Ann Med Interne (Paris). 2000 May;151 (3):178); antiphospholipid syndrome (Flamholz R. et al., J Clin Apheresis 1999;14 (4):171); heart failure, agonist-like 13-15 adrenoceptor antibodies in heart failure (Wallukat G. et al., Am J
Cardiol. 1999 Jun 17;83 (12A):75H), thrombocytopenic purpura (Moccia F. Ann Ital Med Int. 1999 Apr-Jun;14 (2):114); hemolytic anemia, autoimmune hemolytic anemia (Efremov DG. et al., Leuk Lymphoma 1998 Jan;28 (3-4):285), gastrointestinal diseases, autoimmune diseases of the gastrointestinal tract, intestinal diseases, chronic inflammatory intestinal disease (Garcia 20 Herola A. et al., Gastroenterol Hepatol. 2000 Jan;23 (1):16), celiac disease (Landau YE.
and Shoenfeld Y. Harefuah 2000 Jan 16;138 (2):122), autoimmune diseases of the musculature, myositis, autoimmune myositis, Sjogren's syndrome (Feist E. et al., Int Arch Allergy Immunol 2000 Sep;123 (1):92); smooth muscle autoimmune disease (Zauli D. et al., Biomed Pharmacother 1999 Jun;53 (5-6):234), hepatic diseases, hepatic autoimmune 25 diseases, autoimmune hepatitis (Manns MP. J Hepatol 2000 Aug;33 (2):326) and primary biliary cirrhosis (Strassburg CP. etal., Eur J Gastroenterol Hepatol. 1999 Jun;11 (6):595).
Type IV or T cell mediated hypersensitivity, include, but are not limited to, rheumatoid diseases, rheumatoid arthritis (Tisch R, McDevitt HO. Proc Natl Acad Sci U S
A 1994 Jan 18;91 (2):437), systemic diseases, systemic autoimmune diseases, systemic lupus erythematosus (Datta SK., Lupus 1998;7 (9):591), glandular diseases, glandular autoimmune diseases, pancreatic diseases, pancreatic autoimmune diseases, Type diabetes (Castano L. and Eisenbarth GS. Ann. Rev. Immunol. 8:647); thyroid diseases,
et al., 10 Semin Thromb Hemost.2000;26 (2):157); vasculitises, necrotizing small vessel vasculitises, microscopic polyangiitis, Churg and Strauss syndrome, glomerulonephritis, pauci-immune focal necrotizing glomerulonephritis, crescentic glomerulonephritis (Noel LH. Ann Med Interne (Paris). 2000 May;151 (3):178); antiphospholipid syndrome (Flamholz R. et al., J Clin Apheresis 1999;14 (4):171); heart failure, agonist-like 13-15 adrenoceptor antibodies in heart failure (Wallukat G. et al., Am J
Cardiol. 1999 Jun 17;83 (12A):75H), thrombocytopenic purpura (Moccia F. Ann Ital Med Int. 1999 Apr-Jun;14 (2):114); hemolytic anemia, autoimmune hemolytic anemia (Efremov DG. et al., Leuk Lymphoma 1998 Jan;28 (3-4):285), gastrointestinal diseases, autoimmune diseases of the gastrointestinal tract, intestinal diseases, chronic inflammatory intestinal disease (Garcia 20 Herola A. et al., Gastroenterol Hepatol. 2000 Jan;23 (1):16), celiac disease (Landau YE.
and Shoenfeld Y. Harefuah 2000 Jan 16;138 (2):122), autoimmune diseases of the musculature, myositis, autoimmune myositis, Sjogren's syndrome (Feist E. et al., Int Arch Allergy Immunol 2000 Sep;123 (1):92); smooth muscle autoimmune disease (Zauli D. et al., Biomed Pharmacother 1999 Jun;53 (5-6):234), hepatic diseases, hepatic autoimmune 25 diseases, autoimmune hepatitis (Manns MP. J Hepatol 2000 Aug;33 (2):326) and primary biliary cirrhosis (Strassburg CP. etal., Eur J Gastroenterol Hepatol. 1999 Jun;11 (6):595).
Type IV or T cell mediated hypersensitivity, include, but are not limited to, rheumatoid diseases, rheumatoid arthritis (Tisch R, McDevitt HO. Proc Natl Acad Sci U S
A 1994 Jan 18;91 (2):437), systemic diseases, systemic autoimmune diseases, systemic lupus erythematosus (Datta SK., Lupus 1998;7 (9):591), glandular diseases, glandular autoimmune diseases, pancreatic diseases, pancreatic autoimmune diseases, Type diabetes (Castano L. and Eisenbarth GS. Ann. Rev. Immunol. 8:647); thyroid diseases,
26 autoimmune thyroid diseases, Graves' disease (Sakata S. et at., Mol Cell Endocrinol 1993 Mar;92 (1):77); ovarian diseases (Garza KM. el al., J Reprod Immunol 1998 Feb;37 (2):87), prostatitis, autoimmune prostatitis (Alexander RB. et al., Urology 1997 Dec;50 (6):893), polyglandular syndrome, autoimmune polyglandular syndrome, Type I
autoimmune polyglandular syndrome (Hara T. et at., Blood. 1991 Mar 1;77 (5):1127), neurological diseases, autoimmune neurological diseases, multiple sclerosis, neuritis, optic neuritis (Soderstrom M. et al., J Neurol Neurosurg Psychiatry 1994 May;57 (5):544), myasthenia gravis (Oshima M. et al., Eur J Immunol 1990 Dec;20 (12):2563), stiff-man syndrome (Hicmstra HS. et al., Proc Natl Acad Sci U S A 2001 Mar
autoimmune polyglandular syndrome (Hara T. et at., Blood. 1991 Mar 1;77 (5):1127), neurological diseases, autoimmune neurological diseases, multiple sclerosis, neuritis, optic neuritis (Soderstrom M. et al., J Neurol Neurosurg Psychiatry 1994 May;57 (5):544), myasthenia gravis (Oshima M. et al., Eur J Immunol 1990 Dec;20 (12):2563), stiff-man syndrome (Hicmstra HS. et al., Proc Natl Acad Sci U S A 2001 Mar
27;98 .. (7):3988), cardiovascular diseases, cardiac autoimmunity in Chagas' disease (Cunha-Neto E. et al., J Clin Invest 1996 Oct 15;98 (8):1709), autoimmune thrombocytopenic purpura (Semple JW. et al., Blood 1996 May 15;87 (10):4245), anti-helper T lymphocyte autoimmunity (Caporossi AP. ei al., Viral Immunol 1998;11 (1):9), hemolytic anemia (Sallah S. et al., Ann Hematol 1997 Mar;74 (3):139), hepatic diseases, hepatic autoimmune diseases, hepatitis, chronic active hepatitis (Franco A. et at., Clin Immunol Immunopathol 1990 Mar;54 (3):382), biliary cirrhosis, primary biliary cirrhosis (Jones DE. Clin Sci (Colch) 1996 Nov;91 (5):551), nephric diseases, nephric autoimmune diseases, nephritis, interstitial nephritis (Kelly CJ. J Am Soc Nephrol 1990 Aug;1 (2):140), connective tissue diseases, ear diseases, autoimmune connective tissue diseases, autoimmune car disease (Yoo TJ. et al., Cell Immunol 1994 Aug;157 (1):249), disease of the inner ear (Gloddek B. et at., Ann N Y Acad Sci 1997 Dec 29;830:266), skin diseases, cutaneous diseases, dermal diseases, bullous skin diseases, pemphigus vul gari s, bullous pemphigoid and pemphigus foliaceus.
Examples of delayed type hypersensitivity include, but are not limited to, contact dermatitis and drug eruption.
Examples of types of T lymphocyte mediating hypersensitivity include, but are not limited to, helper T lymphocytes and cytotoxic T lymphocytes.
Examples of helper T lymphocyte-mediated hypersensitivity include, but are not limited to, Thl lymphocyte mediated hypersensitivity and Th2 lymphocyte mediated hypersensitivity.
Autoimmune diseases Include, but are not limited to, cardiovascular diseases, rheumatoid diseases, glandular diseases, gastrointestinal diseases, cutaneous diseases, hepatic diseases, neurological diseases, muscular diseases, nephric diseases, diseases related to reproduction, connective tissue diseases and systemic diseases.
Examples of autoimmune cardiovascular diseases include, but are not limited to atherosclerosis (Matsuura E. et al., Lupus. 1998;7 Suppl 2:S135), myocardial infarction (Vaarala 0. Lupus. 1998;7 Suppl 2:S132), thrombosis (Tincani A. et at., Lupus 1998;7 Suppl 2:S107-9), Wegener's granulomatosis, Takayasu's arteritis, Kawasaki syndrome (Praprotnik S. et al., Wien Klin Wochenschr 2000 Aug 25;112 (15-16):660), anti-factor VIII autoimmune disease (Lacroix-Desmazes S. et al., Semin Thromb Hemost.2000;26 (2):157), necrotizing small vessel vasculitis, microscopic polyangiitis, Churg and Strauss syndrome, pauci-immune focal necrotizing and crescentic glomerulonephritis (Noel LH.
Ann Med Interne (Paris). 2000 May;151 (3):178), antiphospholipid syndrome (Flamholz R. et al., J Clin Apheresis 1999;14 (4):171), antibody-induced heart failure (Wallukat G.
et al., Am J Cardiol. 1999 Jun 17;83 (12A):75H), thrombocytopenic purpura (Moccia F.
Ann Ital Med Int. 1999 Apr-Jun;14 (2):114; Semple JW. et al., Blood 1996 May 15;87 (10):4245), autoimmune hemolytic anemia (Efremov DG. et at., Leuk Lymphoma Jan;28 (3-4):285; Sallah S. et al., Ann Hematol 1997 Mar;74 (3):139), cardiac autoimmunity in Chagas' disease (Cunha-Ncto E. et al., J Clin Invest 1996 Oct 15;98 (8):1709) and anti-helper T lymphocyte autoimmunity (Caporossi AP. et at., Viral Immunol 1998;11 (1):9).
Examples of autoimmune rheumatoid diseases include, but are not limited to rheumatoid arthritis (Krenn V. el al., Histol Histopathol 2000 Jul;15 (3):791;
Tisch R, McDevitt HO. Proc Natl Acad Sci units S A 1994 Jan 18;91 (2):437) and ankylosing spondylitis (Jan Voswinkel et al., Arthritis Res 2001; 3 (3): 189).
Examples of autoimmune glandular diseases include, but are not limited to, pancreatic disease, Type I diabetes, thyroid disease, Graves' disease, thyroiditis, spontaneous autoimmune thyroiditis, Hashimoto 's thyroiditis, idiopathic myxedema, ovarian autoimmunity, autoimmune anti-sperm infertility, autoimmune prostatitis and Type I autoimmune polyglandular syndrome. diseases include, but are not limited to autoimmune diseases of the pancreas, Type 1 diabetes (Castano L. and Eisenbarth GS.
Examples of delayed type hypersensitivity include, but are not limited to, contact dermatitis and drug eruption.
Examples of types of T lymphocyte mediating hypersensitivity include, but are not limited to, helper T lymphocytes and cytotoxic T lymphocytes.
Examples of helper T lymphocyte-mediated hypersensitivity include, but are not limited to, Thl lymphocyte mediated hypersensitivity and Th2 lymphocyte mediated hypersensitivity.
Autoimmune diseases Include, but are not limited to, cardiovascular diseases, rheumatoid diseases, glandular diseases, gastrointestinal diseases, cutaneous diseases, hepatic diseases, neurological diseases, muscular diseases, nephric diseases, diseases related to reproduction, connective tissue diseases and systemic diseases.
Examples of autoimmune cardiovascular diseases include, but are not limited to atherosclerosis (Matsuura E. et al., Lupus. 1998;7 Suppl 2:S135), myocardial infarction (Vaarala 0. Lupus. 1998;7 Suppl 2:S132), thrombosis (Tincani A. et at., Lupus 1998;7 Suppl 2:S107-9), Wegener's granulomatosis, Takayasu's arteritis, Kawasaki syndrome (Praprotnik S. et al., Wien Klin Wochenschr 2000 Aug 25;112 (15-16):660), anti-factor VIII autoimmune disease (Lacroix-Desmazes S. et al., Semin Thromb Hemost.2000;26 (2):157), necrotizing small vessel vasculitis, microscopic polyangiitis, Churg and Strauss syndrome, pauci-immune focal necrotizing and crescentic glomerulonephritis (Noel LH.
Ann Med Interne (Paris). 2000 May;151 (3):178), antiphospholipid syndrome (Flamholz R. et al., J Clin Apheresis 1999;14 (4):171), antibody-induced heart failure (Wallukat G.
et al., Am J Cardiol. 1999 Jun 17;83 (12A):75H), thrombocytopenic purpura (Moccia F.
Ann Ital Med Int. 1999 Apr-Jun;14 (2):114; Semple JW. et al., Blood 1996 May 15;87 (10):4245), autoimmune hemolytic anemia (Efremov DG. et at., Leuk Lymphoma Jan;28 (3-4):285; Sallah S. et al., Ann Hematol 1997 Mar;74 (3):139), cardiac autoimmunity in Chagas' disease (Cunha-Ncto E. et al., J Clin Invest 1996 Oct 15;98 (8):1709) and anti-helper T lymphocyte autoimmunity (Caporossi AP. et at., Viral Immunol 1998;11 (1):9).
Examples of autoimmune rheumatoid diseases include, but are not limited to rheumatoid arthritis (Krenn V. el al., Histol Histopathol 2000 Jul;15 (3):791;
Tisch R, McDevitt HO. Proc Natl Acad Sci units S A 1994 Jan 18;91 (2):437) and ankylosing spondylitis (Jan Voswinkel et al., Arthritis Res 2001; 3 (3): 189).
Examples of autoimmune glandular diseases include, but are not limited to, pancreatic disease, Type I diabetes, thyroid disease, Graves' disease, thyroiditis, spontaneous autoimmune thyroiditis, Hashimoto 's thyroiditis, idiopathic myxedema, ovarian autoimmunity, autoimmune anti-sperm infertility, autoimmune prostatitis and Type I autoimmune polyglandular syndrome. diseases include, but are not limited to autoimmune diseases of the pancreas, Type 1 diabetes (Castano L. and Eisenbarth GS.
28 Ann. Rev. Immunol. 8:647; Zimmet P. Diabetes Res Clin Pract 1996 Oct;34 Suppl:S125), autoimmune thyroid diseases, Graves' disease (Orgiazzi J. Endocrinol Metab Clin North Am 2000 Jun;29 (2):339; Sakata S. et al., Mol Cell Endocrinol 1993 Mar;92 (1):77), spontaneous autoimmune thyroiditis (Braley-Mullen H. and Yu S, J Immunol 2000 Dec 15;165 (12):7262), Hashimoto's thyroiditis (Toyoda N. et al., Nippon Rinsho Aug;57 (8):1810), idiopathic myxedema (Mitsuma T. Nippon Rinsho. 1999 Aug;57 (8):1759), ovarian autoimmunity (Garza KM. et at., J Reprod Immunol 1998 Feb;37 (2):87), autoimmune anti-sperm infertility (Diekman AB. et at., Am J Reprod Immunol.
2000 Mar;43 (3):134), autoimmune prostatitis (Alexander RB. et at., Urology Dec;50 (6):893) and Type 1 autoimmune polyglandular syndrome (Hara T. et at., Blood.
1991 Mar 1;77 (5):1127).
Examples of autoimmune gastrointestinal diseases include, but are not limited to, chronic inflammatory intestinal diseases (Garcia Herola A. el al., Gastroenterol Hepatol.
2000 Jan;23 (1):16), celiac disease (Landau YE. and Shoenfeld Y. Harefuah 2000 Jan 16;138 (2):122), colitis, ileitis and Crohn's disease.
Examples of autoimmune cutaneous diseases include, but are not limited to, autoimmune bullous skin diseases, such as, but are not limited to, pemphigus vulgaris, bullous pemphigoid and pemphigus foliaceus.
Examples of autoimmune hepatic diseases include, but are not limited to, hepatitis, autoimmune chronic active hepatitis (Franco A. et al., Clin Immunol Immunopathol 1990 Mar;54 (3):382), primary biliary cirrhosis (Jones DE. Clin Sci (Colch) 1996 Nov;91 (5):551; Strassburg CP. et al., Eur J Gastroenterol Hepatol. 1999 Jun;11 (6):595) and autoimmune hepatitis (Manns MP. J Hepatol 2000 Aug;33 (2):326).
Examples of autoimmune neurological diseases include, but are not limited to, multiple sclerosis (Cross AH. et at., J Neuroimmunol 2001 Jan 1;112 (1-2):1), Alzheimer's disease (Oron L. et al., J Neural Transm Suppl. 1997;49:77), myasthenia gravis (Infante AJ. And Kraig E, Int Rev Immunol 1999;18 (1-2):83; Oshima M.
et at., Eur J Immunol 1990 Dec;20 (12):2563), neuropathies, motor neuropathies (Komberg AJ.
J Clin Neurosci. 2000 May;7 (3):191); Guillain-Barre syndrome and autoimmune neuropathies (Kusunoki S. Am J Med Sci. 2000 Apr;319 (4):234), myasthenia, Lambert-Eaton myasthenic syndrome (Takamori M. Am J Med Sci. 2000 Apr;319 (4):204);
paraneoplastic neurological diseases, cerebellar atrophy, paraneoplastic cerebellar atrophy
2000 Mar;43 (3):134), autoimmune prostatitis (Alexander RB. et at., Urology Dec;50 (6):893) and Type 1 autoimmune polyglandular syndrome (Hara T. et at., Blood.
1991 Mar 1;77 (5):1127).
Examples of autoimmune gastrointestinal diseases include, but are not limited to, chronic inflammatory intestinal diseases (Garcia Herola A. el al., Gastroenterol Hepatol.
2000 Jan;23 (1):16), celiac disease (Landau YE. and Shoenfeld Y. Harefuah 2000 Jan 16;138 (2):122), colitis, ileitis and Crohn's disease.
Examples of autoimmune cutaneous diseases include, but are not limited to, autoimmune bullous skin diseases, such as, but are not limited to, pemphigus vulgaris, bullous pemphigoid and pemphigus foliaceus.
Examples of autoimmune hepatic diseases include, but are not limited to, hepatitis, autoimmune chronic active hepatitis (Franco A. et al., Clin Immunol Immunopathol 1990 Mar;54 (3):382), primary biliary cirrhosis (Jones DE. Clin Sci (Colch) 1996 Nov;91 (5):551; Strassburg CP. et al., Eur J Gastroenterol Hepatol. 1999 Jun;11 (6):595) and autoimmune hepatitis (Manns MP. J Hepatol 2000 Aug;33 (2):326).
Examples of autoimmune neurological diseases include, but are not limited to, multiple sclerosis (Cross AH. et at., J Neuroimmunol 2001 Jan 1;112 (1-2):1), Alzheimer's disease (Oron L. et al., J Neural Transm Suppl. 1997;49:77), myasthenia gravis (Infante AJ. And Kraig E, Int Rev Immunol 1999;18 (1-2):83; Oshima M.
et at., Eur J Immunol 1990 Dec;20 (12):2563), neuropathies, motor neuropathies (Komberg AJ.
J Clin Neurosci. 2000 May;7 (3):191); Guillain-Barre syndrome and autoimmune neuropathies (Kusunoki S. Am J Med Sci. 2000 Apr;319 (4):234), myasthenia, Lambert-Eaton myasthenic syndrome (Takamori M. Am J Med Sci. 2000 Apr;319 (4):204);
paraneoplastic neurological diseases, cerebellar atrophy, paraneoplastic cerebellar atrophy
29 and stiff-man syndrome (Hiemstra HS. et al., Proc Natl Acad Sci units S A 2001 Mar 27;98 (7):3988); non-paraneoplastic stiff man syndrome, progressive cerebellar atrophies, encephalitis, Rasmussen's encephalitis, amyotrophic lateral sclerosis, Sydeham chorea, Gilles de la Tourette syndrome and autoimmune polyendocrinopathies (Antoine JC. and Honnorat J. Rev Neurol (Paris) 2000 Jan;156 (1):23); dysimmune neuropathies (Nobile-Orazio E. et al., Electroencephalogr Clin Neurophysiol Suppl 1999;50:419);
acquired neuromyotonia, arthrogryposis multiplex congenita (Vincent A. et al., Ann N Y
Acad Sci.
1998 May 13;841:482), neuritis, optic neuritis (Soderstrom M. et al., J Neurol Neurosurg Psychiatry 1994 May;57 (5):544) and neurodegenerative diseases.
Examples of autoimmune muscular diseases include, but are not limited to, myositis, autoimmune myositis and primary Sjogren's syndrome (Feist E. et al., Int Arch Allergy Immunol 2000 Sep;123 (1):92) and smooth muscle autoimmune disease (Zauli D.
el al., Biomed Pharmacother 1999 Jun;53 (5-6):234).
Examples of autoimmune nephric diseases include, but are not limited to, nephritis and autoimmune interstitial nephritis (Kelly CJ. J Am Soc Nephrol 1990 Aug;1 (2):140).
Examples of autoimmune diseases related to reproduction include, but are not limited to, repeated fetal loss (Tincani A. etal., Lupus 1998;7 Suppl 2:S107-9).
Examples of autoimmune connective tissue diseases include, but are not limited to, ear diseases, autoimmune ear diseases (Yoo TJ. et al., Cell Immunol 1994 Aug;157 (1):249) and autoimmunc diseases of the inner car (Gloddek B. et al., Ann N Y
Acad Sci 1997 Dec 29;830:266).
Examples of autoimmune systemic diseases include, but are not limited to, systemic lupus erythematosus (Erikson J. et al., Immunol Res 1998;17 (1-2):49) and systemic sclerosis (Renaudineau Y. ei al., Clin Diagn Lab Immunol. 1999 Mar;6 (2):156);
Chan OT. etal., Immunol Rev 1999 Jun;169:107).
Infectious diseases Examples of infectious diseases include, but are not limited to, chronic infectious diseases, subacute infectious diseases, acute infectious diseases, viral diseases, bacterial diseases, protozoan diseases, parasitic diseases, fungal diseases, mycoplasma diseases and prion diseases.
Graft rejection diseases Examples of diseases associated with transplantation of a graft include, but are not limited to, graft rejection, chronic graft rejection, subacute graft rejection, hyperacute graft rejection, acute graft rejection and graft versus host disease.
5 Allergic diseases Examples of allergic diseases include, but are not limited to, asthma, hives, urticaria, pollen allergy, dust mite allergy, venom allergy, cosmetics allergy, latex allergy, chemical allergy, drug allergy, insect bite allergy, animal dander allergy, stinging plant allergy, poison ivy allergy and food allergy.
to According to a specific embodiment the disease is cancer.
Cancerous diseases Examples of cancer include but are not limited to carcinoma, lymphoma, blastoma, sarcoma, and leukemia. Particular examples of cancerous diseases but are not limited to: Myeloid leukemia such as Chronic myelogenous leukemia. Acute 15 myelogenous leukemia with maturation. Acute promyelocytic leukemia, Acute nonlymphocytic leukemia with increased basophils, Acute monocytic leukemia.
Acute myelomonocytic leukemia with eosinophilia; Malignant lymphoma, such as Birkitt's Non-Hodgkin's; Lymphoctyic leukemia, such as Acute lumphoblastic leukemia. Chronic lymphocytic leukemia; Myeloproliferative diseases, such as Solid tumors Benign 20 Mcningioma, Mixed tumors of salivary gland, Colonic adenomas;
Adenocarcinomas, such as Small cell lung cancer, Kidney, Uterus, Prostate, Bladder, Ovary, Colon, Sarcomas, Liposarcoma, myxoid, Synovial sarcoma, Rhabdomyosarcoma (alveolar), Extraskeletel myxoid chonodrosarcoma, Ewing's tumor; other include Testicular and ovarian dysgerminoma, Retinoblastoma, Wilms' tumor, Neuroblastoma, Malignant melanoma, 25 Mesothelioma, breast, skin, paccreas, cervix, prostate, and ovarian.
Thus, the present teachings can be used in disease detection. Following is a non-limiting embdodiment which relates to early cancer detection.
The present teachings provide for an immune system-based approach as a non-invasive diagnostic tool for early detection and staging of cancer.
Conventional
acquired neuromyotonia, arthrogryposis multiplex congenita (Vincent A. et al., Ann N Y
Acad Sci.
1998 May 13;841:482), neuritis, optic neuritis (Soderstrom M. et al., J Neurol Neurosurg Psychiatry 1994 May;57 (5):544) and neurodegenerative diseases.
Examples of autoimmune muscular diseases include, but are not limited to, myositis, autoimmune myositis and primary Sjogren's syndrome (Feist E. et al., Int Arch Allergy Immunol 2000 Sep;123 (1):92) and smooth muscle autoimmune disease (Zauli D.
el al., Biomed Pharmacother 1999 Jun;53 (5-6):234).
Examples of autoimmune nephric diseases include, but are not limited to, nephritis and autoimmune interstitial nephritis (Kelly CJ. J Am Soc Nephrol 1990 Aug;1 (2):140).
Examples of autoimmune diseases related to reproduction include, but are not limited to, repeated fetal loss (Tincani A. etal., Lupus 1998;7 Suppl 2:S107-9).
Examples of autoimmune connective tissue diseases include, but are not limited to, ear diseases, autoimmune ear diseases (Yoo TJ. et al., Cell Immunol 1994 Aug;157 (1):249) and autoimmunc diseases of the inner car (Gloddek B. et al., Ann N Y
Acad Sci 1997 Dec 29;830:266).
Examples of autoimmune systemic diseases include, but are not limited to, systemic lupus erythematosus (Erikson J. et al., Immunol Res 1998;17 (1-2):49) and systemic sclerosis (Renaudineau Y. ei al., Clin Diagn Lab Immunol. 1999 Mar;6 (2):156);
Chan OT. etal., Immunol Rev 1999 Jun;169:107).
Infectious diseases Examples of infectious diseases include, but are not limited to, chronic infectious diseases, subacute infectious diseases, acute infectious diseases, viral diseases, bacterial diseases, protozoan diseases, parasitic diseases, fungal diseases, mycoplasma diseases and prion diseases.
Graft rejection diseases Examples of diseases associated with transplantation of a graft include, but are not limited to, graft rejection, chronic graft rejection, subacute graft rejection, hyperacute graft rejection, acute graft rejection and graft versus host disease.
5 Allergic diseases Examples of allergic diseases include, but are not limited to, asthma, hives, urticaria, pollen allergy, dust mite allergy, venom allergy, cosmetics allergy, latex allergy, chemical allergy, drug allergy, insect bite allergy, animal dander allergy, stinging plant allergy, poison ivy allergy and food allergy.
to According to a specific embodiment the disease is cancer.
Cancerous diseases Examples of cancer include but are not limited to carcinoma, lymphoma, blastoma, sarcoma, and leukemia. Particular examples of cancerous diseases but are not limited to: Myeloid leukemia such as Chronic myelogenous leukemia. Acute 15 myelogenous leukemia with maturation. Acute promyelocytic leukemia, Acute nonlymphocytic leukemia with increased basophils, Acute monocytic leukemia.
Acute myelomonocytic leukemia with eosinophilia; Malignant lymphoma, such as Birkitt's Non-Hodgkin's; Lymphoctyic leukemia, such as Acute lumphoblastic leukemia. Chronic lymphocytic leukemia; Myeloproliferative diseases, such as Solid tumors Benign 20 Mcningioma, Mixed tumors of salivary gland, Colonic adenomas;
Adenocarcinomas, such as Small cell lung cancer, Kidney, Uterus, Prostate, Bladder, Ovary, Colon, Sarcomas, Liposarcoma, myxoid, Synovial sarcoma, Rhabdomyosarcoma (alveolar), Extraskeletel myxoid chonodrosarcoma, Ewing's tumor; other include Testicular and ovarian dysgerminoma, Retinoblastoma, Wilms' tumor, Neuroblastoma, Malignant melanoma, 25 Mesothelioma, breast, skin, paccreas, cervix, prostate, and ovarian.
Thus, the present teachings can be used in disease detection. Following is a non-limiting embdodiment which relates to early cancer detection.
The present teachings provide for an immune system-based approach as a non-invasive diagnostic tool for early detection and staging of cancer.
Conventional
30 diagnostic approaches are mainly focused on the pathology of malignant tissues and on cancer specific antigens and genes. In contrary, the present teachings focus on normal versus abnormal responses of the immune system as a naturally available tool for early
31 detection and staging of cancer (as well as of other diseases). Thus, the present teachings provide for a high throughput functional physiological blood test by measurement of PBLs metabolic activity stimulation profiles (MASPs) of the immune system in response to a wide spectrum of stimulants/inhibitors at different concentrations (metabolites, nutrients, mitogens, natural and synthetic peptides, cytokines, hormones, vitamins, drugs, antibodies, neurotransmitters, cancer specific antigens and various disease-associated tissue-specific normal antigens (TNAs)). By conventional views of immunological responses relatively small effects are anticipated, even under "clonal expansion" of effector subpopulations of PBLs. However, in terms of "systems biology", a minor subgroup response may be amplified throughout network stimulation. It is suggested that the immune system combats cancer by its regular function in detecting abnormal high levels of TNAs. PBLs metabolic activity may also be used for diagnosis of advanced stages of cancer development. At the stage of local tumor, the effective killing response of the immune system is already limited, being unable to destroy the tumor tissue even though specific tumor infiltrating lymphocytes (TILs) are observed. Yet, in this stage such circulating T lymphocytes might be still responsible for killing separate circulating cancer cells. The shift from a local tumor to a metastatic-phase points on a complete specific failure of the immune system, and this transition might be measured by characteristic changes in the MA stimulation profiles.
Disease diagnosis made according to the present teachings is followed by substantiation of the screen results using gold standard methods. Once diagnosis is established either relying on the present teachings or substantiated using Gold standard methods, the subject is informed of the diagnosis and treated as needed.
It will be appreciated that the present teachings have a variety of applications pertaining to individually optimizing disease treatment, monitoring disease treatment in a subject, determining a treatment for a subject and identifying an agent capable of treating a disease associated with abnormal metabolic activity.
Thus, according to an aspect of the invention there is provided a method of disease treatment in a subject in need thereof, the method comprising:
(a) diagnosing a presence of the disease in the subject according to the method described above; and (b) treating the subject based on the diagnosis.
Disease diagnosis made according to the present teachings is followed by substantiation of the screen results using gold standard methods. Once diagnosis is established either relying on the present teachings or substantiated using Gold standard methods, the subject is informed of the diagnosis and treated as needed.
It will be appreciated that the present teachings have a variety of applications pertaining to individually optimizing disease treatment, monitoring disease treatment in a subject, determining a treatment for a subject and identifying an agent capable of treating a disease associated with abnormal metabolic activity.
Thus, according to an aspect of the invention there is provided a method of disease treatment in a subject in need thereof, the method comprising:
(a) diagnosing a presence of the disease in the subject according to the method described above; and (b) treating the subject based on the diagnosis.
32 As used herein the term "treating" refers to abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical or aesthetical symptoms of a condition or substantially preventing the appearance of clinical or aesthetical symptoms of a condition.
According to another aspect of the invention there is provided a method of individually optimizing disease treatment, the method comprising:
(a) contacting a biological sample of the subject which comprises a cell with at least one medicament;
(b) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in the metabolic activity of the cell towards that of a normal healthy cell sample examined under identical conditions is indicative of an efficacious medicament for the disease.
As used herein "individually optimizing treatment" refers to an ex vivo method of tailoring treatment regimen (e.g., type of medicament, dose).
As used herein a "medicament" refers to a formulation of a medicine, medicinal drug or medication, as interchangeably used herein. Examples of medicaments, include but are not limited to, chemotherapy, antibiotics, antiparasitic drugs, antiviral and the like.
As used herein, the term "contacting" refers to bringing the medicament into the vicinity of a cell under conditions such that the medicament contacts the cell membrane and if needed internalizes thereto. Thus, for example, the contacting should be effected under buffer conditions, at a temperature and time sufficient to allow the medicament to affect cell phenotype (e.g., cytotoxic or cytostatic effect). The contacting may be effected in vitro, ex vivo or in vivo. The contacting may be effected in a vessel which is also capable of detecting the product of the enzymatic reaction (i.e., in the electrochemical cell), such that the electrical signal is detected on-line.
Such vessels are
According to another aspect of the invention there is provided a method of individually optimizing disease treatment, the method comprising:
(a) contacting a biological sample of the subject which comprises a cell with at least one medicament;
(b) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in the metabolic activity of the cell towards that of a normal healthy cell sample examined under identical conditions is indicative of an efficacious medicament for the disease.
As used herein "individually optimizing treatment" refers to an ex vivo method of tailoring treatment regimen (e.g., type of medicament, dose).
As used herein a "medicament" refers to a formulation of a medicine, medicinal drug or medication, as interchangeably used herein. Examples of medicaments, include but are not limited to, chemotherapy, antibiotics, antiparasitic drugs, antiviral and the like.
As used herein, the term "contacting" refers to bringing the medicament into the vicinity of a cell under conditions such that the medicament contacts the cell membrane and if needed internalizes thereto. Thus, for example, the contacting should be effected under buffer conditions, at a temperature and time sufficient to allow the medicament to affect cell phenotype (e.g., cytotoxic or cytostatic effect). The contacting may be effected in vitro, ex vivo or in vivo. The contacting may be effected in a vessel which is also capable of detecting the product of the enzymatic reaction (i.e., in the electrochemical cell), such that the electrical signal is detected on-line.
Such vessels are
33 further described herein below. Alternatively, the contacting may be effected in a separate vessel from where the detection takes place such that it is possible to continuously withdraw samples at particular time points and place such samples within the electrochemical cells. Thus, the contacting may be effected in a test tube, flask, tissue culture, chip, array, plate, microplate, capillary, or the like. The cells may be placed on a vibrating plate following the addition of the substrate for continuous thorough mixing of the contents of the cells.
According to a specific embodiment, "a shift in the metabolic activity of the cell towards that of a normal healthy cell sample examined under identical conditions"
refers to at least a 10 % local or global (throughout the profile) shift preferably towards 100 % identity to the control normal healthy cell sample.
A shift beyond a predetermined threshold as will be determined by the skilled artisan is indicative of an efficacious treatment.
Likewise, there is provided a method of monitoring disease treatment in a subject, the method comprising:
(a) administering at least one medicament against the disease to the subject;
(b) retrieving a biological sample which comprises a cell of the subject following the administering;
(c) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in the metabolic activity of the cells towards that of a normal healthy cell sample examined under identical conditions is indicative of an efficacious treatment of the disease. For example, it is suggested that in the metastatic phase the MA profile might regress close to the normal profile.
Likewise, there is provided a method of identifying an agent capable of altering a metabolic activity of cells, the method comprising:
(a) subjecting cells to an agent;
According to a specific embodiment, "a shift in the metabolic activity of the cell towards that of a normal healthy cell sample examined under identical conditions"
refers to at least a 10 % local or global (throughout the profile) shift preferably towards 100 % identity to the control normal healthy cell sample.
A shift beyond a predetermined threshold as will be determined by the skilled artisan is indicative of an efficacious treatment.
Likewise, there is provided a method of monitoring disease treatment in a subject, the method comprising:
(a) administering at least one medicament against the disease to the subject;
(b) retrieving a biological sample which comprises a cell of the subject following the administering;
(c) independently measuring in an extracellular environment of the cell time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products and volatile soluble metabolic products;
and (iii) volatile soluble metabolic products;
wherein at least one of the time dependent acidification profiles is indicative of the metabolic activity of the cell and whereas a shift in the metabolic activity of the cells towards that of a normal healthy cell sample examined under identical conditions is indicative of an efficacious treatment of the disease. For example, it is suggested that in the metastatic phase the MA profile might regress close to the normal profile.
Likewise, there is provided a method of identifying an agent capable of altering a metabolic activity of cells, the method comprising:
(a) subjecting cells to an agent;
34 (b) measuring the metabolic activity of the cells following (a) and optionally prior to (a) according to the method of claim 1, wherein a shift in the acidification profiles is indicative of an agent capable of altering a metabolic activity of cells.
As used herein, the term "agent" refers to a test composition comprising a biological agent or a chemical agent Examples of biological agents that may be tested as potential modulators of metabolic activity according to the method of the present invention include, but are not limited to, nucleic acids, e.g., polynucleotides, ribozymcs, siRNA and antisense molecules (including without limitation RNA, DNA, RNA/DNA hybrids, peptide nucleic acids, and polynucleotide analogs having altered backbone structures or other chemical modifications); proteins, polypeptides (e.g. peptides), carbohydrates, lipids and "small molecule" drug candidates. "Small molecules" can be, for example, naturally occurring compounds (e.g., compounds derived from plant extracts, microbial broths, and the like) or synthetic organic or organometallic compounds having molecular weights of less than about 10,000 daltons, preferably less than about 5,000 daltons, and most preferably less than about 1,500 daltons.
According to a preferred embodiment of this aspect of the present invention the agents are anti-cancer, anti-viral or antibiotic agents.
Examples of conditions that may be tested as potential anti cancer agents according to the method of the present invention include, but are not limited to, radiation exposure (such as, gamma radiation, UV radiation, X-radiation).
It will be appreciated that the shift, as used herein, can be also a different level (e.g., higher level) of MA in same profile; a change in basal state, and/or a shift in the agent concentration that induces maximal MA effect.
Once an agent capable of altering a metabolic activity of cells has been identified along in accordance with the above teachings, the invention further comprises synthesizing the agent or purifying it from a natural source.
As used herein the term "about" refers to 10 %.
The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".
The term "consisting of means "including and limited to".
The term "consisting essentially of' means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
5 As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof Throughout this application, various embodiments of this invention may be 10 presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such 15 as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6.
This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited 20 numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and -ranging/ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
25 As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
30 It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.
Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual"
Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed.
(1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998);
methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531;
5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J.
E., ed.
(1994); "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed.
(1994);
Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton &
Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat.
Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517;
3,879,262;
3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219;
5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); -Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985);
"Transcription and Translation" Hames, B. D., and Higgins S. J., Eds. (1984); "Animal Cell Culture"
Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A
Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL
Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references arc provided throughout this document. The procedures therein arc believed to be well known in the art and are provided for the convenience of the reader.
All the information contained therein is incorporated herein by reference.
Experimental Procedures A. Blood Donors Requirement and Blood Collection by Medical Experts Blood samples were collected in Vacutubes 9m1 with EDTA (Greiner Bio-One 455036).
The study was approved by the institutional Review Boards at the Sheba Medical Center (Ramat Gan Israel) and the Israeli Ministry of Health, (Helsinki Approval number 7780-10-SMC).
B. Collection of Donor's Demographic and Clinical Information For the protection of confidentiality, all collected blood samples were labeled and immediately coded to be used in the database records and diagnostic analysis.
The MA test results were collected from 42 healthy donors and 25 cancer patients from 22 to 81 years old (Table 2). The healthy donors are a mixed population including treated cases of high blood pressure, high cholesterol levels, minor flu and inflammation.
Table 2 ¨ Clinical characteristics of cancer patients:
ac ¨ adencocarcinoma, idc ¨ invasive ductal carcinoma, gej ¨ gastroesphageal junction, NSCLC ¨ Non ¨ small ¨ cell lung carcinoma Tumor Stage Tumor Type Gender Age Patient Number 1 Breast idc Female 53 Breast idc Female 64 2 2 Breast idc Male 63 3 2 Breast idc Female 37 4 2 Breast idc Female 61 5 2 Breast idc Female 38 6 2 Breast idc Female 65 7 3 Breast idc Female 32 8 3 Breast idc Female 42 9 3 NSCLC ac Male 46 10 4 NSCLC ac Male 61 11 4 NSCLC ac Female 60 12 4 NSCLC ac Male 81 13 4 Colon ac Female 70 14 4 Colon Female 49 15 2 Colon ac Female 56 16 2 Rectum ac Female 52 17 4 Rectum ac Male 74 18 3 Gastric ac Male 47 19 4 Gastric gej Male 64 20 3 Pancreas Female 57 21 4 Pancreas Male 58 22 4 Prostate Male 77 23 1 Thyroid Female 54 24 2 Cervix Female 35 25 C. Blood Samples Transport Measures are taken to keep the viability of the blood cells at thermo-stated conditions (Thermo Electric cooling (down to 10'c -18 C) and gently shaking till the PBMCs separation.
D1. Peripheral Blood Mononuclear Cells (PBMCs) Separation Fresh peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque (UNI-SEP, Novamed) and gradient centrifugation. The pellet was resuspended in working solution (WS) (PBS with calcium and magnesium) including the fluorescent probe (HPTS) at a final concentration of 5X106 cells/ml.
D2. High Throughput Parallel Measurements of the MA test Each well in a black non-binding, low-volume 384 multi-well plate (Greiner Bio-One) was loaded with 10 ill of the PBMCs solution and 10 1 of working solution plus is HPTS including one of ten reagents in 8 increasing concentrations. Thus the final concentration of the probe in each well was 1 iuM, and the final concentration of the PBMCs was 2.5X106cells/m1 in 20 1 physiological working solution containing 10 mM
phosphate buffer around pH 7.3. Taking into account the average PBMCs concentration in adult peripheral blood a working concentration of 2.5X106 cells/ml was selected. This concentration of PBMCs is considered to ensure two aspects:
first, to get a reasonable signal¨ to¨noise ratio due to product accumulation during at least 1 hour, and second, to allow for intercellular interaction. The same protocol of 100 loading was carried out at least in triplicates, first on the PBMCs samples and then on the reagents, so as to accurately obtain the final 20 1 volume in the required concentration in each well. Furthermore, in each test two types of controls were included:
one including only the probe (1 ,t1\4), without cells and without the stimulants in 8 wells; the other one including only cells without a stimulant, basal state, in 8 wells.
The acidification process was monitored each 5 min during 1 hour of incubation at 37 C by a commercial fluorescence scanner (TECAN Infinite M200). First, the scanner monitored the acidification process without sealing ("OPEN" mode) during 30 min (6 cycles) and then, to avoid ventilation of CO2 and NH3 from each well, the multi-well plate was sealed hermetically (ThermalSeal RTTm, EXCEL Scientific, Inc.) ("CLOSE"
mode). Next, the acidification process was monitored again during 30 min (6 cycles). In order to increase the signal to noise ratio, the fluorescence intensities at 513nm were measured sequentially under excitation at 455nm and 403 nm per well.
D3. Type, Spectrum and Preparation of Reagents In each test, the metabolic activity profiles of PBMCs were monitored in the basal state and under the influence of the following ten reagents diluted in working solution in 8 different concentrations : PHA, CONA, PMA, LPS, MBP(28), MelanA, PSA(29), Glucose(24), L-glutamine and Rapamycin ( Strauss L, Czystowska M, Szajnik M, Mandapathil M, & Whiteside TL (2009) Differential responses of human regulatory T
cells (Treg) and effector T cells to rapamycin. PLoS One 4(6):e5994.) . The reagents selection was made by their relation to the immune system (TABLE 1, above, note, concentrations are not limited to those in the table, concentration = 0 to non toxic dose).
It should be mentioned that other reagents are under calibration, for example:
(hormones such as estradiol, cancer specific antigens such as carcinoembryonic antigen (CEA), cytokines and chemokines such as il-2, vitamins, hormones, drugs, antibodies of the immune system, neurotransmitters, different cancer peptides and specific viruses or their fragments such as human papilomavirus (HPV) (data not shown).
D4.Ratiometric measurement of the pH sensitive fluorescent probe and WS
acidity calibration The probe used in this test is 8-Hydroxypyrene-1,3,6-trisulfonic acid (HPTS).
HPTS is a cost effective, non-toxic, highly water-soluble membrane-impermeant 5 pH indicator with a pKa of ¨ 7.3 in aqueous buffers. HPTS exhibits a pH-dependent absorption shift, allowing ratiometric pH measurements as function of the ratio between the fluorescence intensities at 513nm that are measured sequentially under excitation at 455nm and 403 nm. This method is essential for the present sensitive measurements of minor pH changes in the physiological range around pH 7.
10 In order to quantify the sensitivity of the probe, a stock solution of HPTS was diluted in water to a concentration of 100 M and then to a final concentration of 1 114 and 10 M. WS acidity calibration was made for two buffer concentrations: the WS
(10mM phosphate buffer) and the WS diluted 5 times by saline (2mM phosphate buffer) (Figures 3A-D, Figures 4A-B).
15 The final calibration curve used in the MA test was carried out by pH-glass electrode measurements of sequential titration of WS (containing 2 M HPTS).
The pH
measurements and the fluorescence measurements of the titrated samples are carried out at 37 C. The samples are loaded into a multi-well plate and the fluorescence intensities under EX403nm and EX455nm are measured at 513nm using the fluorescence scanner.
20 For the "OPEN" and "CLOSE" states, a calibration polynomial curve is constructed (Figures 3C-D), allowing to measure pH values and accumulated acidification equivalents as a function of the ratio between the fluorescence intensities measured at 513nm, under excitations at 403nm and 455 nm, respectively.
25 The equations obtained were used for analysis of every new donor (Table 3, below).
TABLE 3 ¨ The equations obtained from the final calibration curves:
X = Fluorescence intensity at Ex. 403nm / Fluorescence Intensity at Ex. 455nrn pH HCI (iunol/m1) Open Y=0.011X4-0.136X3+0.641X2-1.528X+8.266 Y=0.006X4+0.129X3-0.982X2+3.971X-2.276 Close Y=0.013X4-0.164X3+0.747X2-1.723X+8.415 Y=-0.006X4+0.131X3-1.011X2+4.168X-2.581 E. Data Analysis Computation, analysis and data mining ( Nisbet R, IV JE, & Miner G (2009) Handbook of Statistical Analysis and Data Mining Applications) were done by using the following Statistical Package; EXCEL 2007, OriginPro 8, SAS Edition 9.2, PASW
Modular client 13.0 (formally called Clementine, part of SPSS). Results in Figures 6A-C ¨ 8A-D, 13 are expressed as means standard error of the mean. Statistical significance between healthy and cancer patients for variant models was calculated using chi-square. Results were considered statistically different when p<0.05.
Donor's Data Analysis (Summarized in Flowchart of the MA test Framework -Figure 12) Data Preparation ¨
Step 0: Processing and Normalizing Donor Data The raw data of each record (donor) was processed to yield the results in terms of the acidification rate of metabolic activity in units of pmole H+/
1/hour/2500PBMCs.
Pre Processing - Step la: Probe Analysis and Donor Data Normalization In order to improve the signal to noise ratio, analysis of probe was done by performing k-means cluster analysis on all observations (n=730 ) collected from all donors (Figures 5A-D). These processed results were normalized by subtracting the donor values from the HPTS mean values after removal of probe's outliers (not more than 5 % of the results were removed).
Pre Processing - Step lb: Excluded Outliers in Donor's Data Normalizing "OPEN" and "CLOSE" values by the mean values of "OPEN" and "CLOSE" for each combination of donor, dose and stimulant. Observations with standard score >11.71were discarded (1.77 % of the results).
Data Preparation - Step lc: Representation of Donor Metabolic Activity Results After removing the outliers in each donor, average values of "OPEN" and "CLOSE" were calculated separately for each donor based on the average of at least triplicate results for each dose and each reagent per donor. These results would be used later as representing donor metabolic activity for each reagent and dose. The results were planted in 2D graphs and 3D graphs and would be updated automatically with every donor.
Searching for Classification Model - Step 2: Data Mining Algorithm Since most of the studied cancer patients were older than 39 and in order to minimize as much as possible the effect of age, two cohorts of blood donors including males and females were tested and analyzed. The first cohort includes donors with the age above 40 (n=42 (21 healthy donors and 21 cancer patients)) and the second cohort include the full set of donors (n=67 (42 healthy donors and 25 cancer patients)) from 22-81 years old. For Classification of the step 3 results a set of algorithms from a family of Decision Trees/Rule Induction (C5, CART, CHAID, ASSOCIATION RULE) and log linear model (Logistic Regression) was used. Exploratory analysis methods were used to investigate hidden and unhidden connections in the data.
Model Evaluation - Step 3: Model Building and Classification For classifying the donors into healthy and cancer patients, a set from the family of ten different models including data mining, machine learning and statistical modeling were used applying SAS 9.3 and Clementine software (V13.0). In order to evaluate and compare the performance of the models it was decided to use the graphical method which is based on the cumulative gain charts produce by Clementine software (V13.0) (Figures 9A-D).
Predictive Modeling - Step4: Evaluation Using a Validation Set of 30% of Blood's Donors Data as described in step 3 was randomly partitioned into two groups of "Training" and "Testing" using the Clementine software (V13.0). The "Training set" are used to build the data mining model and includes 70% of the donors. The remaining 30 % of the donors will be used to evaluate the classification result on the "Testing" set using the models that were generated in the Training set (Figures 10A-D).
The whole data analysis process is summarized in the Flowchart of the MA test protocol and analysis Framework (Figure 12).
Example 2 MA test design and characteristics Fresh peripheral blood mononuclear cells (hPBMCs) were isolated by Ficoll-Paque and gradient centrifugation from 42 healthy donors and 25 cancer patients (TABLE 2, above). For each blood sample, a 384 multi-well plate was loaded with 200 containing physiological working solution at 10mM buffer around pH 7.3, hPBMCs at final concentration of ¨2.5X106 cells/ml, 1 iuM pH probe (HPTS), and one of ten stimulating reagents in eight increasing concentrations (TABLE 3, above). The MA test is carried out using a commercial fluorescence scanner. The extracellular acidity kinetic profiles were measured either under air-open ("OPEN") or hermetically-sealed closed ("CLOSE") states. Both records enable to measure the real-time accumulations of 'soluble' versus 'volatile' metabolic products (lactic acid versus CO2 and NH3), thereby differentiating between oxidative phosphorylation, anaerobic glycolysis and aerobic glycolysis ("Warburg effect")( Vander Heiden MG, Cantley LC, & Thompson CB
(2009) Understanding the Warburg effect: the metabolic requirements of cell .. proliferation. Science 324(5930):1029-1033). The MA rate profiles were calculated and examined for cancer diagnosis by dynamic online analysis, including data mining tools (Figure 12).
Example 3 Ratiometric Fluorescence Extracellular pH Measurement and Acidity Calibration The non-toxic, membrane-impermeant, ratiometric molecular pH-probe used in the present MA test is 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS)( Hakonen A &
Hulth S (2008) A high-precision ratiometric fluorosensor for pH: implementing time-dependent non-linear calibration protocols for drift compensation. Anal Chim Acta .. 606(1):63-71; Han J & Burgess K (Fluorescent indicators for intracellular pH. Chem Rev 110(5):2709-2728) with a pKa. of ¨ 7.3 in aqueous physiological buffers.
It is well-known by its low-toxicity, from intracellular pH measurements in many cell types, even under overnight incubation at 2 mM (Overly CC, Lee KB, Berthiaume E, &
Hollenbeck PJ (1995) Quantitative measurement of intraorganelle pH in the endosomal-lysosomal pathway in neurons by using ratiometric imaging with pyranine. Proc Nail Acad Sci U S
A 92(8):3156-3160). Here, HPTS is rather used for extracellular pH
measurements, at a low 1 M concentration, which further ensure its non-toxicity. Calibration polynomial curves were constructed for the "OPEN" and "CLOSE" states, (Figures 3A-D), allowing to measure pH values and accumulated acidification equivalents as a function of the ratio between the fluorescence intensities measured at 513 nm, under excitations at 403 nm and 455 nm, respectively. The acidification calibration curves were obtained for the working solution (WS) and for the WS diluted 5 times with saline (10m/Vi and 2mM
phosphate buffer, respectively) (Figures 3A-D). As expected, this figure verifies that the 10mM buffer capacity allows for about five times of the acidification values compared to that of the 2mM buffer capacity, within the same range of pH changes. These results indicate on the proper sensitivity to acidification within the physiological pH range 6.5-7.5. Further results indicate that the measurement method is independent of the fluorescent probe concentration between 1-10 M. The system is sensitive enough to provide a high signal-to-noise ratio when the extracellular final concentration of HPTS
is only 1 i..11\4 (Figures 4A-B).
The equations obtained from the final calibration curves (Figures 3A-D, TABLE
4) were used for quantitative analysis of the significant measured changes in PBMCs metabolic activity records from all 67 donors (42 healthy and 25 cancer patients).
Example 4 Improving Signal-to-Noise Ratio by Dynamic K-MEANS Cluster Analysis of HPTS Background Aiming at dynamic clinical evaluation of the MA test results, a reliable method was developed that compares any MA test for each donor to previous tests with respect to the reference rate values of the HPTS signal (n=730 observations). By this data collection it is possible to improve the signal to noise ratio of the MA test by filtering exceptional reference results. For that purpose k-means cluster analysis( Nisbet R, IV
JE, & Miner G (2009) Handbook of Statistical Analysis and Data Mining Applications) was applied for the accumulating normalized rate values of the HPTS probe. In each test at least eight control wells were examined, containing 1 tM HPTS in the working solution, without cells and without stimulants. Each value was normalized taking into account the accumulated observations using a standard score. Figure 5A
presents the distribution of the standard scores for "OPEN" and "CLOSE" rate values of all MA
tests. By k-means cluster analysi,s 26 clusters were obtained (Figure 5B), where each observation belongs to the cluster with the nearest mean. The results reported in Figure 5D evaluate the stable performance of the probe. Out of all HPTS reference results (n=730) only 5 clusters (4.66%) were discarded. The rest 21 clusters (95.34%) were finally considered to compose the normal reference range. The mean values of "OPEN"
and mean values of "CLOSE" states were recalculated for each donor. The k-means cluster analysis allows us to extract the probe background rate signal from the cellular data and thereby get the actual rate values of the ongoing MA test results.
Example 5 5 MA Profiles of Control Samples: (i) at Increasing Reagents Concentrations in the Absence of Cells; (ii) with Cells but no Reagents (i) Control experiments in the absence of cells verified that the acidification profiles obtained in the presence of cells indeed measure the rate of cellular metabolic activity. Thus, no acidification was obtained under the same protocol applied in the 10 presence of probe, buffer and each reagent at increasing concentration, but with no cells (e.g glucose (Figure 6A) and PSA (Figure8A)), compared to clear acidification changes in samples with cells. The same control results were obtained for all reagents. (ii) A
basal level of acidification in the presence of cells was measured in the absence of any reagents including glucose. Generally, this basal level increased with increasing glucose 15 concentrations, verifying clear aspects of cellular metabolic activity (Figures 6B-C).
Moreover the MA profiles at the basal state already revealed the general trend of a diagnostic shift from dominant oxidative phosphorylation preferred by the naive hPBMCs of 69 % of the healthy donors, to dominant aerobic glycolysis ("Warburg effect") preferred by activated hPBMCs of 60 % of various cancer patients.
These 20 results emphasize the potential of the MA-test as a diagnostic tool already at the basal state which is the closer scenario to the in vivo state. However the basal state alone is not enough for clear cut differentiation between healthy and cancer patients (Chi-Square, p=0.45). By the present data mining of all the MA-test profiles in response to network of reagents reagents (Figures 10A-D), it can significantly point on 95.24% of 25 .. healthy donors and 88 % of cancer patients (age>4 Chi-Square, p<0.0001) and on 90.48% of healthy donors and and 95.24% of cancer patients (22<age>81, Chi -Square, p<0.0001).
Example 6 Comparison of MA Profiles at Increasing Glucose Concentration, Obtained for Typical Healthy Donor and Breast Cancer Patient First, MA profiles of healthy donors (Figures 6B, 7A) are strikingly similar, despite the significant difference in age (45 (Figure 6B) vs. 69 (Figure 7A)) and gender.
Second, the results in Figure 6A-C reveal significant MA profiles differences between two donors that represent a typical healthy donor and a breast in situ cancer patient (at stage 2, and before any treatment). Additionally, in preliminary experiments where the MA test was applied on few cases of auto-immune diseases and additional non-cancer related infectious diseases, different metabolic activity profiles compared to those obtained for healthy individuals and cancer patients (data not shown) were already revealed. These differences point on 3 clinical diagnostic indexes of cancer (Figures 4A-C). Index 1: MA rate "OPEN" > MA rate "CLOSE" in the basal state (cells in working solution without reagent). Index 2: MA rate "OPEN" > MA rate "CLOSE"
for all glucose concentrations. Index 3: MA rate "OPEN" of cancer > MA rate" OPEN"
of healthy and MA rate "CLOSE" of cancer > MA rate "CLOSE" of healthy. Thus, higher values of oxidative phosphorylation are obtained in fresh PBMCs of healthy samples compared to higher values of aerobic glycolysis in fresh PBMCs of cancer samples. As mentioned in the introduction (Vander Heiden MG, Cantley LC, & Thompson CB
(2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029-1033.; Fox CJ, Hammerman PS, & Thompson CB (2005) Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 5(11):844-852; Michalek RD & Rathmell JC (The metabolic life and times of a T-cell. Immunol Rev 236:190-202) these results presumably indicate on in vivo development of the "Warburg Effect" in activated hPBMCs of cancer patients.
More detailed observations on the MA test results obtained for cancer patients (Figure 6C and Figures 7B-D) reveal that in the "CLOSE" state the total acidification rate is less than in "OPEN" state. These results indicate on a volatile basic product which is responsible for partial titration of the acidity due to lactic acid and CO2. This titration might be physiologically required upon the metabolic switch to the non-volatile lactic acid production. This role is related to ammonia (NH3), which is one of the primary products of protein catabolism and metabolic pathways of purines and pyrimidines. In the instant measurement system, as in-vivo, vital cells must maintain the cytoplasm in a constant pH of about 7.2 ¨ 7.4 by simultaneous metabolic secretion of both the acidic and basic products as described below.
CO2+ H20 TJ2CO3 H+TJCO3-NH3 + H20 NH4' +OH-S
It should be mentioned that in the 3 indexes analysis, different combinations were found at different stages of various cancers (e.g colon, breast, lung, and pancreas) (TABLE 2, above). Therefore, by these variations it is believed that the examination of enough data collection and follow-up of individual donors will provide reliable and more informative diagnostic profiles, as demonstrated in the following case study (Figures 7A-D).
Example 7 Case Study Follow-Up of MA Profiles, at Increasing Glucose Concentration, Obtained for a 65 Years Old Female with Breast Cancer With respect to the preliminary MA-test measurements, it should be mentioned that one case of thyroid cancer and one of breast cancer were diagnosed by the present test before the physicians. The breast cancer case was followed up along two years as evidence for the sensitive informative capability of the MA test compared to typical classification of staging and treatments. This is the first report of a 2 years follow-up study of a female donor, clinically diagnosed to have breast cancer one year after the MA test had revealed a state of cancer. For comparison, MA profiles are presented of a typical healthy 69 years old male (Figure 7A). MA profiles of the cancer patient on TIME ZERO, the patient clinically diagnosed as having breast cancer one year after the MA test had revealed a state of cancer (I.E.,) (Figure 7B). The three cancer diagnostic indexes indicate on a shift from oxidative phosphorylation observed in the healthy profiles (Figure 7A) to aerobic glycolysis observed in the cancer case profiles (Figures 7B). Namely, positive values for "CLOSE-OPEN" of healthy profiles (Figure 7A) and negative values for "CLOSE-OPEN" obtained for the cancer profiles (Figure 7B).
The next MA test obtained for this study case was carried out 10.5 months later (Figure 7C), just after routine mammography diagnosis of breast idc cancer at stage 2. It should be emphasized that at that time the patient didn't report any physiological or palpable symptoms.
From this point on, a follow-up MA test was carried out every 3 weeks. One month later, a tumor surgical removal was carried out. Another month later a chemotherapy treatment was given every 3 weeks. Each MA test was carried out after about 20 days of each treatment, and 2 days before the next treatment. The last MA test presented here (Figure 7D) was carried out after the third chemotherapy treatment, namely about 2 months after beginning the chemotherapy protocol (time =
(+)14.5 months). It should be noticed that according to the three indexes of the MA
test, this last test already reveals MA profiles (Figure 7D) characteristic of healthy donor (Figure 7A). Obviously the MA test verifies a positive trend along with the ongoing treatment.
By these results, it will be important to use the MA test in a follow-up procedure in order to reveal the trend behavior of the MA test profile compared to clinical evaluation during and far behind completion of the chemotherapy treatment. This follow-up program is made available by the clinically-oriented MA test which is simple, non-invasive and non-expensive.
Example 8 Comparison of MA Profiles, at Increasing PSA Concentrations, Obtained for Typical Healthy, Breast Cancer Patient and Breast Cancer-Recovered Donor Up till now the MA profiles were examined under increasing concentration of glucose that were clearly found as a general non-specific clinical tool for cancer diagnosis. In order to gain more specific cancer classification, the MA test explores simultaneously various reagents (TABLE 3) such as tissue-specific normal antigens (e.g PSA, MelanA).
Prostate-specific antigen (PSA) is a normal protein produced by cells of the prostate gland. The PSA is a cancer-associated tissue-specific normal antigen.
This peptide is recognized by cytotoxic T lymphocytes (CTL). Increasing level in human peripheral blood of this peptide is clinically used as a biochemical diagnostic marker of prostate cancer for men ( Greene KL, et al. (2009) Prostate specific antigen best practice statement: 2009 update. J Urol 182(5):2232-2241). But, low levels of PSA are released into the female circulation and up to date the clinical PSA blood test is not used as a diagnostic factor for women. However, numerous studies have shown that PSA is not prostate specific, but is present in some female hormonally regulated tissues, principally the breast and its secretions (Black MH & Diamandis EP (2000) The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast.
Breast Cancer Res Treat 59(1):1-14; Black MH, et al. (2000) Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res 6(2):467-473). In women, PSA is found in female ejaculate at concentration roughly equal to that found in male semen (Wimpissinger F, Stifter K, Grin W, & Stackl W
(2007) The female prostate revisited: perineal ultrasound and biochemical studies of female ejaculate. .1 Sex Med 4(5):1388-1393; discussion 1393). Three MA
profiles are presented in Figures 8A-D, a typical healthy woman (Figure 8B), woman with breast cancer idc in stage 2 and before treatment (Figure 8C), and female recovered from stage 2 breast cancer 18 years ago (Figure 8D). Tissue-specific stimulants e.g PSA
are observed to induce marked peaks at optimal concentrations in the MA-test profiles of cancer patients (Figures 8A-D). Such profiles are considered to reflect disease-specific receptor-mediated stimulation and thereby enable to detect specific tumors (e.g breast by PSA, melanoma by melanA stimulation). The results reveal several significant issues. First, the MA profile of healthy women indicate a higher level of oxidative phosphorylation as already reported above for glucose MA profiles (Figures 6A-C and Figures 7A-D). Second, Figure 8C point on a PBMCs response to PSA by a female with breast idc cancer in stage 2, before any treatment. This profile expresses high metabolic activity rate at the "OPEN" state, already from the basal state. These profiles indicate a high level of aerobic glycolysis, a phenomena which is similar to activated T-cells as obtained for the glucose MA profiles of cancer patients. Another unique profile of the MA test was revealed for 50 years old female recovered from breast cancer 18 years ago (Figure 8D). This profile for PSA stimulation behaves more like that of healthy donor (Figure 8B). Furthermore it reveals higher MA rate in "close" state that indicates a dominant oxidiative phosphorylation pathway at increasing PSA concentrations more than the characteristic profile for healthy donor (figure 8B). This profile maybe related to an increased population of anti-breast cancer memory cells. This relation is consistent with the observation that following pathogen clearance, surviving effector cells differentiate into long-lived memory cells and revert to an oxidative metabolic state ( Michalek RD & Rathmell JC (The metabolic life and times of a T-cell.
Immunol Rev 236:190-202).
Example 9 5 Model Building and Classification Evaluation for the MA test Results by Data Mining Tools Multiple MA profiles including a huge number of MA rate values are obtained for each donor. In order to develop a dynamic clinical analysis that is updated with every new donor, and to extract patterns from this large data base, a computer 10 programming using Data Mining tools were developed, which combine methods from statistics and artificial intelligence with database management (Nisbet R, IV
JE, &
Miner G (2009) Handbook of Statistical Analysis and Data Mining Applications).
Two selected cohorts of the MA test results, for both males and females, were analyzed.
Since most of the cancer patients studied were older than 39, and in order to minimize 15 .. as much as possible the effect of age, this analysis focused on a subgroup of 42 donors with the age above 40 (21 healthy donors and 21 cancer patients). In the second cohort the full set of donors were used from 22-81 years old (n=67, 42 healthy donors and 25 cancer patients). In order to classify the donors into healthy and cancer individuals, a set from the family of ten different models including data mining, machine learning and 20 .. statistical modeling, applying SAS 9.3 and Clementine software (V13.0) were used. Out of these ten models, only four were able to classify with the highest accuracy both healthy donors and cancer patients. Out of the four models, three were from the family of decision tree (CHAID, C5, C&R TREE) and one of log linear model (Logistic Regression). All four are presented in Figures 9A-D. The decision-tree models are 25 considered to be the best classifiers, since these models don't assume any distributions or any assumptions. The fourth model that didn't perform as good as the others is the Logistic regression. This kind of model is best suited when input data behaves exactly as the assumptions of the model, such as assumptions about distribution and independency. In order to minimize as much as possible over-fitting the Logistic 30 Regression model was ran using the forward selection method, which enabled us to order the variables by importance and minimize as much as possible the number of selected variables. Since each model shows different variables/features as a function of different antigens, each at different concentrations, it may be possible to combine the presenet predictions as a function of more than one model. When examining the influence of the overall reagents in different concentrations on the accuracy of the models, the maximal number of variables that were chosen was not more than five (Figures 9A,9C), which is recommended when sample size is not sufficient to minimize as much as possible the over-fitting. By these initial results it was possible to order the ten reagents as predictors by their frequency of appearance in the various models (Figures 9A, 9C). Currently it is possible to pinpoint glucose, MBP, Rapamycin, PSA
and PMA as pivotal players in the MA test and in relation to the immune system (TABLE 3). The immunological relevance of the other five reagents (TABLE 3) is still revealed by the occasional models' choice. In order to evaluate and compare the performance of the models, the present inventors decided to use the graphical method which is based on the cumulative gain charts produced by Clementine software (V13.0).
The gain chart (Figures 9B, D) contains two built-in curves, the random curve (black line) and the best fit curve (sky blue line). All models fall between these two curves. In this method, greater area between a given curve and the random curve (black curve) indicate on a better model. Blood's donors modeling and classification results point on models with performance similar to the best model (Figures 9A-D).
Example 10 Evaluating Model Results of the MA Test Using a Validation Set of 30% of Blood's Donors A partition process described below enables to combine and compare models so as to gain more confidence in the accuracy of the MA test results, to evaluate the robust level of the models, and to minimize over-fitting due to small sampling (n=67 blood sample donations). The data as described in Figures 9A-D was randomly partitioned into two groups of "Training" and "Testing" using the Clementine software V13.0 9 (Figures 10A-D). The validation set included 70% of the donors for both cohorts. First cohort includes 42 donors with the age above 40 (Figures 10A-B) and the second cohort includes full set of donors (n=67) from 22-81 years old (Figures 1 C-D). The first 70%
of the donors are described on the "Training set". The "Training set" is used to build the data mining model as described in Figures 9A-D. The remaining 30% of the donors ("Testing set") enable to evaluate the classification result on the "Testing set" using the models that were generated in the "Training set" (CHAID , Logistic, C5, C&R
tree) (Figures 10A. C). The "Training" and "Testing" sets enable to evaluate model results with greater confidence and eliminate as much as possible the over fitting challenge. In both cohorts it was found that C5 model gave more robust results where the "Testing"
set curve was similar to the "Training" set (Figures 10B, D). C5 model was the best performer in the "Testing" set while in the "Training" set C&R tree was the best performer. By these results it is possible to pinpoint glucose, MBP, PMA, PHA, CONA
and L-Glutamine as pivotal players in the MA test and in relation to the immune system (TABLE 3). Similarly to the best models in Figures 9A-D, these results (Figures 10A-D) support the results of Figures 9A-D.
A physiological approach to cancer diagnosis is presented here by relying on the preliminary experimental results of the metabolic activity profiles obtained for hPBMCs of healthy and cancer patients. By this approach the present inventors have designed a simple high-throughput, short-time and cost effective optical method of the MA
test using fresh hPBMCs extracted from 10-20 ml blood sample. Striking differences of hPBMCs fingerprinting MA patterns were revealed by preliminary examination of two clinical groups, 42 healthy individuals and 25 cancer patients. While the hPBMCs MA
profiles of the 42 healthy donors indicate a similar preferred oxidative phosphorylation pathway, the hPBMCs of the 25 cancer patients have a wide spectrum of MA
profiles, preferring aerobic glycolysis in correlation with staging and treatment. One case of thyroid cancer and one of breast cancer were diagnosed by the MA test before the physicians. This breast cancer case was followed up by the MA test along two years as evidence for the sensitive informative capability of the MA test with respect to typical classification of staging and treatments.
The results reported here, encourage further exploration of the metabolic activity of hPBMCs as a mirror image of tumor development (Figures 9A-D). Preliminary results clearly reflect common, as well as specific, features of hPBMCs metabolic pathways under cancer-induced evasion of the immune system during the pathological development of different tumors.
A tissue-specific cancer diagnostic index may be provided by the MA-test profiles at early and late stages of local tumor development by increase (or decrease) of the MA rates relative to those observed for healthy donors. Certain optimal concentrations of tissue-specific antigens should be sought for the MA-test profiles.
Such tissue-specific diagnostic profiles are expected also at early stages of tumor development, when initial aggressive antitumor immune response is anticipated.
By this approach, it can be postulated that in the healthy state, the immune system is responsible for ongoing early detection and effective eradication of cancer cells in the context of its normal function, by scrutinizing all body tissues. The immune system is therefore proposed to detect and eliminate cancer cells by their excessive expression of tissue-specific normal antigens. Therefore, in homeostasis, a balanced level of an effective immune response should be well controlled, so as to avoid either a decline of effective cytolytic function, or such aggressive activity against self normal cells that might rather precipitate autoimmune diseases. Thus, unfortunately, in advanced stages of cancer the immune system is known to be suppressed, or even educated to support cancer development by tumor-infiltrating lymphocytes, which might be a part of the circulating hPBMCs. In this view, it is further anticipated that at the lethal metastatic phase of cancer the MA-test profiles of hPBMCs might shift back to reflect an apparent healthy state due to tissue-specific immunity tolerance and anergy, unlike in chronic inflamation. This apparent healthy state may be exposed by exhaustion of the relevant tissue-specific antigen stimulation.
Example 11 PBMCs Metabolic-Activity Profiles for increasing glucose concentration obtained for typical healthy, cancer and autoimmune lupus donors In homeostasis, the immune system activity should be well controlled;
hyperactivity is associated with autoimmune diseases while cancer development is probably related to hypoactivity of the immune system.
Significantly different MA Profiles were obtained for increasing glucose concentration obtained for typical healthy, cancer, and autoimmune lupus donors (Figure 13).
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
Citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
REFERENCES
(other references are listed throughout the application) 1. Bassani-Sternberg, M. et al. Feature Article: Soluble plasma HLA
peptidome as a potential source for cancer biomarkers. Proc Nail Acad Sci U SA.
2. Hayden, E. C. Personalized cancer therapy gets closer. Nature 458, 131-2 (2009).
3. Kawakami, Y. et al. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95, 784-91 (2004).
4. Robins, H. S. et al. Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med 2, 47ra64 (2010).
5. Early warnings. Nature 458, 679 (2009).
6. Sawyers, C. L. The cancer biomarker problem. Nature 452, 548-52 (2008).
7. Luebeck, E. G. Cancer: Genomic evolution of metastasis. Nature 467, 1053-5.
8. Rosenberg, S. A. & Dudley, M. E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21, 233-40 (2009).
9. Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8, 299-308 (2008).
10. Terme, M., Ullrich, E., Dclahaye, N. F., Chaput, N. & Zitvogcl, L.
Natural killer cell-directed therapies: moving from unexpected results to successful strategies.
Nat Immunol 9, 486-94 (2008).
11. An autoimmune-mediated strategy for prophylactic breast cancer vaccination.
Womens Health (Load Engl) 6, 493.
12. Alexander-Miller, M. A. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res 31, 13-24 (2005).
13. Michalek, R. D. & Rathmell, J. C. The metabolic life and times of a T-cell.
Immunol Rev 236, 190-202.
14. Maciver, N. J. et al. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol 84, 949-57 (2008).
15. Zhang, Q. Y. et al. Myelin-basic protein-reactive specific CD4+ and CD8+ NK
lymphocytes induce morphological changes in neuronal cell bodies and myelin sheaths: implications for multiple sclerosis. Arch Med Res 39, 45-51(2008).
16. Narita, D., Cimpean, A. M., Anghel, A. & Raica, M. Prostate-specific antigen value as a marker in breast cancer. Neoplasma 53, 161-7 (2006).
17. Bromley, S. K., Mempel, T. R. & Luster, A. D. Orchestrating the orchestrators:
chemokines in control of T cell traffic. Nat Immunol 9, 970-80 (2008).
18. Kaelin, W. G., Jr. & Thompson, C. B. Q&A: Cancer: clues from cell metabolism. Nature 465, 562-4.
19. Fox, C. J., Hammerman, P. S. & Thompson, C. B. Fuel feeds function:
energy metabolism and the T-cell response. Nat Rev Immunol 5, 844-52 (2005).
20. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-33 (2009).
21. Nisbet, R., IV, J. E. & Miner, G. Handbook of Statistical Analysis and Data Mining Applications (ed. Material, C.) (2009).
22. Patolsky, F. et al. Electrical detection of single viruses. Proc Nail Acad Sci US
A 101, 14017-22 (2004).
23. Zheng, G., Patolsky, F., Cui, Y., Wang, W. U. & Lieber, C. M.
Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol 23, 1294-301 (2005).
24. Hakonen, A. & Hulth, S. A high-precision ratiometric fluorosensor for pH:
implementing time-dependent non- linear calibration protocols for drift compensation. Anal Chim Ada 606, 63-71 (2008).
As used herein, the term "agent" refers to a test composition comprising a biological agent or a chemical agent Examples of biological agents that may be tested as potential modulators of metabolic activity according to the method of the present invention include, but are not limited to, nucleic acids, e.g., polynucleotides, ribozymcs, siRNA and antisense molecules (including without limitation RNA, DNA, RNA/DNA hybrids, peptide nucleic acids, and polynucleotide analogs having altered backbone structures or other chemical modifications); proteins, polypeptides (e.g. peptides), carbohydrates, lipids and "small molecule" drug candidates. "Small molecules" can be, for example, naturally occurring compounds (e.g., compounds derived from plant extracts, microbial broths, and the like) or synthetic organic or organometallic compounds having molecular weights of less than about 10,000 daltons, preferably less than about 5,000 daltons, and most preferably less than about 1,500 daltons.
According to a preferred embodiment of this aspect of the present invention the agents are anti-cancer, anti-viral or antibiotic agents.
Examples of conditions that may be tested as potential anti cancer agents according to the method of the present invention include, but are not limited to, radiation exposure (such as, gamma radiation, UV radiation, X-radiation).
It will be appreciated that the shift, as used herein, can be also a different level (e.g., higher level) of MA in same profile; a change in basal state, and/or a shift in the agent concentration that induces maximal MA effect.
Once an agent capable of altering a metabolic activity of cells has been identified along in accordance with the above teachings, the invention further comprises synthesizing the agent or purifying it from a natural source.
As used herein the term "about" refers to 10 %.
The terms "comprises", "comprising", "includes", "including", "having" and their conjugates mean "including but not limited to".
The term "consisting of means "including and limited to".
The term "consisting essentially of' means that the composition, method or structure may include additional ingredients, steps and/or parts, but only if the additional ingredients, steps and/or parts do not materially alter the basic and novel characteristics of the claimed composition, method or structure.
5 As used herein, the singular form "a", "an" and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" may include a plurality of compounds, including mixtures thereof Throughout this application, various embodiments of this invention may be 10 presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the invention. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such 15 as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individual numbers within that range, for example, 1, 2, 3, 4, 5, and 6.
This applies regardless of the breadth of the range.
Whenever a numerical range is indicated herein, it is meant to include any cited 20 numeral (fractional or integral) within the indicated range. The phrases "ranging/ranges between" a first indicate number and a second indicate number and -ranging/ranges from" a first indicate number "to" a second indicate number are used herein interchangeably and are meant to include the first and second indicated numbers and all the fractional and integral numerals therebetween.
25 As used herein the term "method" refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
30 It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination or as suitable in any other described embodiment of the invention. Certain features described in the context of various embodiments are not to be considered essential features of those embodiments, unless the embodiment is inoperative without those elements.
Various embodiments and aspects of the present invention as delineated hereinabove and as claimed in the claims section below find experimental support in the following examples.
EXAMPLES
Reference is now made to the following examples, which together with the above descriptions illustrate some embodiments of the invention in a non limiting fashion.
Generally, the nomenclature used herein and the laboratory procedures utilized in the present invention include molecular, biochemical, microbiological and recombinant DNA techniques. Such techniques are thoroughly explained in the literature. See, for example, "Molecular Cloning: A laboratory Manual"
Sambrook et al., (1989); "Current Protocols in Molecular Biology" Volumes I-III Ausubel, R. M., ed.
(1994); Ausubel et al., "Current Protocols in Molecular Biology", John Wiley and Sons, Baltimore, Maryland (1989); Perbal, "A Practical Guide to Molecular Cloning", John Wiley & Sons, New York (1988); Watson et al., "Recombinant DNA", Scientific American Books, New York; Birren et al. (eds) "Genome Analysis: A Laboratory Manual Series", Vols. 1-4, Cold Spring Harbor Laboratory Press, New York (1998);
methodologies as set forth in U.S. Pat. Nos. 4,666,828; 4,683,202; 4,801,531;
5,192,659 and 5,272,057; "Cell Biology: A Laboratory Handbook", Volumes I-III Cellis, J.
E., ed.
(1994); "Current Protocols in Immunology" Volumes I-III Coligan J. E., ed.
(1994);
Stites et al. (eds), "Basic and Clinical Immunology" (8th Edition), Appleton &
Lange, Norwalk, CT (1994); Mishell and Shiigi (eds), "Selected Methods in Cellular Immunology", W. H. Freeman and Co., New York (1980); available immunoassays are extensively described in the patent and scientific literature, see, for example, U.S. Pat.
Nos. 3,791,932; 3,839,153; 3,850,752; 3,850,578; 3,853,987; 3,867,517;
3,879,262;
3,901,654; 3,935,074; 3,984,533; 3,996,345; 4,034,074; 4,098,876; 4,879,219;
5,011,771 and 5,281,521; "Oligonucleotide Synthesis" Gait, M. J., ed. (1984); -Nucleic Acid Hybridization" Hames, B. D., and Higgins S. J., eds. (1985);
"Transcription and Translation" Hames, B. D., and Higgins S. J., Eds. (1984); "Animal Cell Culture"
Freshney, R. I., ed. (1986); "Immobilized Cells and Enzymes" IRL Press, (1986); "A
Practical Guide to Molecular Cloning" Perbal, B., (1984) and "Methods in Enzymology" Vol. 1-317, Academic Press; "PCR Protocols: A Guide To Methods And Applications", Academic Press, San Diego, CA (1990); Marshak et al., "Strategies for Protein Purification and Characterization - A Laboratory Course Manual" CSHL
Press (1996); all of which are incorporated by reference as if fully set forth herein. Other general references arc provided throughout this document. The procedures therein arc believed to be well known in the art and are provided for the convenience of the reader.
All the information contained therein is incorporated herein by reference.
Experimental Procedures A. Blood Donors Requirement and Blood Collection by Medical Experts Blood samples were collected in Vacutubes 9m1 with EDTA (Greiner Bio-One 455036).
The study was approved by the institutional Review Boards at the Sheba Medical Center (Ramat Gan Israel) and the Israeli Ministry of Health, (Helsinki Approval number 7780-10-SMC).
B. Collection of Donor's Demographic and Clinical Information For the protection of confidentiality, all collected blood samples were labeled and immediately coded to be used in the database records and diagnostic analysis.
The MA test results were collected from 42 healthy donors and 25 cancer patients from 22 to 81 years old (Table 2). The healthy donors are a mixed population including treated cases of high blood pressure, high cholesterol levels, minor flu and inflammation.
Table 2 ¨ Clinical characteristics of cancer patients:
ac ¨ adencocarcinoma, idc ¨ invasive ductal carcinoma, gej ¨ gastroesphageal junction, NSCLC ¨ Non ¨ small ¨ cell lung carcinoma Tumor Stage Tumor Type Gender Age Patient Number 1 Breast idc Female 53 Breast idc Female 64 2 2 Breast idc Male 63 3 2 Breast idc Female 37 4 2 Breast idc Female 61 5 2 Breast idc Female 38 6 2 Breast idc Female 65 7 3 Breast idc Female 32 8 3 Breast idc Female 42 9 3 NSCLC ac Male 46 10 4 NSCLC ac Male 61 11 4 NSCLC ac Female 60 12 4 NSCLC ac Male 81 13 4 Colon ac Female 70 14 4 Colon Female 49 15 2 Colon ac Female 56 16 2 Rectum ac Female 52 17 4 Rectum ac Male 74 18 3 Gastric ac Male 47 19 4 Gastric gej Male 64 20 3 Pancreas Female 57 21 4 Pancreas Male 58 22 4 Prostate Male 77 23 1 Thyroid Female 54 24 2 Cervix Female 35 25 C. Blood Samples Transport Measures are taken to keep the viability of the blood cells at thermo-stated conditions (Thermo Electric cooling (down to 10'c -18 C) and gently shaking till the PBMCs separation.
D1. Peripheral Blood Mononuclear Cells (PBMCs) Separation Fresh peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Paque (UNI-SEP, Novamed) and gradient centrifugation. The pellet was resuspended in working solution (WS) (PBS with calcium and magnesium) including the fluorescent probe (HPTS) at a final concentration of 5X106 cells/ml.
D2. High Throughput Parallel Measurements of the MA test Each well in a black non-binding, low-volume 384 multi-well plate (Greiner Bio-One) was loaded with 10 ill of the PBMCs solution and 10 1 of working solution plus is HPTS including one of ten reagents in 8 increasing concentrations. Thus the final concentration of the probe in each well was 1 iuM, and the final concentration of the PBMCs was 2.5X106cells/m1 in 20 1 physiological working solution containing 10 mM
phosphate buffer around pH 7.3. Taking into account the average PBMCs concentration in adult peripheral blood a working concentration of 2.5X106 cells/ml was selected. This concentration of PBMCs is considered to ensure two aspects:
first, to get a reasonable signal¨ to¨noise ratio due to product accumulation during at least 1 hour, and second, to allow for intercellular interaction. The same protocol of 100 loading was carried out at least in triplicates, first on the PBMCs samples and then on the reagents, so as to accurately obtain the final 20 1 volume in the required concentration in each well. Furthermore, in each test two types of controls were included:
one including only the probe (1 ,t1\4), without cells and without the stimulants in 8 wells; the other one including only cells without a stimulant, basal state, in 8 wells.
The acidification process was monitored each 5 min during 1 hour of incubation at 37 C by a commercial fluorescence scanner (TECAN Infinite M200). First, the scanner monitored the acidification process without sealing ("OPEN" mode) during 30 min (6 cycles) and then, to avoid ventilation of CO2 and NH3 from each well, the multi-well plate was sealed hermetically (ThermalSeal RTTm, EXCEL Scientific, Inc.) ("CLOSE"
mode). Next, the acidification process was monitored again during 30 min (6 cycles). In order to increase the signal to noise ratio, the fluorescence intensities at 513nm were measured sequentially under excitation at 455nm and 403 nm per well.
D3. Type, Spectrum and Preparation of Reagents In each test, the metabolic activity profiles of PBMCs were monitored in the basal state and under the influence of the following ten reagents diluted in working solution in 8 different concentrations : PHA, CONA, PMA, LPS, MBP(28), MelanA, PSA(29), Glucose(24), L-glutamine and Rapamycin ( Strauss L, Czystowska M, Szajnik M, Mandapathil M, & Whiteside TL (2009) Differential responses of human regulatory T
cells (Treg) and effector T cells to rapamycin. PLoS One 4(6):e5994.) . The reagents selection was made by their relation to the immune system (TABLE 1, above, note, concentrations are not limited to those in the table, concentration = 0 to non toxic dose).
It should be mentioned that other reagents are under calibration, for example:
(hormones such as estradiol, cancer specific antigens such as carcinoembryonic antigen (CEA), cytokines and chemokines such as il-2, vitamins, hormones, drugs, antibodies of the immune system, neurotransmitters, different cancer peptides and specific viruses or their fragments such as human papilomavirus (HPV) (data not shown).
D4.Ratiometric measurement of the pH sensitive fluorescent probe and WS
acidity calibration The probe used in this test is 8-Hydroxypyrene-1,3,6-trisulfonic acid (HPTS).
HPTS is a cost effective, non-toxic, highly water-soluble membrane-impermeant 5 pH indicator with a pKa of ¨ 7.3 in aqueous buffers. HPTS exhibits a pH-dependent absorption shift, allowing ratiometric pH measurements as function of the ratio between the fluorescence intensities at 513nm that are measured sequentially under excitation at 455nm and 403 nm. This method is essential for the present sensitive measurements of minor pH changes in the physiological range around pH 7.
10 In order to quantify the sensitivity of the probe, a stock solution of HPTS was diluted in water to a concentration of 100 M and then to a final concentration of 1 114 and 10 M. WS acidity calibration was made for two buffer concentrations: the WS
(10mM phosphate buffer) and the WS diluted 5 times by saline (2mM phosphate buffer) (Figures 3A-D, Figures 4A-B).
15 The final calibration curve used in the MA test was carried out by pH-glass electrode measurements of sequential titration of WS (containing 2 M HPTS).
The pH
measurements and the fluorescence measurements of the titrated samples are carried out at 37 C. The samples are loaded into a multi-well plate and the fluorescence intensities under EX403nm and EX455nm are measured at 513nm using the fluorescence scanner.
20 For the "OPEN" and "CLOSE" states, a calibration polynomial curve is constructed (Figures 3C-D), allowing to measure pH values and accumulated acidification equivalents as a function of the ratio between the fluorescence intensities measured at 513nm, under excitations at 403nm and 455 nm, respectively.
25 The equations obtained were used for analysis of every new donor (Table 3, below).
TABLE 3 ¨ The equations obtained from the final calibration curves:
X = Fluorescence intensity at Ex. 403nm / Fluorescence Intensity at Ex. 455nrn pH HCI (iunol/m1) Open Y=0.011X4-0.136X3+0.641X2-1.528X+8.266 Y=0.006X4+0.129X3-0.982X2+3.971X-2.276 Close Y=0.013X4-0.164X3+0.747X2-1.723X+8.415 Y=-0.006X4+0.131X3-1.011X2+4.168X-2.581 E. Data Analysis Computation, analysis and data mining ( Nisbet R, IV JE, & Miner G (2009) Handbook of Statistical Analysis and Data Mining Applications) were done by using the following Statistical Package; EXCEL 2007, OriginPro 8, SAS Edition 9.2, PASW
Modular client 13.0 (formally called Clementine, part of SPSS). Results in Figures 6A-C ¨ 8A-D, 13 are expressed as means standard error of the mean. Statistical significance between healthy and cancer patients for variant models was calculated using chi-square. Results were considered statistically different when p<0.05.
Donor's Data Analysis (Summarized in Flowchart of the MA test Framework -Figure 12) Data Preparation ¨
Step 0: Processing and Normalizing Donor Data The raw data of each record (donor) was processed to yield the results in terms of the acidification rate of metabolic activity in units of pmole H+/
1/hour/2500PBMCs.
Pre Processing - Step la: Probe Analysis and Donor Data Normalization In order to improve the signal to noise ratio, analysis of probe was done by performing k-means cluster analysis on all observations (n=730 ) collected from all donors (Figures 5A-D). These processed results were normalized by subtracting the donor values from the HPTS mean values after removal of probe's outliers (not more than 5 % of the results were removed).
Pre Processing - Step lb: Excluded Outliers in Donor's Data Normalizing "OPEN" and "CLOSE" values by the mean values of "OPEN" and "CLOSE" for each combination of donor, dose and stimulant. Observations with standard score >11.71were discarded (1.77 % of the results).
Data Preparation - Step lc: Representation of Donor Metabolic Activity Results After removing the outliers in each donor, average values of "OPEN" and "CLOSE" were calculated separately for each donor based on the average of at least triplicate results for each dose and each reagent per donor. These results would be used later as representing donor metabolic activity for each reagent and dose. The results were planted in 2D graphs and 3D graphs and would be updated automatically with every donor.
Searching for Classification Model - Step 2: Data Mining Algorithm Since most of the studied cancer patients were older than 39 and in order to minimize as much as possible the effect of age, two cohorts of blood donors including males and females were tested and analyzed. The first cohort includes donors with the age above 40 (n=42 (21 healthy donors and 21 cancer patients)) and the second cohort include the full set of donors (n=67 (42 healthy donors and 25 cancer patients)) from 22-81 years old. For Classification of the step 3 results a set of algorithms from a family of Decision Trees/Rule Induction (C5, CART, CHAID, ASSOCIATION RULE) and log linear model (Logistic Regression) was used. Exploratory analysis methods were used to investigate hidden and unhidden connections in the data.
Model Evaluation - Step 3: Model Building and Classification For classifying the donors into healthy and cancer patients, a set from the family of ten different models including data mining, machine learning and statistical modeling were used applying SAS 9.3 and Clementine software (V13.0). In order to evaluate and compare the performance of the models it was decided to use the graphical method which is based on the cumulative gain charts produce by Clementine software (V13.0) (Figures 9A-D).
Predictive Modeling - Step4: Evaluation Using a Validation Set of 30% of Blood's Donors Data as described in step 3 was randomly partitioned into two groups of "Training" and "Testing" using the Clementine software (V13.0). The "Training set" are used to build the data mining model and includes 70% of the donors. The remaining 30 % of the donors will be used to evaluate the classification result on the "Testing" set using the models that were generated in the Training set (Figures 10A-D).
The whole data analysis process is summarized in the Flowchart of the MA test protocol and analysis Framework (Figure 12).
Example 2 MA test design and characteristics Fresh peripheral blood mononuclear cells (hPBMCs) were isolated by Ficoll-Paque and gradient centrifugation from 42 healthy donors and 25 cancer patients (TABLE 2, above). For each blood sample, a 384 multi-well plate was loaded with 200 containing physiological working solution at 10mM buffer around pH 7.3, hPBMCs at final concentration of ¨2.5X106 cells/ml, 1 iuM pH probe (HPTS), and one of ten stimulating reagents in eight increasing concentrations (TABLE 3, above). The MA test is carried out using a commercial fluorescence scanner. The extracellular acidity kinetic profiles were measured either under air-open ("OPEN") or hermetically-sealed closed ("CLOSE") states. Both records enable to measure the real-time accumulations of 'soluble' versus 'volatile' metabolic products (lactic acid versus CO2 and NH3), thereby differentiating between oxidative phosphorylation, anaerobic glycolysis and aerobic glycolysis ("Warburg effect")( Vander Heiden MG, Cantley LC, & Thompson CB
(2009) Understanding the Warburg effect: the metabolic requirements of cell .. proliferation. Science 324(5930):1029-1033). The MA rate profiles were calculated and examined for cancer diagnosis by dynamic online analysis, including data mining tools (Figure 12).
Example 3 Ratiometric Fluorescence Extracellular pH Measurement and Acidity Calibration The non-toxic, membrane-impermeant, ratiometric molecular pH-probe used in the present MA test is 8-hydroxypyrene-1,3,6-trisulfonic acid (HPTS)( Hakonen A &
Hulth S (2008) A high-precision ratiometric fluorosensor for pH: implementing time-dependent non-linear calibration protocols for drift compensation. Anal Chim Acta .. 606(1):63-71; Han J & Burgess K (Fluorescent indicators for intracellular pH. Chem Rev 110(5):2709-2728) with a pKa. of ¨ 7.3 in aqueous physiological buffers.
It is well-known by its low-toxicity, from intracellular pH measurements in many cell types, even under overnight incubation at 2 mM (Overly CC, Lee KB, Berthiaume E, &
Hollenbeck PJ (1995) Quantitative measurement of intraorganelle pH in the endosomal-lysosomal pathway in neurons by using ratiometric imaging with pyranine. Proc Nail Acad Sci U S
A 92(8):3156-3160). Here, HPTS is rather used for extracellular pH
measurements, at a low 1 M concentration, which further ensure its non-toxicity. Calibration polynomial curves were constructed for the "OPEN" and "CLOSE" states, (Figures 3A-D), allowing to measure pH values and accumulated acidification equivalents as a function of the ratio between the fluorescence intensities measured at 513 nm, under excitations at 403 nm and 455 nm, respectively. The acidification calibration curves were obtained for the working solution (WS) and for the WS diluted 5 times with saline (10m/Vi and 2mM
phosphate buffer, respectively) (Figures 3A-D). As expected, this figure verifies that the 10mM buffer capacity allows for about five times of the acidification values compared to that of the 2mM buffer capacity, within the same range of pH changes. These results indicate on the proper sensitivity to acidification within the physiological pH range 6.5-7.5. Further results indicate that the measurement method is independent of the fluorescent probe concentration between 1-10 M. The system is sensitive enough to provide a high signal-to-noise ratio when the extracellular final concentration of HPTS
is only 1 i..11\4 (Figures 4A-B).
The equations obtained from the final calibration curves (Figures 3A-D, TABLE
4) were used for quantitative analysis of the significant measured changes in PBMCs metabolic activity records from all 67 donors (42 healthy and 25 cancer patients).
Example 4 Improving Signal-to-Noise Ratio by Dynamic K-MEANS Cluster Analysis of HPTS Background Aiming at dynamic clinical evaluation of the MA test results, a reliable method was developed that compares any MA test for each donor to previous tests with respect to the reference rate values of the HPTS signal (n=730 observations). By this data collection it is possible to improve the signal to noise ratio of the MA test by filtering exceptional reference results. For that purpose k-means cluster analysis( Nisbet R, IV
JE, & Miner G (2009) Handbook of Statistical Analysis and Data Mining Applications) was applied for the accumulating normalized rate values of the HPTS probe. In each test at least eight control wells were examined, containing 1 tM HPTS in the working solution, without cells and without stimulants. Each value was normalized taking into account the accumulated observations using a standard score. Figure 5A
presents the distribution of the standard scores for "OPEN" and "CLOSE" rate values of all MA
tests. By k-means cluster analysi,s 26 clusters were obtained (Figure 5B), where each observation belongs to the cluster with the nearest mean. The results reported in Figure 5D evaluate the stable performance of the probe. Out of all HPTS reference results (n=730) only 5 clusters (4.66%) were discarded. The rest 21 clusters (95.34%) were finally considered to compose the normal reference range. The mean values of "OPEN"
and mean values of "CLOSE" states were recalculated for each donor. The k-means cluster analysis allows us to extract the probe background rate signal from the cellular data and thereby get the actual rate values of the ongoing MA test results.
Example 5 5 MA Profiles of Control Samples: (i) at Increasing Reagents Concentrations in the Absence of Cells; (ii) with Cells but no Reagents (i) Control experiments in the absence of cells verified that the acidification profiles obtained in the presence of cells indeed measure the rate of cellular metabolic activity. Thus, no acidification was obtained under the same protocol applied in the 10 presence of probe, buffer and each reagent at increasing concentration, but with no cells (e.g glucose (Figure 6A) and PSA (Figure8A)), compared to clear acidification changes in samples with cells. The same control results were obtained for all reagents. (ii) A
basal level of acidification in the presence of cells was measured in the absence of any reagents including glucose. Generally, this basal level increased with increasing glucose 15 concentrations, verifying clear aspects of cellular metabolic activity (Figures 6B-C).
Moreover the MA profiles at the basal state already revealed the general trend of a diagnostic shift from dominant oxidative phosphorylation preferred by the naive hPBMCs of 69 % of the healthy donors, to dominant aerobic glycolysis ("Warburg effect") preferred by activated hPBMCs of 60 % of various cancer patients.
These 20 results emphasize the potential of the MA-test as a diagnostic tool already at the basal state which is the closer scenario to the in vivo state. However the basal state alone is not enough for clear cut differentiation between healthy and cancer patients (Chi-Square, p=0.45). By the present data mining of all the MA-test profiles in response to network of reagents reagents (Figures 10A-D), it can significantly point on 95.24% of 25 .. healthy donors and 88 % of cancer patients (age>4 Chi-Square, p<0.0001) and on 90.48% of healthy donors and and 95.24% of cancer patients (22<age>81, Chi -Square, p<0.0001).
Example 6 Comparison of MA Profiles at Increasing Glucose Concentration, Obtained for Typical Healthy Donor and Breast Cancer Patient First, MA profiles of healthy donors (Figures 6B, 7A) are strikingly similar, despite the significant difference in age (45 (Figure 6B) vs. 69 (Figure 7A)) and gender.
Second, the results in Figure 6A-C reveal significant MA profiles differences between two donors that represent a typical healthy donor and a breast in situ cancer patient (at stage 2, and before any treatment). Additionally, in preliminary experiments where the MA test was applied on few cases of auto-immune diseases and additional non-cancer related infectious diseases, different metabolic activity profiles compared to those obtained for healthy individuals and cancer patients (data not shown) were already revealed. These differences point on 3 clinical diagnostic indexes of cancer (Figures 4A-C). Index 1: MA rate "OPEN" > MA rate "CLOSE" in the basal state (cells in working solution without reagent). Index 2: MA rate "OPEN" > MA rate "CLOSE"
for all glucose concentrations. Index 3: MA rate "OPEN" of cancer > MA rate" OPEN"
of healthy and MA rate "CLOSE" of cancer > MA rate "CLOSE" of healthy. Thus, higher values of oxidative phosphorylation are obtained in fresh PBMCs of healthy samples compared to higher values of aerobic glycolysis in fresh PBMCs of cancer samples. As mentioned in the introduction (Vander Heiden MG, Cantley LC, & Thompson CB
(2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029-1033.; Fox CJ, Hammerman PS, & Thompson CB (2005) Fuel feeds function: energy metabolism and the T-cell response. Nat Rev Immunol 5(11):844-852; Michalek RD & Rathmell JC (The metabolic life and times of a T-cell. Immunol Rev 236:190-202) these results presumably indicate on in vivo development of the "Warburg Effect" in activated hPBMCs of cancer patients.
More detailed observations on the MA test results obtained for cancer patients (Figure 6C and Figures 7B-D) reveal that in the "CLOSE" state the total acidification rate is less than in "OPEN" state. These results indicate on a volatile basic product which is responsible for partial titration of the acidity due to lactic acid and CO2. This titration might be physiologically required upon the metabolic switch to the non-volatile lactic acid production. This role is related to ammonia (NH3), which is one of the primary products of protein catabolism and metabolic pathways of purines and pyrimidines. In the instant measurement system, as in-vivo, vital cells must maintain the cytoplasm in a constant pH of about 7.2 ¨ 7.4 by simultaneous metabolic secretion of both the acidic and basic products as described below.
CO2+ H20 TJ2CO3 H+TJCO3-NH3 + H20 NH4' +OH-S
It should be mentioned that in the 3 indexes analysis, different combinations were found at different stages of various cancers (e.g colon, breast, lung, and pancreas) (TABLE 2, above). Therefore, by these variations it is believed that the examination of enough data collection and follow-up of individual donors will provide reliable and more informative diagnostic profiles, as demonstrated in the following case study (Figures 7A-D).
Example 7 Case Study Follow-Up of MA Profiles, at Increasing Glucose Concentration, Obtained for a 65 Years Old Female with Breast Cancer With respect to the preliminary MA-test measurements, it should be mentioned that one case of thyroid cancer and one of breast cancer were diagnosed by the present test before the physicians. The breast cancer case was followed up along two years as evidence for the sensitive informative capability of the MA test compared to typical classification of staging and treatments. This is the first report of a 2 years follow-up study of a female donor, clinically diagnosed to have breast cancer one year after the MA test had revealed a state of cancer. For comparison, MA profiles are presented of a typical healthy 69 years old male (Figure 7A). MA profiles of the cancer patient on TIME ZERO, the patient clinically diagnosed as having breast cancer one year after the MA test had revealed a state of cancer (I.E.,) (Figure 7B). The three cancer diagnostic indexes indicate on a shift from oxidative phosphorylation observed in the healthy profiles (Figure 7A) to aerobic glycolysis observed in the cancer case profiles (Figures 7B). Namely, positive values for "CLOSE-OPEN" of healthy profiles (Figure 7A) and negative values for "CLOSE-OPEN" obtained for the cancer profiles (Figure 7B).
The next MA test obtained for this study case was carried out 10.5 months later (Figure 7C), just after routine mammography diagnosis of breast idc cancer at stage 2. It should be emphasized that at that time the patient didn't report any physiological or palpable symptoms.
From this point on, a follow-up MA test was carried out every 3 weeks. One month later, a tumor surgical removal was carried out. Another month later a chemotherapy treatment was given every 3 weeks. Each MA test was carried out after about 20 days of each treatment, and 2 days before the next treatment. The last MA test presented here (Figure 7D) was carried out after the third chemotherapy treatment, namely about 2 months after beginning the chemotherapy protocol (time =
(+)14.5 months). It should be noticed that according to the three indexes of the MA
test, this last test already reveals MA profiles (Figure 7D) characteristic of healthy donor (Figure 7A). Obviously the MA test verifies a positive trend along with the ongoing treatment.
By these results, it will be important to use the MA test in a follow-up procedure in order to reveal the trend behavior of the MA test profile compared to clinical evaluation during and far behind completion of the chemotherapy treatment. This follow-up program is made available by the clinically-oriented MA test which is simple, non-invasive and non-expensive.
Example 8 Comparison of MA Profiles, at Increasing PSA Concentrations, Obtained for Typical Healthy, Breast Cancer Patient and Breast Cancer-Recovered Donor Up till now the MA profiles were examined under increasing concentration of glucose that were clearly found as a general non-specific clinical tool for cancer diagnosis. In order to gain more specific cancer classification, the MA test explores simultaneously various reagents (TABLE 3) such as tissue-specific normal antigens (e.g PSA, MelanA).
Prostate-specific antigen (PSA) is a normal protein produced by cells of the prostate gland. The PSA is a cancer-associated tissue-specific normal antigen.
This peptide is recognized by cytotoxic T lymphocytes (CTL). Increasing level in human peripheral blood of this peptide is clinically used as a biochemical diagnostic marker of prostate cancer for men ( Greene KL, et al. (2009) Prostate specific antigen best practice statement: 2009 update. J Urol 182(5):2232-2241). But, low levels of PSA are released into the female circulation and up to date the clinical PSA blood test is not used as a diagnostic factor for women. However, numerous studies have shown that PSA is not prostate specific, but is present in some female hormonally regulated tissues, principally the breast and its secretions (Black MH & Diamandis EP (2000) The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast.
Breast Cancer Res Treat 59(1):1-14; Black MH, et al. (2000) Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res 6(2):467-473). In women, PSA is found in female ejaculate at concentration roughly equal to that found in male semen (Wimpissinger F, Stifter K, Grin W, & Stackl W
(2007) The female prostate revisited: perineal ultrasound and biochemical studies of female ejaculate. .1 Sex Med 4(5):1388-1393; discussion 1393). Three MA
profiles are presented in Figures 8A-D, a typical healthy woman (Figure 8B), woman with breast cancer idc in stage 2 and before treatment (Figure 8C), and female recovered from stage 2 breast cancer 18 years ago (Figure 8D). Tissue-specific stimulants e.g PSA
are observed to induce marked peaks at optimal concentrations in the MA-test profiles of cancer patients (Figures 8A-D). Such profiles are considered to reflect disease-specific receptor-mediated stimulation and thereby enable to detect specific tumors (e.g breast by PSA, melanoma by melanA stimulation). The results reveal several significant issues. First, the MA profile of healthy women indicate a higher level of oxidative phosphorylation as already reported above for glucose MA profiles (Figures 6A-C and Figures 7A-D). Second, Figure 8C point on a PBMCs response to PSA by a female with breast idc cancer in stage 2, before any treatment. This profile expresses high metabolic activity rate at the "OPEN" state, already from the basal state. These profiles indicate a high level of aerobic glycolysis, a phenomena which is similar to activated T-cells as obtained for the glucose MA profiles of cancer patients. Another unique profile of the MA test was revealed for 50 years old female recovered from breast cancer 18 years ago (Figure 8D). This profile for PSA stimulation behaves more like that of healthy donor (Figure 8B). Furthermore it reveals higher MA rate in "close" state that indicates a dominant oxidiative phosphorylation pathway at increasing PSA concentrations more than the characteristic profile for healthy donor (figure 8B). This profile maybe related to an increased population of anti-breast cancer memory cells. This relation is consistent with the observation that following pathogen clearance, surviving effector cells differentiate into long-lived memory cells and revert to an oxidative metabolic state ( Michalek RD & Rathmell JC (The metabolic life and times of a T-cell.
Immunol Rev 236:190-202).
Example 9 5 Model Building and Classification Evaluation for the MA test Results by Data Mining Tools Multiple MA profiles including a huge number of MA rate values are obtained for each donor. In order to develop a dynamic clinical analysis that is updated with every new donor, and to extract patterns from this large data base, a computer 10 programming using Data Mining tools were developed, which combine methods from statistics and artificial intelligence with database management (Nisbet R, IV
JE, &
Miner G (2009) Handbook of Statistical Analysis and Data Mining Applications).
Two selected cohorts of the MA test results, for both males and females, were analyzed.
Since most of the cancer patients studied were older than 39, and in order to minimize 15 .. as much as possible the effect of age, this analysis focused on a subgroup of 42 donors with the age above 40 (21 healthy donors and 21 cancer patients). In the second cohort the full set of donors were used from 22-81 years old (n=67, 42 healthy donors and 25 cancer patients). In order to classify the donors into healthy and cancer individuals, a set from the family of ten different models including data mining, machine learning and 20 .. statistical modeling, applying SAS 9.3 and Clementine software (V13.0) were used. Out of these ten models, only four were able to classify with the highest accuracy both healthy donors and cancer patients. Out of the four models, three were from the family of decision tree (CHAID, C5, C&R TREE) and one of log linear model (Logistic Regression). All four are presented in Figures 9A-D. The decision-tree models are 25 considered to be the best classifiers, since these models don't assume any distributions or any assumptions. The fourth model that didn't perform as good as the others is the Logistic regression. This kind of model is best suited when input data behaves exactly as the assumptions of the model, such as assumptions about distribution and independency. In order to minimize as much as possible over-fitting the Logistic 30 Regression model was ran using the forward selection method, which enabled us to order the variables by importance and minimize as much as possible the number of selected variables. Since each model shows different variables/features as a function of different antigens, each at different concentrations, it may be possible to combine the presenet predictions as a function of more than one model. When examining the influence of the overall reagents in different concentrations on the accuracy of the models, the maximal number of variables that were chosen was not more than five (Figures 9A,9C), which is recommended when sample size is not sufficient to minimize as much as possible the over-fitting. By these initial results it was possible to order the ten reagents as predictors by their frequency of appearance in the various models (Figures 9A, 9C). Currently it is possible to pinpoint glucose, MBP, Rapamycin, PSA
and PMA as pivotal players in the MA test and in relation to the immune system (TABLE 3). The immunological relevance of the other five reagents (TABLE 3) is still revealed by the occasional models' choice. In order to evaluate and compare the performance of the models, the present inventors decided to use the graphical method which is based on the cumulative gain charts produced by Clementine software (V13.0).
The gain chart (Figures 9B, D) contains two built-in curves, the random curve (black line) and the best fit curve (sky blue line). All models fall between these two curves. In this method, greater area between a given curve and the random curve (black curve) indicate on a better model. Blood's donors modeling and classification results point on models with performance similar to the best model (Figures 9A-D).
Example 10 Evaluating Model Results of the MA Test Using a Validation Set of 30% of Blood's Donors A partition process described below enables to combine and compare models so as to gain more confidence in the accuracy of the MA test results, to evaluate the robust level of the models, and to minimize over-fitting due to small sampling (n=67 blood sample donations). The data as described in Figures 9A-D was randomly partitioned into two groups of "Training" and "Testing" using the Clementine software V13.0 9 (Figures 10A-D). The validation set included 70% of the donors for both cohorts. First cohort includes 42 donors with the age above 40 (Figures 10A-B) and the second cohort includes full set of donors (n=67) from 22-81 years old (Figures 1 C-D). The first 70%
of the donors are described on the "Training set". The "Training set" is used to build the data mining model as described in Figures 9A-D. The remaining 30% of the donors ("Testing set") enable to evaluate the classification result on the "Testing set" using the models that were generated in the "Training set" (CHAID , Logistic, C5, C&R
tree) (Figures 10A. C). The "Training" and "Testing" sets enable to evaluate model results with greater confidence and eliminate as much as possible the over fitting challenge. In both cohorts it was found that C5 model gave more robust results where the "Testing"
set curve was similar to the "Training" set (Figures 10B, D). C5 model was the best performer in the "Testing" set while in the "Training" set C&R tree was the best performer. By these results it is possible to pinpoint glucose, MBP, PMA, PHA, CONA
and L-Glutamine as pivotal players in the MA test and in relation to the immune system (TABLE 3). Similarly to the best models in Figures 9A-D, these results (Figures 10A-D) support the results of Figures 9A-D.
A physiological approach to cancer diagnosis is presented here by relying on the preliminary experimental results of the metabolic activity profiles obtained for hPBMCs of healthy and cancer patients. By this approach the present inventors have designed a simple high-throughput, short-time and cost effective optical method of the MA
test using fresh hPBMCs extracted from 10-20 ml blood sample. Striking differences of hPBMCs fingerprinting MA patterns were revealed by preliminary examination of two clinical groups, 42 healthy individuals and 25 cancer patients. While the hPBMCs MA
profiles of the 42 healthy donors indicate a similar preferred oxidative phosphorylation pathway, the hPBMCs of the 25 cancer patients have a wide spectrum of MA
profiles, preferring aerobic glycolysis in correlation with staging and treatment. One case of thyroid cancer and one of breast cancer were diagnosed by the MA test before the physicians. This breast cancer case was followed up by the MA test along two years as evidence for the sensitive informative capability of the MA test with respect to typical classification of staging and treatments.
The results reported here, encourage further exploration of the metabolic activity of hPBMCs as a mirror image of tumor development (Figures 9A-D). Preliminary results clearly reflect common, as well as specific, features of hPBMCs metabolic pathways under cancer-induced evasion of the immune system during the pathological development of different tumors.
A tissue-specific cancer diagnostic index may be provided by the MA-test profiles at early and late stages of local tumor development by increase (or decrease) of the MA rates relative to those observed for healthy donors. Certain optimal concentrations of tissue-specific antigens should be sought for the MA-test profiles.
Such tissue-specific diagnostic profiles are expected also at early stages of tumor development, when initial aggressive antitumor immune response is anticipated.
By this approach, it can be postulated that in the healthy state, the immune system is responsible for ongoing early detection and effective eradication of cancer cells in the context of its normal function, by scrutinizing all body tissues. The immune system is therefore proposed to detect and eliminate cancer cells by their excessive expression of tissue-specific normal antigens. Therefore, in homeostasis, a balanced level of an effective immune response should be well controlled, so as to avoid either a decline of effective cytolytic function, or such aggressive activity against self normal cells that might rather precipitate autoimmune diseases. Thus, unfortunately, in advanced stages of cancer the immune system is known to be suppressed, or even educated to support cancer development by tumor-infiltrating lymphocytes, which might be a part of the circulating hPBMCs. In this view, it is further anticipated that at the lethal metastatic phase of cancer the MA-test profiles of hPBMCs might shift back to reflect an apparent healthy state due to tissue-specific immunity tolerance and anergy, unlike in chronic inflamation. This apparent healthy state may be exposed by exhaustion of the relevant tissue-specific antigen stimulation.
Example 11 PBMCs Metabolic-Activity Profiles for increasing glucose concentration obtained for typical healthy, cancer and autoimmune lupus donors In homeostasis, the immune system activity should be well controlled;
hyperactivity is associated with autoimmune diseases while cancer development is probably related to hypoactivity of the immune system.
Significantly different MA Profiles were obtained for increasing glucose concentration obtained for typical healthy, cancer, and autoimmune lupus donors (Figure 13).
Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.
Citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting.
REFERENCES
(other references are listed throughout the application) 1. Bassani-Sternberg, M. et al. Feature Article: Soluble plasma HLA
peptidome as a potential source for cancer biomarkers. Proc Nail Acad Sci U SA.
2. Hayden, E. C. Personalized cancer therapy gets closer. Nature 458, 131-2 (2009).
3. Kawakami, Y. et al. Identification of human tumor antigens and its implications for diagnosis and treatment of cancer. Cancer Sci 95, 784-91 (2004).
4. Robins, H. S. et al. Overlap and effective size of the human CD8+ T cell receptor repertoire. Sci Transl Med 2, 47ra64 (2010).
5. Early warnings. Nature 458, 679 (2009).
6. Sawyers, C. L. The cancer biomarker problem. Nature 452, 548-52 (2008).
7. Luebeck, E. G. Cancer: Genomic evolution of metastasis. Nature 467, 1053-5.
8. Rosenberg, S. A. & Dudley, M. E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol 21, 233-40 (2009).
9. Rosenberg, S. A., Restifo, N. P., Yang, J. C., Morgan, R. A. & Dudley, M. E.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8, 299-308 (2008).
10. Terme, M., Ullrich, E., Dclahaye, N. F., Chaput, N. & Zitvogcl, L.
Natural killer cell-directed therapies: moving from unexpected results to successful strategies.
Nat Immunol 9, 486-94 (2008).
11. An autoimmune-mediated strategy for prophylactic breast cancer vaccination.
Womens Health (Load Engl) 6, 493.
12. Alexander-Miller, M. A. High-avidity CD8+ T cells: optimal soldiers in the war against viruses and tumors. Immunol Res 31, 13-24 (2005).
13. Michalek, R. D. & Rathmell, J. C. The metabolic life and times of a T-cell.
Immunol Rev 236, 190-202.
14. Maciver, N. J. et al. Glucose metabolism in lymphocytes is a regulated process with significant effects on immune cell function and survival. J Leukoc Biol 84, 949-57 (2008).
15. Zhang, Q. Y. et al. Myelin-basic protein-reactive specific CD4+ and CD8+ NK
lymphocytes induce morphological changes in neuronal cell bodies and myelin sheaths: implications for multiple sclerosis. Arch Med Res 39, 45-51(2008).
16. Narita, D., Cimpean, A. M., Anghel, A. & Raica, M. Prostate-specific antigen value as a marker in breast cancer. Neoplasma 53, 161-7 (2006).
17. Bromley, S. K., Mempel, T. R. & Luster, A. D. Orchestrating the orchestrators:
chemokines in control of T cell traffic. Nat Immunol 9, 970-80 (2008).
18. Kaelin, W. G., Jr. & Thompson, C. B. Q&A: Cancer: clues from cell metabolism. Nature 465, 562-4.
19. Fox, C. J., Hammerman, P. S. & Thompson, C. B. Fuel feeds function:
energy metabolism and the T-cell response. Nat Rev Immunol 5, 844-52 (2005).
20. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-33 (2009).
21. Nisbet, R., IV, J. E. & Miner, G. Handbook of Statistical Analysis and Data Mining Applications (ed. Material, C.) (2009).
22. Patolsky, F. et al. Electrical detection of single viruses. Proc Nail Acad Sci US
A 101, 14017-22 (2004).
23. Zheng, G., Patolsky, F., Cui, Y., Wang, W. U. & Lieber, C. M.
Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat Biotechnol 23, 1294-301 (2005).
24. Hakonen, A. & Hulth, S. A high-precision ratiometric fluorosensor for pH:
implementing time-dependent non- linear calibration protocols for drift compensation. Anal Chim Ada 606, 63-71 (2008).
Claims (25)
- WHAT IS CLAIMED IS:
. An in-vitro method of measuring a metabolic activity (MA) of a cell, the method comprising independently measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of:
(i) non-volatile soluble metabolic products and volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products; and (iii) volatile soluble metabolic products;
wherein said measuring acidification profile of said (ii) is effected in an air-exposed chamber, and wherein said measuring acidification profile of said (i) is effected in an air-sealed chamber, and wherein said measuring acidification profile of said (iii) is by subtracting an acidification profile of said (ii) from an acidification profile of said (i), wherein said cell is a non-pathogenic immune cell. - 2. An in-vitro method of measuring a metabolic activity (MA) of a cell, the method comprising independently measuring in an extracellular environment of the cell, time-dependent acidification profiles due to secretion of:
non-volatile soluble metabolic products and volatile soluble metabolic products;
(ii) non-volatile soluble metabolic products; and (iii) volatile soluble metabolic products;
wherein said measuring acidification profile of said (ii) is effected in an air-exposed chamber, and wherein said measuring acidification profile of said (i) is effected in an air-sealed chamber, and wherein said measuring acidification profile of said (iii) is by subtracting an acidification profile of said (ii) from an acidification profile of said (i), and further wherein said time-dependent acidification profile due to secretion of volatile soluble metabolic products and/or said time-dependent acidification profile due to secretion of non-volatile soluble metabolic products are indicative of the metabolic activity of the cell, wherein said cell is a non-pathogenic immune cell. - 3. The method of claim 1 or claim 2, wherein said extracellular environment comprises a defined solution having a calibrated buffer capacity.
- 4. The method of claim 1 or claim 2, wherein said measuring is effected using a non-toxic membrane impermeable probe.
- 5. The method of claim 4, wherein said non-toxic membrane impermeable probe comprises a pH probe.
- 6. The method of claim 5, wherein said pH probe comprises a ratiometric pH
probe. - '7. The method of claim 4, wherein said non-toxic membrane impermeable probe comprises a CO2 probe.
- 8. The method of claim 4, wherein said non-toxic membrane impermeable probe comprises a NH3 probe.
- 9. The method of claim 4, wherein said non-toxic membrane impermeable probe comprises a lactate probe.
- 10. The method of claim 1 or claim 2, wherein said non-volatile metabolites comprise lactate.
- 11. The method of claim 1 or claim 2, wherein said volatile metabolites comprise NH3 and CO2.
- 12. The method of claim 1 or claim 2, further comprising subjecting said cell to a stimulant or inhibitor prior to, or concomitant with measuring said acidification profile.
- 13. The method of claim 12, wherein said stimulant or inhibitor comprises a cell.
- 14. The method of claim 12, wherein said stimulant or inhibitor comprises a cell-free antigen.
- 15. The method of claim 13, wherein said subjecting said cell to a stimulant or inhibitor comprises a lymphocyte and said stimulant or inhibitor cell comprises a non-syngeneic lymphocyte with respect to said lymphocyte.
- 16. An in-vitro method of diagnosing a disease associated with a modified metabolic activity in a subject-in-need thereof, the method comprising:
(a) providing a biological sample of the subject which comprises a cell;
(b) measuring a metabolic activity of said cell according to the method of any one of claims 1 to 15 and whereas a shift in said metabolic activity compared to that of a normal unaffected cell sample examined under identical conditions is indicative of a disease associated with modified metabolic activity. - 17. An in-vitro method of optimizing disease treatment, the method comprising:
(a) contacting a biological sample of the subject which comprises a cell with at least one medicament;
(b) measuring a metabolic activity of said cell according to the method of any one of claims 1 to 15 and whereas a shift in said metabolic activity of said cell towards that of a normal healthy cell sample examined under identical conditions is indicative of an efficacious medicament for said disease. - 18. The method of claim 1 6 or claim 17, wherein said disease is cancer.
- 19. The method of claim 16 or claim 17, wherein said disease is pathogenic infection.
- 20. The method of claim 16 or claim 17, wherein said disease is an inflammatory disease.
- 21. The method of claim 16 or claim 17, wherein said disease is an allergic disease.
- 22. The method of claim 16 or claim 17, wherein said disease is a graft versus host disease.
- 23. The method of claim 16 or claim 17, wherein said disease is graft rejection.
- 24. The method of claim 16 or claim 17, wherein said disease is an autoimmune disease.
- 25. The method of any one of claims 1 to 24, wherein said non-pathogenic immune cell is a lymphocyte.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161472213P | 2011-04-06 | 2011-04-06 | |
US61/472,213 | 2011-04-06 | ||
PCT/IL2012/050125 WO2012137207A1 (en) | 2011-04-06 | 2012-04-04 | Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2832031A1 CA2832031A1 (en) | 2012-10-11 |
CA2832031C true CA2832031C (en) | 2019-09-17 |
Family
ID=46124593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2832031A Active CA2832031C (en) | 2011-04-06 | 2012-04-04 | Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same |
Country Status (11)
Country | Link |
---|---|
US (3) | US8728758B2 (en) |
EP (1) | EP2694962B1 (en) |
JP (1) | JP5990254B2 (en) |
KR (1) | KR102010600B1 (en) |
CN (1) | CN103518133B (en) |
AU (1) | AU2012240953B2 (en) |
BR (1) | BR112013025782B1 (en) |
CA (1) | CA2832031C (en) |
DK (1) | DK2694962T3 (en) |
ES (1) | ES2627154T3 (en) |
WO (1) | WO2012137207A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013025782B1 (en) | 2011-04-06 | 2022-09-06 | Ramot At Tel-Aviv University Ltd | METHOD OF MEASUREMENT OF A METABOLIC ACTIVITY (AM) OF A CELL, EX-VIVO METHOD OF DIAGNOSIS OF A DISEASE ASSOCIATED WITH A MODIFIED METABOLIC ACTIVITY IN AN INDIVIDUAL IN RESPECTIVE NEED, EX-VIVO METHOD OF OPTIMIZATION OF THE TREATMENT OF A DISEASE, EX METHOD - VIVO MONITORING OF TREATMENT OF A DISEASE IN AN INDIVIDUAL AND EX-VIVO METHOD OF IDENTIFICATION OF AN AGENT CAPABLE OF CHANGING A METABOLIC ACTIVITY OF CELLS |
WO2015057713A1 (en) * | 2013-10-14 | 2015-04-23 | Case Western Reserve University | Metabolic analyzer for optimizing health and weight management |
AU2014338510A1 (en) | 2013-10-22 | 2016-06-09 | Ramot At Tel-Aviv University Ltd. | Method and system for sensing |
ITRM20130700A1 (en) * | 2013-12-19 | 2015-06-20 | Stichting Katholieke Univ | METHOD FOR DETECTION OF CIRCULATING CANCER CELLS |
CN105303035A (en) * | 2015-09-29 | 2016-02-03 | 上海新窝信息科技有限公司 | Health monitoring method and system |
RU2018124345A (en) | 2015-12-09 | 2020-01-09 | Рамот Ат Тель-Авив Юниверсити Лтд. | METHOD AND SYSTEM FOR TOUCH DETECTION |
KR20190040010A (en) | 2016-08-22 | 2019-04-16 | 라모트 앳 텔-아비브 유니버시티 리미티드 | METHOD AND SYSTEM FOR DETECTING BIOLOGICAL ANALYSIS |
AU2018320264A1 (en) * | 2017-08-21 | 2020-04-02 | Ramot At Tel-Aviv University Ltd. | Methods of diagnosing and treating lung cancer |
CN110491511B (en) * | 2019-07-24 | 2023-04-07 | 广州知汇云科技有限公司 | Multi-model complementary enhanced machine learning method based on perioperative risk early warning |
IT202000016429A1 (en) * | 2020-07-07 | 2022-01-07 | Univ Degli Studi Udine | METHOD FOR EVALUATING THE METABOLIC ACTIVITY OF A NON-CANCER CELL |
WO2023023114A1 (en) * | 2021-08-17 | 2023-02-23 | Orgenesis Inc. | Tumor infiltrating lymphocytes with increased metabolic activity |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (en) | 1971-02-10 | 1977-09-15 | Organon Nv | METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES. |
NL154598B (en) | 1970-11-10 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING. |
NL154599B (en) | 1970-12-28 | 1977-09-15 | Organon Nv | PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (en) | 1972-05-11 | 1983-06-01 | Akzo Nv | METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US20060073539A1 (en) * | 2001-08-06 | 2006-04-06 | Wikswo John P | Apparatus and methods for using biological material to discriminate an agent |
JP4625946B2 (en) * | 2004-11-02 | 2011-02-02 | 国立大学法人 岡山大学 | pH measuring device and pH measuring method |
EP1736780A1 (en) | 2005-06-24 | 2006-12-27 | Eppendorf Array Technologies S.A. | Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus |
WO2008018905A2 (en) * | 2006-01-17 | 2008-02-14 | Cellumen, Inc. | Method for predicting biological systems responses |
JP5107943B2 (en) | 2006-03-06 | 2012-12-26 | ゼティク テクノロジーズ リミテッド | Methods and compositions for identifying cellular phenotypes |
WO2011000572A1 (en) | 2009-07-02 | 2011-01-06 | Patenthandel Portfoliofonds I Gmbh & Co. Kg | Method and device for detecting long-term biological effects in cells |
CN102625932A (en) * | 2009-09-08 | 2012-08-01 | 诺达利蒂公司 | Analysis of cell networks |
BR112013025782B1 (en) | 2011-04-06 | 2022-09-06 | Ramot At Tel-Aviv University Ltd | METHOD OF MEASUREMENT OF A METABOLIC ACTIVITY (AM) OF A CELL, EX-VIVO METHOD OF DIAGNOSIS OF A DISEASE ASSOCIATED WITH A MODIFIED METABOLIC ACTIVITY IN AN INDIVIDUAL IN RESPECTIVE NEED, EX-VIVO METHOD OF OPTIMIZATION OF THE TREATMENT OF A DISEASE, EX METHOD - VIVO MONITORING OF TREATMENT OF A DISEASE IN AN INDIVIDUAL AND EX-VIVO METHOD OF IDENTIFICATION OF AN AGENT CAPABLE OF CHANGING A METABOLIC ACTIVITY OF CELLS |
-
2012
- 2012-04-04 BR BR112013025782-2A patent/BR112013025782B1/en active IP Right Grant
- 2012-04-04 KR KR1020137027588A patent/KR102010600B1/en active IP Right Grant
- 2012-04-04 AU AU2012240953A patent/AU2012240953B2/en active Active
- 2012-04-04 WO PCT/IL2012/050125 patent/WO2012137207A1/en active Application Filing
- 2012-04-04 EP EP12721945.9A patent/EP2694962B1/en active Active
- 2012-04-04 CA CA2832031A patent/CA2832031C/en active Active
- 2012-04-04 DK DK12721945.9T patent/DK2694962T3/en active
- 2012-04-04 JP JP2014503276A patent/JP5990254B2/en active Active
- 2012-04-04 ES ES12721945.9T patent/ES2627154T3/en active Active
- 2012-04-04 US US13/817,543 patent/US8728758B2/en active Active
- 2012-04-04 CN CN201280022396.9A patent/CN103518133B/en active Active
-
2014
- 2014-05-18 US US14/280,612 patent/US9784731B2/en active Active
-
2017
- 2017-10-04 US US15/724,299 patent/US20180038849A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9784731B2 (en) | 2017-10-10 |
CA2832031A1 (en) | 2012-10-11 |
KR102010600B1 (en) | 2019-08-13 |
EP2694962B1 (en) | 2017-03-01 |
JP2014512006A (en) | 2014-05-19 |
US20130224789A1 (en) | 2013-08-29 |
KR20140024871A (en) | 2014-03-03 |
JP5990254B2 (en) | 2016-09-07 |
CN103518133B (en) | 2016-08-17 |
DK2694962T3 (en) | 2017-06-12 |
US20180038849A1 (en) | 2018-02-08 |
US20140255972A1 (en) | 2014-09-11 |
WO2012137207A1 (en) | 2012-10-11 |
BR112013025782B1 (en) | 2022-09-06 |
AU2012240953B2 (en) | 2017-02-23 |
AU2012240953A1 (en) | 2013-10-17 |
EP2694962A1 (en) | 2014-02-12 |
US8728758B2 (en) | 2014-05-20 |
ES2627154T3 (en) | 2017-07-26 |
BR112013025782A2 (en) | 2016-12-20 |
CN103518133A (en) | 2014-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2832031C (en) | Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same | |
Gueguen et al. | Contribution of resident and circulating precursors to tumor-infiltrating CD8+ T cell populations in lung cancer | |
Wei et al. | Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade | |
Riou et al. | Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells | |
Meghraoui-Kheddar et al. | Two new neutrophil subsets define a discriminating sepsis signature | |
Sklavenitis-Pistofidis et al. | Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma | |
Oberbeck et al. | Noncanonical effector functions of the T-memory–like T-PLL cell are shaped by cooperative TCL1A and TCR signaling | |
Caldeira et al. | Immunophenotype of neutrophils in oral squamous cell carcinoma patients | |
JP7356412B2 (en) | How to detect lung cancer | |
Bocanegra et al. | Potent clinical predictive and systemic adjuvant therapeutic value of plasma fractalkine in PD-L1/PD-1 blockade immunotherapy for lung cancer | |
Tornatore et al. | Clinical proof of concept for a safe and effective NF‐κB‐targeting strategy in multiple myeloma | |
Zhang et al. | Single-cell analysis highlights a population of Th17-polarized CD4+ naïve T cells showing IL6/JAK3/STAT3 activation in pediatric severe aplastic anemia | |
Tenuta et al. | Circulating natural killer cells as prognostic value for non-small-cell lung cancer patients treated with immune checkpoint inhibitors: correlation with sarcopenia | |
Gore et al. | Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products | |
Tian et al. | HLA‐DR+ mucosal‐associated invariant T cells predict poor prognosis in patients with sepsis: A prospective observational study | |
Rodriguez et al. | Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy | |
Chu et al. | Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission | |
Leelatian et al. | High risk glioblastoma cells revealed by machine learning and single cell signaling profiles | |
Lee et al. | Use of a Platform with Lens-free Shadow Imaging Technology to Monitor Natural Killer Cell Activity | |
Shakiba et al. | Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine ligand-receptor pairs that drive disease | |
Kim | Dissection of Macrophage Diversity in Hepatocellular Carcinoma Elucidates Molecular Correlates to aPD-1 Response | |
Shi et al. | CXCR6 defines therapeutic subtypes of CD4+ cytotoxic T cell lineage for adoptive cell transfer therapy in pediatric B cell acute lymphoblastic leukemia | |
Balog et al. | Peripheral immunophenotyping reveals lymphocyte stimulation in healthy women living with hereditary breast and ovarian cancer syndrome | |
Chen et al. | Expression of regulatory T cells in driver-gene-negative advanced non-small cell lung cancer as well as its effect on the therapeutic efficacy and prognosis of immune checkpoint inhibitors | |
Ptacek et al. | A Systems Immunology Approach Identifies Cytokine-Induced STAT Signaling Pathways Critical to Rheumatoid Arthritis Disease Activity and Treatment Response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20170313 |